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Abstract
The aim of this work is to study the effect of removing the flattening filter (FF) from the 
head of a linear accelerator (linac) on photon beam dosimetric properties and treatment 
outcomes with emphasis on photoneutron production.
An Intensive Monte Carlo (MC) study was carried out for this purpose using two 
MC codes: FLUKA and BEAMnrx/DOSXYZnrc. These codes were used to model the 
head of Varian Clinac and/or TrueBeam linacs with and without a FF. For the Varian 
Clinac, several aspects of the FF removal were addressed. These include: first, study 
of the dosimetric characteristics of the 15 MV unflattened beam such as dose rate, per­
centage depth dose on the central axis, beam profile, out-of-field dose, surface dose and 
neutron contamination. Second, the neutron fluence in treatment rooms housing flatten­
ing filter free (FFF) linacs at different energies. Third, the quality of megavoltage cone 
beam computed tomography (MVCBCT) images by using the 6 FFF photon beam with 
a copper target. Fourth, the feasibility of using the 15FFF beam in intensity modulated 
radiotherapy (IMRT) for prostate cancer with regard to planning target volume (PTV) 
coverage, organs at risk sparing (OAR) and neutron dose to the patient was studied. Fi­
nally, the dosimetric effect of combining two FFF beams and investigating its practicality 
was studied.
For the Varian TrueBeam, the dosimetric properties of 6  and 10 MV photon beams 
with and without a FF were calculated using the second version of Varian TrueBeam 
phase-space flies and compared with measurements. In addition, four volumetric modu­
lated radiotherapy (VMAT) plans of a prostate cancer case for these photon beams were 
modelled using MC techniques for comparison.
Results obtained showed that the 15FFF photon beam of the Varian Clinac has a 
dose rate 4.86±0.09% times higher than the flattened one and the average out-of-fleld 
dose from the edge of the field to the edge of the phantom was reduced by 4 4 .0 ± 0 .5 %.
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The neutron fluence and neutron dose equivalent at the isocentre were also reduced 
by 77i3% . However, the photon surface dose of the unflattened beam increased by 
13.0i0.3%. Moreover, a signiflcant drop-off in neutron fluence at different locations 
inside the treatment room was found when the FF was removed. For example: the 
neutron fluence at the isocentre decreased by 54.0±4.2%, 76.04:1.4% and 75.04:0.8% for 
10, 15 and 18 MV, respectively. This would decrease the neutron dose to patient and 
medical staff as well as reduce the shielding cost of the treatment room. A reduction was 
observed in the mean energy of the photon spectrum and an increase is obtained in the 
low energy photon ratio when the 6 FFF beam with the copper target was used leading to 
an improvement in the quality of MVCBCT images. The local contrast in the MVCBCT 
images when two cylindrical bones with a 2  cm diameter were placed inside a. water 
phantom with a 5 cm thickness was improved by 31.04:1.3% when the copper target was 
used. The 15FFF did not provide sufficient coverage to the PTV because the modelled 
15FFF plan was not optimised as the hospital treatment planning system did not have 
the 15FFF data required for the optimising process. However, the calculated neutron 
dose from a full step and shoot IMRT plan on a water phantom decreased significantly 
with the use of the 15FFF. Combining the 6  and 15FFF beams provided better sparing of 
the rectum and bladder and less surface dose. This technique could improve the current 
IMRT treatments.
The calculated dosimetric properties using new TrueBeam phase-space files agreed 
with measured data. Results of out-of-field dose were found to decrease by 30.44:0.6% 
and 44.84:0.8% for the unflattened 6  and 1 0  MV beams, respectively, compared to the 
flattened beams. The homogeneity index (HI) within the PTV for 6  and 10 photon beams 
with and without FF plans were found to be 0.08, 0.07, 0.09, and 0.11, respectively. 
The volume receiving 70 Cy within the bladder were 11.9% ,11.3%, 11.0% and 4.7%, 
respectively. The VMAT plan treated with the conventional 10 MV beam provided the 
lowest HI, while the VMAT plan treated with the lOFFF beam provided the highest 
OAR sparing. All VMAT plans were found to be acceptable clinically.
From all results obtained, it can be concluded that the unflattened beam can lead to 
better treatment outcomes and could provide a step forward towards optimum photon 
radiotherapy.
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Chapter 1
Introduction
Caner is one of the most increasing causes of death in the UK and Europe. Last year, 
about 2 .6  million new cases of cancer were diagnosed and around 1 .2  million cancer 
patients died in the European Union (Ferlay et al. 2013). Radiotherapy is the second 
important method for the treatment of cancer where the patient undergoes to it entirely 
or after other kinds of treatment methods (Mayles et al. 2007). This method utilises the 
energy of ionisation radiation to kill cancerous cells in the human body. The radiation 
can be directed as a beam at a particular volume within the patient from outside the 
body known as external radiotherapy (teletherapy) or can be inserted into the patient 
using radioactive sources known as brachytherapy (Podgorsak & IAEA 2005).
However, using radiotherapy for tumour eradication or control means that both can­
cerous and normal tissues are going to receive part of the radiation dose. To reduce the 
complication of normal tissue after treatments, a large fraction of the dose should be 
delivered to the tumour with as low as possible fraction to normal tissues. This concept 
is the aim of radiotherapy (ICRU 2010).
1.1 Medical linear accelerators
Medical linear accelerators (linacs) are still the most frequently used radiotherapy system 
to treat cancer. Electrons are generated in these devices and accelerated to energies 
between 4-25 MeV. After that, the electron beam is focused on the patient using steering 
and collimation devices to be used for superficial tumours. For deeper tumours, the 
accelerated electrons are focused onto a thick target made of a high Z material such
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as tungsten to produce an X-ray beam. Figure 1 .1  shows a schematic diagram of the 
conventional medical linac (Mayles et al. 2007, Podgorsak & IAEA 2005).
During the last two decades, several developments have been introduced using linacs. 
The introducing of the multi-leaf collimator (MLC), which has up to 80 pairs of high Z 
material leaves that move independently to form any irregularly shaped beam required 
allows delivery of the dose with more flexibility to any tumour shape. This technique is 
known as conformai radiotherapy (CRT) (Mayles et al. 2007).
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Figure 1.1: A schematic diagram of the conventional medical linac (Podgorsak & IAEA
2005).
In addition, the great improvement in imaging modalities, which provides the poten­
tial of better tumour localisation, permits to develop new treatment modalities that can 
increase the dose to tumour while reducing the dose to normal tissues such as intensity 
modulated radiotherapy (IMRT) (ICRU 2010). In IMRT the dose can be delivered in 
fixed angled beams with either static or dynamic segmentations (step and shoot IMRT 
or dynamic IMRT) or in rotational movements of beams with changing field patterns
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known as volumetric modulated arc therapy (VMAT) (ICRU 2010). Furthermore, an­
other technique has been introduced called image-guided radiotherapy (IGRT) to solve 
the problem that arises from physical uncertainties related to patient position on the linac 
couch, organ movements, and deformation of tissues (Sharpe et al. 2007). This technique 
improves the precision of patient positioning and localisation of target volume by provid­
ing a 3D imaging system placed on the treatment machine to scan the patient prior each 
treatment fraction (Mayles et al. 2007, Yoo & Yin 2006). In addition. Stereotactic Body 
Radiotherapy (SBRT) was also introduced to treat small tumours by focusing high dose 
on it using a numbers of static beams (Gunderson & Tepper 2007).
Although, these techniques reduce the dose to normal tissues, they distribute a larger 
fraction of low doses in larger volumes of normal tissues than in conventional treatment 
plans. The problem arises because of concerns about secondary induced cancer risks 
(ICRU 2010).
1.2 Challenges and limitations of conventional linacs
Several problems arise in using conventional linacs which limit the ability of the techniques 
mentioned above (e.g. IMRT, SBRT, etc.) to obtain the optimum result of the overall 
treatment course. These problems arise for three main reasons . The first is the relatively 
low dose rate of conventional linacs which increases the total treatment time especially 
for treatments requiring high dose such as SBRT. The second is the relatively high out- 
of-field dose that raises concerns about the risk of secondary induced cancers. The final 
point is the high neutron contamination level when linacs are operated at photon beam 
energies higher than 8  MV which put several restrictions to the use of IMRT at these 
energies (Georg et al. 2011).
1.3 Flattening filter free linacs
One way to reduce these problems is to remove the flattening filter (FF) from the head of 
the linac or to operate in what is known as the flattening filter free mode (FFF) (Georg 
et al. 2 0 1 1 , Kry et al. 2008, Vassiliev et al. 2006a). A number of studies have showed 
interesting results with the use of FFF linacs in terms of increasing the dose rate and
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reducing the out-of-field dose and neutron level (Georg et al. 2011). In addition, the use of 
FFF linacs improves the image quality of Megavoltage cone beam computed tomography 
(MVCBCT) which is one of the imaging modalities used in IGRT (Georg et al. 2 0 1 1 ).
1.4 Aim of this work
The use of FFF linacs in treating different sites in a patient such as prostate, breast, lung, 
etc. looks promising (Georg et al. 2011). At present, the main interest in the use of FFF 
linacs is at a photon beam energy of 6  MV and not more than 10 MV. Few studies have 
investigated the use of FFF linacs at energy higher than 10 MV and particularly at the 18 
MV photon beams (Vassiliev et al. 2007). Thus, the effect of the fiattening filter removal 
on the dosimetric properties and treatment outcome at energies higher than 6  MV still 
needs further investigation. In addition, it has been shown that the removal of the FF 
improves the image quality of MVCBCT images with the combination of low Z target 
but different target materials and thicknesses have still to be explored. Furthermore, the 
new Varian TrueBeam phase-space files  ^ have not been validated in any previous study. 
Thus, it is important for these files to be tested in dosimetric property calculations as 
well as in a full radiotherapy plan.
The main purpose of this project can be summarised in four objectives. Firstly, 
studying the effect of removing the fiattening filter from high energy (> 8  MV) linacs 
on beam characteristics, especially on neutron production. Secondly, exploring the use 
of a copper target with the unfiattened beam in portal imaging (MVCBCT). Thirdly, 
validation of the new Varian TrueBeam phase space files by first calculating the dosimetric 
properties of the 6  and 10 MV beams with and without a FF and comparing them with 
measurements and second by comparing clinical plans modelled using these files with 
those created by the treatment planning system (TPS) at the hospital. Finally, assessing 
IMRT and VMAT plans for prostate cancer planned using different FFF photon beams 
energies by comparing them with those planned with conventional photon beams.
The objectives listed above were studied mainly using Monte Carlo (MC) techniques 
and the results obtained were verified, where possible, with commissioning data and
^Phase-space file is a file which contains information associated to the position, direction, charge, 
energy, etc. of each scored particle. This file can be used as an alternative source in several MC codes 
(Rogers et al. 2001).
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treatment planning system (TPS) plans obtained from the Royal Surrey County Hospital 
(RSCH) and the University College London Hospital (UCLH).
1.5 Outline of the thesis
Chapter 1 is a general introduction to the thesis, and describes the main purpose of 
this project and the structure of the thesis.
C h a p te rs  2  is a definition for important parameters and terminology used in radiother­
apy and mentioned or applied in this thesis.
Chapter 3 describes the concepts of neutron production and detection from medical 
linacs operating in high energy photon mode (> 8  MV) as well as reviewing the litera­
ture about neutron measurements and calculations from linac irradiation.
Chapter 4 summarises the effect of removal of the ffattening filter on linac beam char­
acteristics and several clinical trials and it contains an up-to-date review of the literature 
with regard to FFF photon beams.
Chapter 5 contains the materials and methods used to model the Varian Clinac linac 
with and without a FF using MC simulations along with the results obtained and discus­
sion. This chapter discusses the effect of the FF removal on the dosimetric properties of 
the 15 MV photon beam and the infiuence of the field size on the out-of-field dose and 
neutron levels. It provides a MC study of treatment rooms housing this type of linac 
with respect to neutron production. In addition it describes the use of FFF photon beam 
with a copper target and its effect on portal images, it also discusses the impact of FF 
removal on IMRT for prostate cancer. Finally, the dosimetric impact of combining two 
FFF photon beams in IMRT for prostate cancer is discussed.
Chapter 6 explains the methodology, results and discussion of modelling the Varian 
TrueBeam linac using the second version of phase space files obtained from the Varian 
manufacturer. It also contains a comparison study of VMAT for prostate cancer using 
the 6  and 10 MV photon beams with and without a FF.
Finally, a conclusion and recommendations for future work are discussed in Chapter 7. 
Since the MC IMRT and VMAT plans need to be assessed, A MATLAB code was writ­
ten to extract evaluation parameters from these plans. This code is presented in the 
A ppendices as well as the list of publications and conference participations.
Chapter 2
Important definitions
This Chapter contains brief definitions to a number of important quantities used or 
mentioned in this thesis. It should be said that not all quantities, defined in this chapter, 
have been previously encountered by the writer. However, they are defined because they 
relate with the other quantities and provide the reader with a complete description in 
case he/she is interested in using them in future work.
2.1 Quantities and definitions
The dosimetric concepts and the definitions of specific quantities used for radiological 
protection have been under continuous modification and improvement by various na­
tional and international bodies such as the International Commission for Radiological 
Protection (ICRP), the International Commission on Radiation Units and Measurements 
(ICRU) and the National Council on Radiation Protection and Measurements (NCRP). 
The basic concepts and recommendations, set by these organisations, were used to form 
the fundamental regulations in the UK. Radiological protection quantities can be classi­
fied in three linked categories: physical quantities, protection quantities and operational 
quantities illustrated in figure 2 .1  (Wernli 2009).
2.1.1 Physical quantities
Basic physical quantities have been specified in various ICRU reports such as ICRU 3 3 , 
39, 43 and 51 (ICRU 1980, 1985, 1988, 1993). These quantities are utilised in radiation 
dosimetry, they do not give any consideration of radiation protection aspects, they should
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Physical quantities
•  Fluence,
•  Kenna, K
•  Absorbed dose, D
Protection qnutities
I Equivalent dose, H j 
I Effective dose, E 
I committed dose, H x ( t ) ,  E(t) 
I collective effective dose, S
<
Operationalqnantities
•  Ambient dose equivalent, 
H‘(d)
•  Directional dose equivalent
•  Personal dose equivalent
Figure 2 .1 : Schematic diagram of quantities used in radiological protection (ICRP 1991).
be defined at every point in the radiation field, they should be directly measurable and 
their units are obtained from primary standards at national standards laboratories. Three 
physical quantities are defined: kerma to quantify photons, absorbed dose to quantify 
electrons and fiuence to quantify neutrons (ICRP 1991, 2007).
Kerma
The kerma (kinetic energy released per unit mass), K , is defined as (ICRP 2007):
dEtrK  =
dm (2 .1)
Where dE j^. is the sum of the initial kinetic energies of all charged ionising particles 
released by uncharged ionising radiation in a volume element of mass dm. The unit of 
kerma is J kg~k
Absorbed dose
The absorbed dose, D, is defined as (ICRP 2007):
d  = E
dm (2 .2)
Where ds is the mean energy imparted by ionising radiation to matter of mass dm. The 
unit of absorbed dose is Gy.
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Fluence
The fluence, y?, is defined as (ICRP 2007):
dN
^  =  &  (2,3)
Where dN  is the number of particles incident on a sphere of cross-sectional area da. The 
unit of y) is m Fluence can often be used in different terms as fiuence rate or fiux, 
(fiuence per unit time ).
2.1.2 Radiation protection quantities
Since basic physical quantities do not have any consideration of radiation protection 
aspects, they are not appropriate for use in dose limitation purposes. That is because 
the same dose from different radiations (e. g. photons, electrons, neutrons, protons) 
cause different biological effects. In addition, different organs and tissues in the human 
body are more sensitive to radiation than others. Two quantities, extracted from the 
physical quantities, were defined in the ICRP report no. 60 (ICRP 1991) then updated 
in the ICRP report no. 103 (ICRP 2007): the equivalent dose to quantify the effect of 
radiation type and effective dose to quantify the effect of organ type (ICRP 1991, 2007, 
Wernli 2009).
Equivalent Dose
The equivalent dose, Ht ,r , is defined as (ICRP 2007):
Ht ,r = ^  w rDt ,r (2.4)
R
Where H t ,r  is the equivalent dose in a tissue or an organ T  due to radiation R  and has 
the unit Sv. D t ,r  is the average absorbed dose in T  from R  and has the unit Cy and W r  
is the radiation weighting factor and it is dimensionless. w r  has specific value for each 
type of radiation introduced in the ICRP 60 (1991) then modified in ICRP 103 (2007) as 
shown in Table 2 .1 .
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Table 2 .1 : The radiation weighting factor, w r , for various radiation type (ICRP 1991, 2007).
Radiation type
ICRP 60
W r
ICRP 103
Photons, electrons positrons and muons 1 1
Protons other than recoil protons and energy > MeV 5 2
Alpha particles, fission fragments and heavy nuclei 
Neutrons;
20 20
E n  <  10 keV 5
10 keV < E n <  100 keV 10
100 keV < E n < 2  MeV 20 a function of E n
2 MeV <  E n  < 2 0  MeV 10 seen in figure 2.2
E n  >  20 MeV 5
T h e effective dose
The effective dose E  is defined as the summation of the equivalent doses in a particular 
tissue multiplied by the appropriate tissue weighting factor wt (ICRP 2007).
E  = ^  Wt Ht ,r (2.5)
T
Where E  is the effective dose in a tissue or an organ T  and has the unit Sv and Wt  is 
the tissue weighting factor and it is dimensionless. wt has specific value for each tissue 
or organ defined in the ICRP 60 then modified in ICRP 103 as shown in Table 2 .2 .
Table 2.2: The tissue weighting factors for different tissues as defined in ICRP 60 and 103. 
The values in brackets are recommended values in ICRP 60 (1991) if they are different form
ICRP 103 (2007).
T iusse Wx
Bone-marrow (red), Colon, Lung, Stomach 0 .1 2
Conads 0.08 (0 .2 0 )
Bladder, Oesophagus, Liver, Thyroid 0.04 (0.05)
Bone surface. Skin 0 .0 1
Brain, Salivary glands 0.01(0.05)
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Figure 2 .2 . Radiation weighting factor for neutrons as a function of neutron energy 
introduced in the ICRP 103 (ICRP 2007).
2.1.3 Operational quantities
Since the protection quantities are not directly measurable and cannot be calculated ex­
cept the characteristics of the irradiation geometry and radiation field are known with 
appropriate accuracy, Operational quantities have been defined by the ICRU as measur­
able quantities to give an acceptable estimation of the protection quantities. In the case 
of neutrons, three operational quantities have been introduced: the personal dose equiv­
alent, l/p(10), the directional dose equivalent, H'{d, Q), and the ambient dose equivalent. 
All have been extracted from the quantity called the dose equivalent, H  (it 
is different from the equivalent dose) and has the units of Sv. The dose equivalent at a 
specific point is defined as:
H  = QD (2.6)
Where D is the absorbed dose and Q is the quality factor at that point and is a function 
of charged particle linear energy transfer, LET, in water as shown in equation 2.7. LET 
is defined as the energy deposited in a medium along the path of charged particle or 
photon. The unit of LET is J m  ^ but it is usually expressed as another unit such
10
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keV/xm“’ (ICRP 2007).
Q{LET) = <
1 fo r  L E T  < 10keVtJ,m~'
0.32 L E T  -  2.2 fo r  10 <  L E T  < lOOkeV/im-^ (2.7)
fo r  L E T  > lOOkeVfim - 1
LET values in water have been specified in ICRP 60 then updated in ICRP 74 (1996). 
In order to calculate the dose equivalent and other operational quantities the ICRU has 
defined a standard phantom called the ICRU sphere. It is a 30 cm diameter sphere 
phantom made of tissue-equivalent material with a mass composition of 76.2% oxygen, 
11.1% carbon, 10.1% hydrogen and 2.6% nitrogen with a density equal to 1 g cm“^(ICRP 
1991, 2007, Wernli 2009).
Am bient dose equivalent
Ambient dose equivalent, H  (d), at a point in the radiation field is defined as the dose 
equivalent produced in the corresponding expanded and aligned field in the ICRU sphere 
at depth, d, on a radius opposite to the incident radiation field. The recommended 
reference depth, d, is chosen as 1 0  mm for strongly penetrating radiation while it is 
chosen as 0.07 mm or 3 mm for weakly penetrating radiation in case of skin or eye, 
respectively (ICRP 2007, Wernli 2009).
Directional dose equivalent
The directional dose equivalent, H  (d, fl), at a point in the radiation field, is defined as 
the dose equivalent produced by the corresponding expanded field in the ICRU sphere at 
a depth d, on a radius in a specified direction 0. The recommended reference depths for 
weakly and strongly penetrating radiation are the same as for ambient dose equivalent 
(ICRP 2007, Wernli 2009).
Personal D ose Equivalent
The personal dose equivalent, dfp(d), at a point in the radiation field is defined as the 
dose equivalent in soft tissue under a specified point at depth, d, on the body. Once 
more, d for weakly and strongly penetrating radiation are the same as for the ambient 
dose equivalent and the directional dose equivalent (ICRP 2007, Wernli 2009).
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2.1.4 RBE ratio
Since the dose-response curve depends on the type of radiation used and on the biological 
endpoint studied, the effect of high LET radiation (e.g. neutrons) on biological tissues is 
greater than low LET radiation (e.g. photons). This effect can be described in terms of 
the relative biological effectiveness (RBE) which is defined as the ratio of the X-ray dose 
that produces a specific biological damage to the dose of a given type of radiation under 
the same conditions to produce the same biological damage.
2.1.5 OER ratio
The presence or absence of molecular oxygen within a cell infiuences the biological effect 
of ionizing radiation: the larger the cell oxygenation above anoxia, the larger is the 
biological effect of ionizing radiation. Especially for low LET radiations, the larger the 
cell oxygenation above anoxia, the larger the biological effect until saturation of the 
effect of oxygen occurs. As shown in figure 2.3 , the effect is quite dramatic for low 
LET (sparsely ionizing) radiations, While for high LET (densely ionizing) radiations it is 
much less pronounced. The ratio of doses without and with oxygen (hypoxic versus well 
oxygenated cells) to produce the same biological effect is called the oxygen enhancement 
ratio (OER). The OER for X rays and electrons is about three at high doses and falls to 
about two for doses of 1-2 Gy. The OER decreases as the LET increases until approaching 
unity (Podgorsak & IAEA 2005).
2.2 Treatment modalities
Several developments have been introduced in use of linacs in order to improve radio­
therapy treatment by increasing the dose to tumour and sparing the normal tissues as 
much as possible.
2.2.1 Three-dimensional conformai radiotherapy
Three-dimensional conformai radiotherapy (3D-CRT) is a treatment modality tha t radi­
ation beam directions, weights and shapes are defined to match the shape of the tumour 
(figure 2.4b) instead of matching only the tumour height and width in the conventional
12
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Figure 2.3: OER plotted against LET. The vertical dashed line separates the low LET 
region, where LET <  10 keV/mm, from the high LET region, where LET >  10 keV/mm
(Podgorsak & IAEA 2005).
treatment (figure 2.4a) (Gunderson & Tepper 2007).
2.2.2 Intensity m odulated radiotherapy
3D-CRT becomes Intensity modulated radiotherapy (IMRT) when each beam is divided 
into sub-beams with different intensities and/or collimator postions (ICRU 2010). IMRT 
can be achieved by using different ways such as:
Electronic tissue compensator (ETC): Can be done by adapting the MLC computationally 
to produce a non-homogenous fields. This technique has been introduced to reduce the 
time significantly for preparing physical compensators in the mould room and setting 
them up during the treatment. In addition, this technique is used when multiple-held 
IMRT cannot be applied for certain patients (Kinhikar et al. 2007, Spruijt et al. 2013). 
Step and Shoot IM RT  : Uses several static MLC positions for each beam. The beam is 
switched off when the MLC moves from one position to another (ICRU 2010).
Dynamic IMRT: In this case, several dynamic sub-helds shaped by MLC are used in 
each beam. Thus, the beam is kept on during the MLC movement from one position to 
another (ICRU 2010). Dynamic IMRT can be fully inverse planning (the planner starts 
with setting the desired results then the software work backwards using mathematical 
algorithms to achieve the best way to reach the desired results (ICRU 2010)) and called 
Pull IMRT or it can be a combination between inverse and forward planning and called 
hybrid IMRT (Spruijt et al. 2013).
13
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F igure 2.4: Comparison between (a) conventional radiotherapy techniques and (b) 3D-CRT. 
The 3D-CRT provide more sparing to critical organs than conventional radiotherapy 
(Gunderson & Tepper 2007, ICRU 2010).
Rotational IM RT : In this case, not only the MLC move dynamically, but also the beam 
itself changes its angle in rotational movement during the treatment (the gantry rotates 
in arc). This technique has several names including volumetric modulated arc therapy 
(VMAT) and rapid arc radiotherapy (RapidArc®). Since in VMAT both MLC and gantry 
move simultaneously, the delivery time is reduced significantly especially when the dose 
rate is increased by using an unfiattened beam (see section 4 .1 .1 ) (Gunderson & Tepper 
2007).
2.2.3 Image guided radiotherapy
Image guided radiotherapy (IGRT) is a technique that improves the precision of patient 
positioning and localisation of target volume by providing a 3D-imaging system placed 
on the treatment machine (Mayles et al. 2007).
14
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2.2.4 Stereotactic body radiotherapy
Stereotactic body radiotherapy (SBRT) is a technique that uses several numbers of static 
small field-size beams with a very high dose to tumour (Gunderson & Tepper 2007).
2.3 Treatment-planning parameters
2.3.1 Planning volumes
For radiotherapy treatment, several regions have been introduced In ICRU reports 50, 62 
and recently updated in report number 83, to define both cancerous and normal tissues 
in order to be used in treatment planning Procedures (ICRU 1993, 1999, 2010). These 
regions are:
Gross tumour volume (GTV): This is the visible region of the tumour.
Glinical target volume (GTV): This region contains the GTV plus the microscopic sur­
rounding cancerous cells. The GTV and GTV regions do not change with changing the 
treatment modality.
Internal target volume (ITV): This region contains the CTV and a margin added to it 
to include the uncertainty in the position and the size of the CTV inside the patient. 
Planning target volume (PTV): This region contains the ITV and a margin added to 
it to include the uncertinty in patient positioning and alignment during the treatment 
course. The size of the ITV and PTV can change depending on treatment modalities but 
it cannot be eliminated especially the ITV because error always exists in tumour position 
due to the limitation in the resolution and accuracy of imaging modalities.
Organs at risk (OAR): This region contains the organs that can cause a substantial mor­
bidity if it receives a certain amount of radiation. OAR can be classified into three groups: 
serial OAR (which can cause organ malfunction if any part of it was not preserved from 
irradiation such as the spinal cord), parallel OAR (which if part of it is irradiated, the 
rest of the organ can work normally such as the lung) and serial-parallel OAR (which 
has mix of serial and parallel tissues such as the kidney).
Planning organs-at-risk volume (PRY): This region contains the OAR plus a margin to 
include the uncertainty in positioning the OAR.
Treated volume (TV): This region contains the treated volume which could be different
15
M. A. Najem ___________________ CHAPTER 2. IMPORTANT DEFINITIONS
than the PTV. This region can change depending on treatment modalities. For example 
the TV in IMRT is smaller than in conventional and 3D-CRT.
Remaining volume at risk (RVR): This region contains all normal tissues irradiated ex­
cluding the OAR. This region is very important in assessing any treatment plan.
2.3.2 Treatment plan evaluation
Several parameters have been introduced in order to evaluate any treatment plan, in this 
section, we are going to define the most commonly used parameters.
D ose Voulm e H istogram s (DVH s)
These parameters have been used in assessing treatment plans since the late 1970s. DVHs 
can be defined as the histograms of the percentage volume with the minimum absorbed 
dose received (ICRU 2 0 1 0 ). The DVHs are very important parameters to indicate hot 
and cold regions (regions having high and low absorbed doses, respectively).
D
Dy% is defined as the absorbed dose received by a certain percentage of the volume. For 
example, Dgg% =  2  Gy is the absorbed dose ,2  Gy, that is received in 98% of the volume 
(ICRU 2010).
D
Vd is defined as the percentage volume receiving at least a certain absorbed dose D. For 
example, V2 = 30% is the percentage volume, 30%, receiving at least 2  Gy. Dy% and Vd 
are very powerful parameters in assessing treatment plans (ICRU 2010).
H om ogeneity index
The Homogeneity index, H I, is a parameter illustrating the dose uniformity within the 
PTV. The H I  can be defined by the following equation (ICRU 2010):
=  (2.8) 
the Homogeneity in the PTV is better as H I  Approaches the zero.
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Conform ity index
The conformity index, C I, is described as the quotient of the volume that receives at least 
the dose prescribed, Lioo, to the target volume that receives at least the dose prescribed, 
Vtioo, (Zhang et al. 2011). The Cl is always lager than 1 . The better the treatment plan, 
the nearer is C l to  1 .
Conformity number
The Conformity number, C N , can be defined by the following equation:
™
Where; Vt: is the total target volume, the CN is always smaller than 1 . The better the 
treatment plan, the nearer is CN to 1 (Zhang et al. 2011).
Gradient index
The Gradient index, GI, is the quotient of the volume that receives at least 50% of the 
dose prescribed, V50 to the volume that receives at least the dose prescribed, Vloo, (Zhang 
et al. 2 0 1 1 ).
The GI is always lager than 1 . The nearer G7 to 1 , the faster fall-off in the absorbed 
dose outside the PTV and the better the treatment plan.
Total m onitor units
The total number of monitor units (MUs) is a very important parameter as it represent 
the amount of head and MLC leakage to normal tissues. As the total number of MUs 
increases, the probability of induced secondary cancer also increases (Zhang et al. 2011).
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N eutron production from linacs
3.1 Introduction
Photon beams of linear accelerators operating above 8  MV are contaminated with neu­
trons. Since these neutrons cause more damage to tissues than photons and electrons, 
they have been a significant concern to different international organisations such as the 
NCRP (National Council on Radiation Protection and Measurements), ICRP (Interna­
tional Commission on Radiological Protection) and IAEA (International Atomic Energy 
Agency) with respect to their accumulation in the total dose received by patients and to 
the protection aspects of operating staff and public (Barquero et al. 2005, NCRP 1984,
2005).
3.2 Neutron production
The main concern about neutrons is that they add extra dose to a patient which may 
increase the possibility of secondary cancer induction (Xu et al. 2008). Neutron produc­
tion is the result of the giant resonance dipole (GDR) reaction. The GDR reaction can 
be subdivided into two main reactions (Barquero et al. 2005, NCRP 1984):
or (3/, yzj react%07%: This occurs aa a result of the interaction of Bremsstrah- 
lung X-rays with the nuclei of the linac components (target, flattering filter, collimator, 
head shielding, etc.), the wall of the bunker and the patient. The cross-section of pho­
toneutron reactions increases with photon energy up to a certain energy then decreases
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with photon energy^ (it has slightly a bell shape distribution). The maximum photon 
energy to produce this reaction is about 20 to 25 MeV for most light nuclei while it 
decreases for heavier nuclei. The full width at half maximum (FWHM) of this reaction 
is about 4 to 1 0  MeV. Photonuclear reactions can also produce more than one neutron 
such as the (7 , 2 n) reaction or charged particles accompanied by neutrons such as (7 , pn) 
and (7 , a  n ) reactions. However, these reactions are less important because they have 
small cross-section and high threshold^ (IAEA 2006, McGinley 2002, Swanson & IAEA 
1979).
Electronuclear (e, C n) reaction: This occurs by the interaction of electrons with the 
nuclei of the linac's components (wave guide, target, etc.) and the patient. However, this 
reaction has cross-section 137 times smaller than (7 , n)^.
3.3 Neutron interactions
Since neutrons are uncharged particles, they can travel considerable distances in m atter 
without any interaction. Neutrons interact with the nuclei and electrons of m atter but 
the interaction with electrons is considered negligible. The interaction of neutrons can be 
divided into three categories: elastic and inelastic scattering and neutron capture. The 
way neutrons interact with nuclei of matter depends on their energy and the physical 
properties of the interacting material. Neutron energies can be classified into three broad 
groups (Knoll 2000, Turner 2008):
1. Thermal neutrons: neutron energy E„ <  0.025 eV
2 . Epithermal neutrons: 0.025 eV < E„ <  0 .1  MeV
3. Fast neutrons: E„ >  0.1 MeV.
There is no simple relation between the photoneutron reaction and the mass or atomic number of 
nuclei.
2Por example, the maximum cross section { ( i m a x )  and the energy threshold ( E t h )  for ^°^Pb(7 , n)
reaction is about 700 mb and 7.37 MeV, respectively, whereas the a m a x  and E t h  for °^®Pb(7 , 2n) reaction
is about 90 mb and 14.11 MeV, respectively (Chadwick et al. 2000).
^This number in the literature comes from the fine structure constant.
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3.4 The effect of linac components on photoneutron  
production
The neutron source strength, defined as the number of neutrons produced by linac 
components per X-ray dose at the isocentre, is an important parameter for fiuence and 
dose calculations. The magnitude of the neutron source strength depends on several 
factors: the linac operating energy, the head structure and the field size. Table 3.1 sum­
marises the neutron source strength of different linacs with closed jaws. It is important 
to mention that the differences in values for the same linac model are due to the large 
uncertainties between neutron measurement techniques and the discrepancies in Monte 
Carlo (MC) calculations for different codes (Followill et al. 2003, McCall 1987, Naseri & 
Mesbahi 2010).
Although the total photoneutron yield has been measured using different techniques, 
the origin of photoneutrons can only be obtained by MC simulation (Allen & Chaudhri 
1988, Facure et al. 2007). Several studies have calculated the contribution of head com­
ponents on photoneutron yields (Mesbahi 2009, Ongaro et al. 2000, Pena et al. 2005, 
Swanson & IAEA 1979). Table 3.2 shows the percentage contribution of the target, 
primary collimator, flattening filter, jaws and other components (i.e. magnet, shielding, 
etc.) on the total photoneutron yield form a Varian 2100C linac (Varian Medical Systems, 
Palo Alto, CA, USA) at different energies (Mao et al. 1997). The contribution of target 
and flattening filter in photoneutron yield from Varian linacs, as seen in Table 3 .2 , was 
found to be 25 to 75% higher than that calculated from Siemens linacs (Siemens Medical 
Solutions, Concord, CA, USA) and that due to the different composition between the 
two manufactures (Pena et al. 2005).
3.4.1 Effect of field-size
The effect of field-size on the photoneutrons yield has been estimated by several authors 
(Chibani & Ma 2003, Garnica-Garza 2005, Kim et al. 2007, Mao et al. 1997). The neutron 
yield increases with field size until it reaches its maximum at a 2 0 x 2 0  cm^ field size then 
it decreases as the field size increases. The reason for that is because when the jaws 
close, the photoneutron production is maximum but also the neutron attenuation is also 
maximum and when the jaws are fully opened (40x40 cm^) the neutron attenuation is
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Table 3.1: Neutron source strength for different medical linear accelerators adapted from
(Naseri k. Mesbahi 2010).
M a n u fa c tu r e r  M o d e l E n e r g y  m o d e  (M V )  Q „ X lO ^ ^ (n /G y ) M e a s u r e d /M C R e f r e n c e s
1800C 10 0.06 M easured (M cG in ley  & Landry 1989)
15 1.23 - -
- 18 2.27 - -
2 100C /2300C 10 0.038 MC (M ao et al. 1997)
- 15 0.68 - -
- 18 1.2 - -
- 20 1.2 - -
V a r ia n  2100C 18 0.96 M easured (Follow ill e t  al. 2003)
2100C  (w ith  MLC) 18 0 .87 - -
2300 CD 18 0.95 - -
2500 24 0.77 - -
20C 15 0.93 - (M cC all 1987)
18C 10 0.059 - -
21EX 15 0 .74 - (H ow ell e t  al. 2009)
- 18 1.26 - -
- 20 1.80 - -
SL-20 18 0.69 - (M cG in ley  e t al. 1993)
18 0.46 - (Follow ill e t al. 2003)
SL-25 18 0.46 - -
-  . 22 2 .37 - (M cG in ley  e t al. 1993)
E L E K T A  Prim us 15 0.31 - (H ow ell e t al. 2009)
- 18 0 .37 - -
O N C O R 15 0.14 - -
- 18 0.43 - -
KD 18 0.88 - (Follow ill e t  al. 2003)
20 3.2 - (M cC all 1987)
MD 15 0.2 - (Follow ill e t al. 2003)
M D2 10 0.08 - _
S ie m e n s  Prim us 15 0.2 MC (Lin et al. 2001)
- 0 .17 - (P ena  et al. 2005)
- 0.14 - (Becker et al. 2007)
Prim us (w ith  MLC) - 0.21 M easured (Follow ill e t  al. 2003)
Prim us (w ith  M iM LC) - 0.12 - -
- 10 0.02 - -
Saturne 41 12 0.24 - (Fenn & M cG inley 1995)
- 15 0 .47 - -
G E  S aturne 43 18 1.5 M easured -
25 2.4 - -
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Table 3.2: The contribution of Varian 2100C linac head component in photoneutron yield
(Mao et al. 1997).
Component 10 M V 15 M V 18 M V 20 M V
Target (W) 0.01% 9% 16% 17.2%
Primary collimator (W) 45% 38% 41% 36%
Flattening filter 0.03% (Cu) 22% (W) 9% (Steel) 10.4% (Steel)
Jaws(W ) 56% 29% 35% 36%
Other com ponents 1% 1.2% 1.4% 1%
the minimum but photoneutron production is also minimum. So, the photoneutron yield 
has the maximum when the field size is 20x20 cm^. For example, Chibani k  Ma (2003) 
calculated the dose equivalents for field sizes 5x5 and 20x20 cm^ of an 18 MV Siemens 
linac using MC simulation and they found that the dose equivalent was 2.82±0.08 and 
6.96±0.21 mSv Cy“ ,^ respectively.
3.4.2 Effect of m ulti-leaf collimator and IMRT
Several studies have explored the effect of the multi-leaf collimator (MLC), used in the 
IMRT technique, in photoneutron fiuence (Rebello et al. 2008, Zanini et al. 2004). The 
contribution of MLC in the total neutron fiuence has been found to be 6 .6 % of the total 
photoneutron yield. The effect of using the IMRT technique has been also examined 
and found that it increases the neutron dose to patients compared with the conventional 
radiotherapy. This results in an increase in the monitor units (MUs) and the use of 
modulation scaling factor (MSF)^ to produce the same photon dose to the tumour. The 
measurements of neutron dose equivalent with TLD placed inside a Bonner sphere sys­
tem showed that the neutron dose for the IMRT was 6  times higher than that for the 
conventional radiotherapy (Chibani k  Ma 2003, Howell et al. 2006, Stathakis et al. 2007).
Followill et al. (2007) discussed the usage of high energy photon beams with IMRT 
based on published data. They estimated the risk of neutron to produce secondary cancers 
to be 2 .2 % and 5.1% for 15 and 18 MV beams, respectively. The risk in pediatric patients 
could increase from 5 to 10 times. They claimed that the 15 MV beam is preferred when
'^ It is the ratio between the maximum number of MU required by the intensity map and the total 
MU needed to achieve the final pattern.
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the PTV is close to the OAR even in head and neck cancer cases. In addition, they 
found that in few cases, the 2 0 % reduction in entrance dose by using a high energy beam 
would prevent patient hair loss, they found that a number of authors agreed about many 
favourable features of IMRT treatment with 15 MV not 25 MV or higher but other factors 
should be taken in account.
Hussein et al. (2012) studied the possibility of using 15 MV in IMRT of prostate 
cancer. They found better organ sparing but a slightly increase in rectum normal tissues 
complication probability (NTCP) (3 to 3.6% for 6  and 15 MV, respectively). They used 
a set of PADCs (poly-allyl diglycol carbonate detectors) placed on a Rando phantom 
to measure the neutron dose. They found that the overall neutron dose equivalent was
2.010.3 mSvCy They concluded that the choice of 15 MV IMRT should take as risk 
vs benefit which includes patient’s age and life expectancy.
3.4.3 Effect of wedge filter
The effect of the wedge filter on the neutron contamination has also been evaluated. 
Hashemi et al. (2008) used polycarbonate film dosimeters to study the effect of wedges 
for the 18 MV photon beam of an Elekta linac (Elekta Ltd, Crawley, UK). They found 
that the neutron dose was 3-5 times higher (depending on field size) for the wedged 
beam compared with the open beam. In another study, (Mesbahi et al. 2010) using MC 
calculations found that the neutron dose for the same linac is 6 .5  times higher when 
the wedge filter is used. The reason for that is the placing of a high Z material in 
the path of the photon beam will increase scattering photons inside the linac head and 
therefore increase the number of photoneutrons produced. Also, more MUs are required 
to compensate for the decrease in photon fiuence at d^ax due to the wedge filter (Ghavami 
et al. 2010, Hashemi et al. 2008, Mesbahi et al. 2010).
3.4.4 Effect of concrete wall com position
The effect of photoneutrons due to concrete wall composition has been studied by several 
groups and individuals. Facure et al. (2008) calculated the photoneutron production from 
a 1 0  MV linac from concrete walls with steel or lead composition using MC simulation. 
They found that the concrete walls with steel composition do not affect the photoneutron
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production. However, concrete walls with lead composition increase the dose equivalent 
to 20± 2% //Sv/week and up to 75± 2 % /xSvCy”  ^in uncontrolled areas and the isocentre, 
respectively. Mesbahi et al. (2012, 2011) studied the effect of different types of concrete 
on the photoneutron production for 18 MV linac beam. They found that the fiuence 
of photoneutrons at the isocentre remains relatively constant for all type of concretes. 
However, it varies up to 36% at the maze. They referred that to the composition of 
concretes especially for those that have high Z materials such as lead and iron in them. 
They concluded that a high density concrete will increase the photoneutron production 
which makes it unsuitable for shielding purposes of linacs operating in high energy mode.
3.4.5 Electroneutron yield
Although the neutrons produced by electrons are relatively small compared with those 
produced by photons, however, some studies have reported the neutron dose for 1 2 , 15, 
18, and 2 1  MV electron beams. For a 1 2  MV electron beam, the neutron dose was not 
detected. For 15, 18 and 2 1  MV electron beams, the neutron dose was found to be 
100.0±20.4, 262.7±61.2 and 349.0±29.6 /iSvGy“ \  respectively (Lin et al. 2001). Loi 
et al. (2006) measured the electroneutron leakage from a mobile linear accelerator^ op­
erating at 1 2  MeV using bubble detectors at different places inside the treatment room. 
They found that the maximum neutron dose equivalent was 0.33±20% ^uSvGy"^ at the 
linac head which is about 1 0 0  times less than that for a conventional linac because it 
requires less shielding materials than the conventional linac which means less electroneu­
tron interactions. They concluded that a mobile linac can be used without any neutron 
shielding if the bremsstrahlung radiation is reduced to negligible level (Loi et al. 2006).
3.5 Photoneutron Spectra
3.5.1 The production mechanisms of photoneutron spectra
Photoneutron spectra are produced by two different mechanisms:
The évaporation mechanism, the largest contribution, is dominant at the low energy
 ^A new type of medical linac producing only electron beams and used in unshielded or lightly shielded 
treatment rooms for intraoperative radiotherapy aspects.
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region. Neutrons produced via this mechanism have a Maxwellian distribution and are 
emitted isotropically (i.e. the direction of neutron is independent of the direction of the 
photon beam). The Maxwellian distribution is given as (Zabihzadeh et al. 2009):
dNn 0.89 _E^
dE„ ~  ^ (^ 7
Where is the emitted neutron energy and T  is the nuclear temperature in MeV.
The direct mechanism, the smallest contribution to the photoneutron spectrum (^  11%), 
is however dominant at the high energy region. Neutrons produced via this process are 
emitted unisotropically (i.e. the direction of the neutrons is dependent on the direction 
of photon beam). The distribution of the direct mechanism is given as (Zabihzadeh et al. 
2009):
0.111n(^%)
Where Emax is the maximum incident photons energy and is the neutron binding 
energy. The values 0.89 and 0.11 in equations 1 and 2 , respectively, indicate the ratio 
of evaporation and direct contributions in the total photoneutron spectrum, respectively. 
The photoneutron spectrum, as seen in figure 3.1, has a peak around 2  MeV and has 
a shape similar to the fission spectrum of ^^^Cf (McCall et al. 1979). Carnica-Carza 
(2005) studied the effect of field size on photoneutron spectra and he found that the 
photoneutron spectrum and the neutron mean energy were independent on the field size 
(the deviation was within 1 %). He found that photoneutron production occurs mainly in 
the components above the secondary collimator (the jaws) and increasing the field size 
allows more neutrons to reach the patient plan. Pena et al. (2005) used the MC method to 
study the photoneutron spectra for a 15 MV Primus, Siemens linac, at different locations 
in the treatment room (Figure 3.2 ). The photoneutron spectra at the iso centre, the 
room corner and the maze have two peaks: a peak at 0.7 MeV and a peak at 0.05 eV. 
They found that the epithermal neuron distribution does not vary significantly between 
the three locations, whereas the fast neutron distribution is about 7  times higher at the 
isocentre compared to the other locations.
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Figure 3.1: The photoneutron spectrum of a 15 MV medical linear accelerator compared 
with the fission spectrum of ^^^Cf (McCall 1979).
3.5.2 The effect of linac and treatm ent room shielding on neu­
tron spectra
The number of neutrons produced increases as a function of the atomic number of target 
material as well as the incident electron energy. Although heavy Z materials such as lead 
and tungsten provide excellent shielding for photons, they do not provide good shielding 
for photoneutrons (except the reduction in the mean neutron energy through inelastic 
scattering) and even then they may produce extra neutrons via the (n, 2n) process. The 
neutron fiuence at the patient plane arises from three components given by (McGinley 
2002):
^tot — ^dir T ^sc T ^th (3.3)
The first component (p^ ir is the direct neutron fiuence and is given by (McGinley
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F igure 3.2: Neutron spectra at different points of a typical treatment room for the 15 MeV 
photon beam of a Primus linac (Pena et al 2005).
2002):
^di dQnAndl (3.4)
Where; a is the neutron transmission factor penetrating the head shielding, di is 
the distance between the target and the point of calculation and is the neutron 
source strength. Direct neutrons can be subdivided into two components: direct neutrons 
reaching the patient plane without any interaction with shielding materials (they have 
approximately no change in their origin energy and the mean energy is about 1 MeV) 
and direct neutrons having interactions with the linear accelerator shielding materials 
(their mean energy are from about 0.3 to 0.5 MeV). The second component (psc is the 
scattered neutron fiuence from the concrete room and is given by (McGinley 2 0 0 2 ):
dQn
^sc '— 5.4- (3.5)
Where; S  is the treatment room surface area excluding the maze. Scattered neutrons 
have mean neutron energy around 0.24 MeV. The last component ipth is the thermal 
neutron fluence and it is given by (McGinley 2002):
dQn
^th  —  12 S' (3.6)
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Therefore, The total fluence at any location inside the treatment room excluding the 
maze can be given by (McGinley 2 0 0 2 ):
{ » ')
On the other hand, the total fiuence inside the maze is given by (NCRP 2005):
(3.8)
Where; da is the distance between the isocentre and the point of calculation and Sr is 
the treatment room surface area including the maze.
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Chapter 4
Flattening Filter Free linac
Conventional linacs operating in the photon mode have a component inside the head 
known as the flattening fllter (FF). Its benefit is to produce approximately uniform dose 
distribution inside the beam field size along the patient body. This uniformity allows a 
reduction of complications in dose calculations when computers were not widely available. 
However, the FF has several drawbacks such as (Georg et al. 2011, Milan & Bentley 1974):
1. Increase of the scattered radiation that leads to relatively high out-of-field and 
leakage doses and therefore high doses to normal tissues.
2 . Reduction of the linac dose rate which in turn increases the treatment delivery 
time.
3. Increase of photoneutron production when linacs are operated at energies higher 
than 8  MV due to the increase in scattered radiations inside the linac head.
In the 1990s a number of studies based on removing the FF (also called flattening filter 
free (FFF) mode) were carried out. These studies were mainly concerned in increasing 
the dose rate for radiosurgery proposes or determining the physical characteristic of 
the FFF beam such as the X-ray spectra or the variation of head-scatter factor. The 
first commercial medical accelerator operated on the FFF mode was the Scanditronix 
racetrack microtron MM50 (Uppsalla, Sweden). The head of this accelerator was filled 
with helium to reduce the electron contamination on the beam (Karlsson et al. 1993, 
O’Brien et al. 1991). The introduction of new treatment techniques such as SBRT and 
both static and rotational IMRT which produce an inhomogeneous dose distribution have 
created significant interest in FFF linacs (Georg et al. 2011).
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4.1 Characteristics of FFF beam
4.1.1 Dose rate
The greatest benefit of removing the FF is the increase in the linac output. Several studies 
measured the increase in dose rate or calculated it using Monte Carlo (MC) techniques.
Vassiliev et al. (2006a) measured the increase in dose rate for the 6  and 18 MV FFF 
beams of a Varian 21EX linac. they found that the increase in dose rate at 10 cm depth 
in a water phantom and 10 x 10 cm? field size for the 6  and 18 MV FFF beams was 
2.304:0.05 and 5.504:0.11 times higher than with FF, respectively.
Cashmore (2008) measured the increase in dose rate for the 6  MV FFF beam of an 
Elekta Precise. The dose rate increased by a factor of 2.304:0.02 at dmax when the FF 
was removed.
Kragl et al. (2009) found that the dose rate for several Elekta Precise linacs increased 
by 1.704:0.01 to 2.104:0.01 and 2.304:0.01 at dmax when the F F  was replaced by a 6  mm  
copper plate for 6  and 1 0  MV beams, respectively. This plate was used to produce a 
detectable signal in the ion chamber and for safety issues.
In addition, 0  Brien et al. (1991) obtained an increase in dose rate by a factor of 
2.754:0.06 for the 6  MV FFF beam of a Therac- 6  linac (Atomic Energy of Canada Ltd., 
Ontario, Canada) under stereotactic radiosurgery conditions.
Similarly, Dzierma et al. (2 0 1 2 ) reported that the dose rate of the 7 MV FFF beam of 
a Siemens Artiste linac increased up to a 2000 MUs/min compared with a 300 MUs/min 
dose rate of the conventional 6  MV beam.
Vassiliev et al. (2006b) calculated the increase in dose rate for the 6  and 18 MV 
unfiattened beams of a Varian Clinac 2100 linac using MC technique. They found that 
the dose rate increased by 2.304:0.01 and 5.504:0.03 times at dmax for 6  and 18 MV FFF 
beams, respectively.
The dose rate could be increased more by changing the nominal energy of the incident 
electron beam. Tsiamas et al. (2 0 1 1 ) reported an increase in dose rate up to 4  times when 
the nominal electron energy was increased from 6  MeV to 8 .5  MeV to obtain a percentage 
depth dose curve similar to that of the 6  MV conventional beam. Table 4.1 summarises 
the increase in dose rate for different medical linacs under different conditions.
The increase in dose rate reduces the beam-on time which could translate into a
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Table 4.1: The increase in dose rate by removing the FF for different linacs measured (M) or
using MC simulation (MC).
M anufacturer M odel Energy Increase in dose ra te  M /M C Ref.
21EX 6 2.3 M (Vassiliev et al. 2006a)
- 18 5.5 - -
- 6 2 .1“ - -
- 6 4.0*'& - (Tsiamas et al. 2011)
Varian 6 1.9* MC -
Clinac 2100 6 2.31 - (Vassiliev et al. 2006b)
- 18 5.45 - -
TrueBeam 6 2.26 M (Hrbacek et al. 2011)
- 10 4.03 - -
Precise 6 2.3 M (Cashmore 2008)
- 6 1.68-2.06* - (Kragl et al. 2009)
- 10 2 j f - -
- 6 1.76* MC (Dalaryd et al. 2010)
E lekta 10 2 .6 6 * - -
- 6 2.33 - -
- 10 3.23 - -
- 6 2 j - (Almberg et al. 2 0 1 2 )
- 6 4.24^ . - -
SL25 18 4.24 - (Mesbahi 2009)
Artiste 6 6 .6 6 * M (Dzierma et al. 2 0 1 2 )
ONCOR 6 5.0/ - (Huang et al. 2012)
Siemens Primus 6 2 ^# MC (Chofor et al. 2011)
- 15 3.96 - -
- 6 1.679 - -
- 15 2.549 - -
Therac -6 6 2L75& M (O’Brien et al. 1991)
Beijing (Bj) -6 B 6 1.82 - (Fu et al. 2004)
a: T h e FF  w as replaced by a 2 m m  copper p la te  
b: T h e nom inal electron  energy Increased to  8.5 M eV  
c: T h e FF  w as replaced by a 6 mm  copper p late  
d: T h e nom inal electron  energy increased to  8 .0  M eV
e: T h e nom inal electron  energy increased to  7 .0  M eV  and th e  linac head w as m odified  to  
conventional linac
f: T h e head w as m odified  to  produce th e  sam e F D D  as th e  conventional linac  
g: T h e head w as m odified  to  enhance th e  beam  fiatness  
h: T h ey  used a sm all field size
produce th e  sam e F D D  as th e
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reduction in delivery time in a number of treatment cases such as SBRT lung cancer 
and respiratory gating in treatments requiring an organ motion control (Vassiliev et al. 
2006a, Wang et al. 2 0 1 2 ). Boda-Heggemann et al. (2013) found that the treatment time 
for each fraction in hypofractionated image-guided SBRT can be decreased from 27±5 
min using the flattened 6  MV beam to 15.774:8.58 min for the first fraction and to 9.10± 
5.54 min for later fractions using the lOFFF beam.
The reduction in treatment time is related to treatment modality. When a dynamic 
IMRT is used, the reduction is related directly to beam-on time. However, when a static 
IMRT is used, the reduction is affected by several factors: beam-on time, verification time, 
leaf-travel time, characteristics of MLC and segmentation algorithm (Fu et al. 2004). It 
is also good to mention that the maximum dose rate is not always achievable because it 
is limited to the speed of MLC (Sharma 2011). Changing the dose rate in FFF linacs to 
obtain dose rate down to that of conventional linacs can be done by changing the pulse 
repetition frequency (PRF) (Lohse et al. 2011). The biological effect of increasing the 
dose rate will be discussed later on (see section 4 .1 .1 0 ).
To my knowledge, no one has assessed the 15 MV photon beams of Varian and Elekta 
linacs and the only study done on a 15 MV photon beam was for a Siemens linac (Chofor 
et al. 2 0 1 1 ).
4.1.2 X-ray Spectra
The effect of removing the FF on X-ray spectra has been examined by several groups and 
individuals using MC calculations. The X-ray spectrum of a FFF beam was found to be 
softer than that of the FF beam which has an effect on the penetration of the beam inside 
the patient. Thus, in order to get the same penetration as the FF beam the energy of the 
incident electron beam should increase (Georg et al. 2 0 1 1 ). Another result of softening 
the beam is the increase in patient surface dose (Vassiliev et al. 2006a). However, there 
is an advantage in the softness of X-ray spectra in terms of portal imaging which will be 
described in section 4.3.
Dalaryd et al. (2010) found that the X-ray spectra of FFF beams have less off-axis 
variations inside the beam field. Figure 4.1 shows the difference between the shape of 
X-ray spectra of FF and FFF beam of a 6  MV linac at the iso centre and at the edge of 
the field-size (Dalaryd et al. 2010).
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Tsiamas et al. (2014) carried out an intensive MC study to determine the spectra of 
large number of clinical field sizes without a EE. They found that the variation in spectra 
between different field sizes is smaller with the absence of the EE. This is due to the 
increase in the number of low energy photons.
In addition, the increase in low energy photons was found to increase the dose en­
hancement factor using nanoparticles. Detappe et al. (2013) studied the effect of using 
the FEE beam on endothelial dose enhancement factors (EDEE) if gold nanoparticles 
were used. They found that (using MC method) the EDEE increased when the FEE 
beam was used. Moreover, the EDEE was found to be also increased with field size.
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F igure 4.1: Comparison between photon spectra at central axis (solid) and at field edge 
(dashed line) of a 40x40 cm  ^ field-size for FF (a) and FFF (b) of a 6 MV beam (Dalaryd
et al. 2 0 1 0 ).
4.1.3 D epth dose
The change in the photon spectrum and mean energy of FFF beams has an effect on the 
depth dose in the central axis. The percentage depth dose (FDD) curves of FFF beams 
show a slightly faster fall-off after the depth at maximum dose (dmax) compared to the 
FF beams (figure 4.2).
Almberg et al. (2012) found that the decrease in FDD at depth after 25 cm is about 
10%. The FDD of FFF beams were found to be equivalent to those of FF beams with 
lov/er eiiergries. I^ 3r ezcample, tlue F>DI) afteir of tile 6  M l/ ]M?ir beam Tanis foiinci to 
be similar to that of the 4 MV FF beam. Similarly, the FDD after dmax of the 18 MV
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FFF beam was found to be similar to that of the 15 MV FF beam (Georg et al. 2011, 
Tsiamas et al. 2 0 1 1 , Vassiliev et al. 2006a).
—  wrth fiher, 6 MV
  no filter, 6 MV
* with filter, 4 MV
0.8 
8  0.7
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Q
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20
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F igure 4.2: The FDD curves of the 6 MV FF (dashed) and FFF beams (solid) and the 4 
MV FF beam (filled circles) for a 10x10 cm^ field-size (Vassiliev et al. 2006a).
4.1.4 Entrance dose
The entrance or surface dose is a parameter defined as the relative dose at the first few 
millimetres (usually between 0-5 mm) with respect to the dose at d^ax- Since removing 
the FF increases the portion of low energy photons as well as increasing the electron 
contamination, the entrance dose increases (Vassiliev et al. 2006a).
Wang et al. (2012) measured the surface dose for 6  and 10 MV FF and FFF beams 
of a TrueBeam linac for different field sizes up to 10x10 cm^. They found that the 
surface dose increases with field size and energy. In addition, the FFF surface dose 
was found to be slightly higher than that of the FF beam. For example, the doses at
5 mm below the water phantom surface for a 10x10 cm^ field size were found to be 
0.87±0.01(1SD), 0.91±0.02(1SD), 0.72±0.01(1SD) and 0.77±0.00(1SD) for 6  MV FF,
6  MV FFF, 10 MV FF and 10 MV FFF beams, respectively (Wang et al. 2012). For 
larger field sizes (> 1 0 x 1 0  cm^), the difference in surface dose between flattened and 
unfiattened beams decreases with field sizes (Cashmore 2008, Kragl et al. 2009, Vassiliev 
et al. 2006a). Figure 4.3 shows that as the field size increases, the variation in surface
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dose between flattened and unflattened beams decreases.
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F igure 4.3: The varation in entrance dose at 0.3 mm from the water phantom surface with 
field size for 6 (circle)and 18 MV (square) beams with (solid line) and without (dashed line) a
FF (Vassiliev et al. 2006a).
Hrbacek et al. (2011) reported that the surface dose increased by 10% when the FF 
was removed for 6  and 10 MV photon beams during commissioning of a TrueBeam linac. 
On the other hand, measurement done by Dzierma et al. (2013), showed that there is no 
significant difference in surface dose between flat 6  MV photon beams and FFF 7 MV 
beams of a Siemens Artiste linac.
4.1.5 Beam profile
Removing the FF, as mentioned before, affects the linac beam uniformity. However, this 
is not a problem nowadays since new techniques have been introduced such as IMRT 
which can compensate for this effect by adapting the MLC during the treatment course 
to adjust the fluence distribution inside the beam field. Besides, the flattened beam 
produces only a uniform dose distribution inside a homogenous phantom and therefore, 
a flattened beam does not provide an advantage in a realistic case. In addition, the beam 
profile of the unflattened beam has less variation with depth in the homogenous phantom 
compared with a flattened beam as seen in figure 4.4 (Titt et al. 2006, Vassiliev et al. 
2 0 0 6 a ) .
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F igure 4.4: The variation in beam profile with depth for 10x10 cm^ 6 MV FF and FFF
beams (Vassiliev et al. 2006a).
Vassiliev et al. (2006a) found that the variations between depth 3 and 2 0  cm for a 
10x10 cm^ field size were 1.1 and 0.74 for 18 MV FF and FFF beams, respectively. 
Several studies have explored the possibility of modifying the linac head or incident 
electron beam properties to produce beam profiles with better fiatness.
Chofor et al. (2011) introduced a Model for the linac head between the FF and FFF 
modes using the MC technique. They introduced what was called a directional-selective 
filter instead of the conventional FF to produce a uniform beam field up to a field within 
a 15 cm diameter circle.
Tsiamas et al. (2 0 1 1 ) found that by increasing the nominal electron energy up to 8 .5  
MeV and changing the electron beam angular spread up to 1 0 °, complete fiatness for beam 
profiles up to 15x15 cm^ field size and partial fiatness for beam profiles between 15x15 
- 30x30 cm^ field sizes. They also found that the beam profile fiatness is independent of 
the spatial spread of the electron beam.
(Zavgorodni 2013) carried out several MC simulations in order to find out the optimum 
angular distribution of the incident electron beam that hits the target. He found that 
by changing the convergence angles of the incident electron beam up to 2 0 °, the flatness 
of the 6 FFF beam was better or at least comparable with the fiattend beam up to field 
size within a 35 cm diameter circle. However, the dose rate in this scenario decreased to
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become only 1.25 higher than the flattened 6  MV beam.
In addition, the slight change in the FF positioning severely affects the beam flatness 
and symmetry. Cashmore (2008) changed the 2 R current (which controls the symmetry 
along the electron gun- target axis) and the bending fine current by ±50 and ±20 mA,
respectively. He found that the asymmetry and the non-fiatness were more than 50%
higher for the flattened beam compared with the unfiattened one.
4.1.6 Penumbra
Penumbra is defined, according to existing protocols, as the distance between the 2 0 % 
and the 80% dose levels in the field edge at àmax when the beam profile is measured at 
100 cm SSD (Podgorsak & IAEA 2005). The penumbra of FFF beam for small field sizes 
(less than 10x10 cm^) was found slightly smaller than that for the FF beam.
Cashmore (2008) found this reduction of the order of 0 .5  mm. The penumbra for a 
field shaped by MLC was found to be higher than that shaped with jaws (Ponisch et al.
2006). However, as the field size increases, the 80% will move towards the central axis 
and thus a new definition of the penumbra is required (Cashmore 2008).
Ponisch et al. (2006) derived a new definition of penumbra for FFF beams from the 
spatial distance between 2 0 % and the 80% dose levels of the nominal dose, which is 
defined as (see fig 4.5):
-^n — D q a x  (4 .1)
Where; is the FFF dose at the inflection point, D f  i s  the FF dose at the inflection 
point and D c a x  is the FF dose at the central axis.
Using this definition, Hrbacek et al. (2011) found that the penumbra of the 6  MV 
FFF beam, during the commissioning of a TrueBeam linac, to be 0.3 mm less than that 
for 6  MV FF beam for a 10x10 cm^ field size. However, this value decreases with depth 
and the penumbra of the FFF beam for large field sizes becomes slightly larger than that 
of the FF beam.
In addition, Yarahmadi et al. (2013) calculate the penumbra of the 6 FFF photon beam 
in for small radiosurgical fields using MC technique. They found that the penumbra width 
improved by 0.5, 0.3, 0.2 and 0.2 mm for field sizes with diameter of 0.5, 1, 2 and 3 cm, 
respectively. They concluded that the penumbra can decrease up to 17% if the nominal 
electron energy decreased to 2  MeV.
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Figure 4.5: The definition of the of the 6 MV FFF beam. The left axis shows the defined 
parameters of the FF beam profile (grey), whereas the right axis shows the defined parameters 
of the FFF beam profile (black) (Ponisch et al. 2006).
4.1.7 Out-of-Field dose
Another advantage of removing the FF is the reduction of the out-of-field dose which 
reduces the probability to induce secondary cancers. Diallo et al. (2009) have reported 
that about 6 6 % of secondary cancers occur at the edge of the treatment field and 2 2 % 
at a distance > 5 cm from the edge of the treatment field. The out-of-field dose depends 
on several factors, the head and MLC leakage and the patient and linac head scatter.
Dalaryd et al. (2010) calculated the ratio of scattered photons from the linac head 
using MC techniques and they found that the scattered ratio was reduced by 31.74:0.1% 
and 47.64:0.2% for 6  MV and 10 MV beams, respectively. In addition. The leakage of 
MLC was also reduces by the removal of FF. Kragl et al. (2009) reported that the leakage 
of MLC was 1.704:0.01%, 1.40±0.1%, 1.704:0.01%, 1.504:0.01% for 6  MV FF, 6  MV FFF, 
10 MV FF and 10 MV FFF beams, respectively.
However, another study by Kry et al. (2010) reported that the reduction in out-of-field 
dose is not always achievable and depends on the patient and treatment parameters such 
as the field-size. Kry et al. (2010) studied the out-of-field dose from 6  and 18 MV FFF
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beams and they divided the out-of-field region into three regions. The first region was 
located at a distance < 3 cm from the field edge. The dose, in this region, reduced due 
to the reduction in the linac head scatter. The second region was located between 3-15 
cm from the field edge. The dose increased in this region due to the increase in patient 
scatter. The last region was located 15 cm from the field edge and the dose decreased 
in this region due to the reduction in head leakage. They also concluded that the FEE 
plays a role only for treatment field sizes less than 4x4 cm^ and therefore the optimal 
effect from FFF beam would only be achieved with stereotactic treatments.
In addition, Cashmore et al. (2 0 1 1 ) reported that 2 2 % of pediatric cancers occur at > 5  
cm from the PTV. They investigated the benefit of using IMRT with an FFF beam. They 
compared 5 IMRT cases with and without FF. Both beams produced similar covering to 
the PTV and sparing to OAR but FFF beam reduced the out of field doses to normal 
tissues up to 50 cm from the tumour on average by 64%. They concluded that this 
reduction would reduce the secondary induced cancer.
4.1.8 Total scatter factors
The total scatter factors (also called the output ratio in-air). Sc, is defined as the ratio 
of the dose rate for a specified field size at dmax over the dose rate at the same depth 
for the reference field size 10x10 cm^ (Ponisch et al. 2006). This factor indicates the 
variation in the incident photon fluence per MU with collimator settings. The factor is 
a very important parameter to achieve accurate dose calculations especially for complex 
treatment modalities such as IMRT and VMAT (Georg et al. 2011). The variation in the 
total scatter factor with field size for the unfiattened beam was found to be lower than 
that of the FF one (Cashmore 2008, Ponisch et al. 2006, T itt et al. 2006). Figure 4.6 
shows the variation in total scatter factor with field size for the FF and FEE beams.
4.1.9 Neutron Contamination
Flattening filters are made of medium and/or high Z materials which firstly, increase the 
head scatter that increases the photoneutron production from various head components 
(i.e. primary collimator, jaws and MLC) and secondly, can produce noticeable photoneu­
tron contributions (in the case when high Z materials are used). Several studies have
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F igu re 4.6; The variation in total scatter factor with field size for FF and FFF beams
(Cashmore 2008)
investigated the effect of removing the flattening filter on photoneutron production (Kry 
et al. 2008, 2007, Mesbahi 2009, Mesbahi & Nejad 2008).
Kry et al. (2007) used gold activation foils inside polyethylene cylinders with cadmium 
cover to measure the neutron fluence and neutron dose equivalent for the 18 MV FFF 
beam of a Varian 21 EX linac in different positions and field sizes. In their measurement 
the dose per MU was 1 and 3.65 cGy MU  ^ for EE and FFF beams, respectively. They 
found that the neutron dose equivalent reduced by 20.O i l .2 % per MU which is equivalent 
to a 76±5% reduction per Gy at the dmax- The total reduction in neutron dose for IMRT 
treatment was about 69.0±4.1%.
Kry et al. (2008) used gold foils with a set of six Bonner spheres ranging from 5 
to 30 cm to measure the neutron fluence and neutron dose equivalent for the 18 MV 
FFF beam. Both MLC and Jaws were closed. They found that the Q was reduced 
by 81±5% and neutron dose equivalent at surface, Hq, reduced from 2.31i0.14 (with a 
FF) to 0.45i0.03 mSv Gy“  ^ (without a FF). They also used the MCNPX MC code to 
calculate the ratio of neutrons produced from each linac head component for different 
field sizes. The contribution of FF on neutron production ranged from 12.80i0.13% to
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13.50±0.14% for 0x0 to 10x10 cm^ field sizes, respectively.
Mesbahi (2009) carried out a MC simulation to model the 18 MV FFF beam of an 
Elekta linac and calculate the electron and neutron contaminations. He found that the 
electron contamination increased by 1.6 and 1.45 times for 10x10 and 30x30 cm^ field 
sizes, respectively. While the neutron level reduced by 61±0.6% and 47±0.5% for 10x10 
and 30x30 cm^ field sizes, respectively, when the FF was taken out.
The neutron reduction results in a decrease in the number of photons created in the 
target required to produce the same dose at the iso centre as well as a decrease in the head 
scatter. To my knowledge, no one has studied the effect of removing the FF on neutron 
production from the FFF linac beam with energy other than 18 MV except Chofor et al. 
(2011) who calculated the difference in photoneutron strength for a 15 MV FF and FFF 
Siemens Primus linac) and the effect of field-size of FFF linacs on neutron production 
has not been studied in detail even for a 18 MV FFF beam.
4.1.10 Biological effects
Since removing the FF increases the dose rate or in other words the dose per pulse (DPP), 
several questions have been raised if this increase causes any biological consequences to 
both normal and cancerous cells such as increasing or decreasing in cell survival factors. 
Several studies have been carried out in the last three years to investigate this effect.
Lohse et al. (2011) studied the radiobiological effect of high DPP of FFF beams. 
They used the human gilioblastoma cell lines T98G and U87-MG with the p53 mutation. 
They irradiated both cell lines with 5 and 1 0  Gy at different dose rates (2 0 , 400 and 2400 
cGy/min) using 10 FF or 10 FFF beams. In addition, they irradiated both cell lines with 
the same dose rate (400 cGy/min) using both 10 FF and 10 FFF beams by changing 
the PER and DPP. They found that by increasing the DPP, the cell survival reduced. 
Furthermore, there was no difference between FF and FFF if they have the same DPP. 
However, other studies have obtained different results with different cell lines.
Sprensen et al. (2 0 1 1 ) used the cell line V79 of Chinese hamster lung fibroblasts and 
FaDuDD a subline of FaDu a human head and neck squamous cell carcinoma. They 
irradiated them with 6  MV FF and/or FFF beams at different dose rates ( 5, 10 and 30 
Gy/min). They found that there was no change in cell survival.
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Karan et al. (2013) studied the same effect on two human carcinomas (H460 (lung) 
and SiHa (cervix)) and the cell line V79 of Chines hamster lung fibroblasts to model 
the normal cell response. They irradiated these cell lines with 6  MV FF and/or FFF 
beams at different dose rates (400 cGy/min FF, 400 cGy/min FFF and 1200 cGy/min 
FFF). The total dose was 2 , 5 and 10 Gy depending on the cell line. There results agreed 
with Sprensen et al. (2 0 1 1 ) as they did not observe any change on cell survival for both 
beams. They concluded that the use of a FF beam is a better option for gated lung 
cancer treatment and SBRT since it reduces the time with no effect on cell survival as 
well as increasing the irradiation time (using the conventional beam) reduces the tumour 
local control especially for the lung cancer.
Verbakel et al. (2013) compared the cell survival between high dose rate from a FFF 
beam with low dose rate from a FF beam. They used different cell lines (D384, T98 and 
SW1573). They irradiated them with single doses (0 - 1 2  Gy) and with fractional doses 
2-3 Gy for 5 days. They used different dose rates (600 cGy/min) using a 6  MV FF and 
(2400 cGy/min) using a 10 MV FFF beams. They found that there was no change in 
cell survival for all cell lines. King et al. (2013) studied in vitro the effect of increasing 
the dose rate of FFF linacs. They used two human cancer cells DU-145 (prostate) and 
H460 (lung). They irradiated them with 6  MV FF and FFF beams. Different dose per 
pulses were used (400MU/min FF (DPP=2688.2 Gy m in~\ PRF=240 Hz) , 400 MU/min 
FFF (DPP=6272.4 Gy m in '^  PRF=103 Hz) and 1400 MU/min FFF (DPP=6272.4 Gy 
min“ ,^ PRF=360 Hz)). Again no effect was found.
Moreover, Berbeco et al. (2012) studied the damage to DNA enhancement by using the 
FFF beam with gold nanoparticles in vitro. They found that the damage enhancement 
increased by using the FFF beam due to the increase in low energy photons.
In my point of view, the biological effect still needs more investigation in vitro for 
different cancerous and normal cells as they respond differently to radiation. In addition, 
a clear opinion whether the increase in DPP using FFF beams could cause any toxicity in 
vivo will be obtained after statistical analysis of several years of patients being followed- 
up. Until now, most studies evaluated only the early side effects after no more that 
one year of patient follow-up as reported by the Alongi et al. (2013) study who did not 
observe any high-risk for all patients (n=40) having hypo-fractionated SBRT prostate 
cancer using FFF-VMAT after 1 1  months in being followed-up.
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4.2 The effect of adding a plate in place of the FF 
on ionisation chamber response and beam char­
acteristics
In order to reduce the entrance dose of the FFF linac, several studies have investigated 
the effect on surface dose by adding a plate made of different materials in place of the 
FF and increasing the signal in the ionization chamber.
Cashmore (2008) examined the effect of 1 .1  mm Al and 1 .9  mm Cu plates for an 
Elekta 6  MV photon beam on surface dose and ionisation chamber response. Both plates 
increased the signal in the ionization chamber but the reduction in the surface dose was 
not achieved.
T itt et al. (2006) used MC methods to study the effect of 1 1  mm nylon and 2  mm 
copper plates on electron and photon fluences for a 6  MV Varian photon beam. The elec­
tron fluence decreased by a factor of 2.7 and 3.1 for nylon and copper plates, respectively, 
but still only 48% and 28% higher compared to the FF beam, respectively. The photon 
fluence was found to be 40% and 37% higher than that for the FF beam by adding the 
nylon and copper plates, respectively. Similarly, a 1 mm steel plate was used in a Varian 
2300C linac by Stathakis et al. (2009) on both photon modes 6  MV and 18 MV for the 
same purpose but no results regarding the surface dose were published. Thicker plates 
have also been examined by several authors. 6  mm copper was used in studies on Elekta 
linacs (Kragl et al. 2009, Tyner et al. 2009). The thicker plates have the advantage in 
safety aspects if any failure occurs in the target (Georg et al. 2011).
However, more investigations in the plate thickness and composition are required 
in order to obtain the optimum result in the ion chamber response and surface dose. 
Additionally, the effect of the plate on neutron production and out-of field doses has not 
been examined.
4.3 Portal Imaging
Megavoltage cone beam CT (MVCBCT) is one of a number of image guided modalities 
that are used to reduce the physical uncertainties occurring during the course of radio­
therapy treatment, related to patient position on the couch of a linear accelerator from
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fraction to fraction, including organ movement and deformation of tissues (Sharpe et al. 
2007). Although the introduction of kilovoltage cone beam CT (kVCBCT) provides the 
opportunity to acquire images of much improved quality, interest in MVCBCT images 
still exists due to the simplicity of dose modelling in the treatment planning system 
(Gayou 2 0 1 2 ).
Several studies have been conducted to improve the quality of MVCBCT images by 
changing acquisition parameters such as number of projections, dose exposure and the 
scan arc length or by changing image reconstruction parameters such as the reconstruction 
filter, image thickness and pixel size (Gayou 2 0 1 2 ). Improvements in image quality were 
obtained by changing the material and thickness of the target and by removal of the 
flattening filter from the linac head.
Tsechanski et al. (1998) introduced a thin target approach for portal imaging, sim­
ulating several targets with different materials and thicknesses, finding the production 
of sharper images in using a 4 M V unfiattened beam with a 1.5 mm copper or 5 mm  
aluminium target and a new Kodak mammographie him. They concluded that using 
lower atomic number Z materials did not produce significant improvement.
Tsechanski et al. (2005) proved that 150 keV photons produced from the copper target 
of an unfiattened beam. Low-energy photons (<150 keV) were essential for obtaining high 
quality X-ray radiographs. They found that the relative low-energy photons contribution 
in the images produced using Kodak ECL films is about (12-14)%.
Flampouri et al. (2 0 0 2 ) found the optimum imaging arrangement for a 6  MV beam 
to be a 6  mm aluminium target, improving the contrast by 19% for a 1 .4  cm slab of bone 
inside 5 cm of water.
Roberts et al. (2008) carried out a MC simulation and experiment to study the effect of 
using a low Z target with an X-ray Volume Imaging-panel (XVI-panel) detector (Elekta, 
Stockhholm) instead of the conventional imaging technique. They found that by using 
this setup, the contrast for a 1 .6  cm slab of bone inside 5 .8  cm of water was improved 
by a factor of 4.62 while it reduced to a factor of 1.3 if the same slab of bone was placed 
inside 25.8 cm of water.
Faddegon et al. (2010, 2008) developed a new image beam line (IBL) to be used with 
Siemens LINACs. They used a carbon target instead of electron foils and irradiated 
it with a 4.2 MeV electron beam, obtaining an improvement in contrast and spatial
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resolution of a factor of 3 and 2 respectively, with the same dose to patient or in acquiring 
an image with the same quality but at a lower dose.
Connell & Robar (2010) performed several MC simulations to study three target 
materials (beryllium, aluminium and tungsten) with different thicknesses, irradiating 
them with 4.5 and 7.0 MeV electron energies. They found that the thinner target with 
the higher electron energy produced images with better modulation transfer function 
(MTF).
In addition, Tyner et al. (2009) examined the change in the response of the electronic 
portal imaging device (EPID) of unfiattened beams. They found that the sensitivity 
of the EPID increased and the measured profile had minimum change with increasing 
phantom thickness. Additionally, the shape of X-ray spectra of FFF beam does not have 
as much dependency on the position inside the field-size as the FF beam.
All studies above suggest modification of linacs by adding a thick low Z or thin 
medium Z target and/or the design of a new imaging line. Such changes would present 
a number of developmental issues, at least in developing countries in which linacs in 
many cases lack an on-board imager and have not yet established an IGRT protocol. In 
addition, some of these suggestions have either not been accompanied by studies of the 
effect of reducing the thickness of the target on the electron contamination or have added 
a plate of Perspex to reduce the electron contamination in the imaging beam leading to 
absorption of a fraction of the low energy photons.
4.4 Shielding
As discussed in the previous sections, FFF beams have several advantages compared with 
FF beams regarding the head radiation leakage. X-ray Spectra, photoneutron production, 
total scatter factor and out-of-field dose. These advantages depend on a number of fac­
tors: distance, depth, beam energy, treatment unit and treatment technique. Therefore, 
new treatment vaults hosted FFF linacs can have benefets in term of structural shield­
ing design by reducing the concrete thickness and building cost. However, as advanced 
radiotherapy treatment modalities have been receiving significant interest recently, all ra­
diation protection aspects must be critically examined since they can affect staff, patients, 
bystanders and the public.
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The main purpose of radiation shielding is to keep radiation exposures of humans at 
an acceptable level. In the case of medical linacs as radiation sources, it is important to 
have treatment rooms with appropriate shielding to prevent any radiation hazards that 
may arise during the usage of these linacs (NCRP 2005).
The two important factors associated with the FF removal and have an impact on the 
structural shielding design of a treatment vault are the softer X-ray spectra and lower ra­
diation leakage. Both factors have been confirmed to affect radiation dose measurements 
around the linac head and inside and outside the treatment vault. A few studies have 
been performed recently regarding the effect of FF removal on shielding design such as 
that carried out by Kry et al. (2009) and Jank et al. (2014).
Kry et al. (2009) calculated basic shielding parameters such as the primary tenth value 
layers (TVLs) for linacs operated with FF and FFF modes. They found that the primary 
TVLs reduced on average by 1 2 % and the total concrete thickness was reduced by 10-20%. 
The latter is equivalent to a 36 m^ reduction of the total amount of concretes required 
for building a treatment vault for dual energy linac. The total number of neutrons is 
expected to be reduced by a factor of 3.7 depending on the previous study by Kry et al. 
(2008, 2007) who found that the total number of MUs required for a teatment with a 
FFF beam is 0.38 of what is required with a FF beam. This reduction can reduce the 
occupational exposure and/or shielding cost.
Jank et al. (2014) assessed the effect of an Elekta FFF linac operated at energies of 
6  and 10 MV on shielding constriction. They found that the reduction in primary and 
secondary barrier thicknesses was 8 % and 11.4%, respectively. They concluded that the 
installation of a FFF linac reduced the shielding cost and if the installation was carried 
out in an exist vault, it could increase the workload per week and reduce the occupational 
exposure to staff. They did not consider the neutron production in their work. However, 
as reported in these previous studies, the reduction in the number of neutrons is only 
estimated based on one energy and the reduction in MUs from a certain case of an IMRT. 
Thus further investigation on the neutron dose from FFF linacs for different energies and 
radiotherapy teatements is required as the number of MUs for FFF treatments is found 
to be the same, lower or higher than that for FF treatments from case to case.
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4.5 Planning studies
Although most trials used FFF beam with IMRT and VMAT because of the non- 
unifomity of the FFF beam, Kretschmer et al. (2013) assessed the impact of using a 
FFF beam with 3D-CRT. They created 52 plans (13 breast, 11  neurocranium, 7 lung, 
10 bone métastasés and 11 prostate) using both conventional and FFF 3D-CRT. Their 
results showed similar PTV coverage for most cases. Some significant reduction in OAR 
dose for breast and neurocranium cases when the FFF beam was used. However, for 
prostate and lung cases, some OAR doses were higher when the FFF beam was used. 
In addition, for all FFF plans the number of fields to produce the objective coverage 
increased 1.9-4.5 times and the average total number MUs increased by 1 .3 -2 .2  times 
which might affect the benefit of reducing the out-of-field dose resulting form the usage 
of the FFF beam.
More studies with different cases, tumour size and beam energy are required to obtain 
a clearer opinion weather the FFF beam is suitable for treatments with 3D-CRT or is it 
only limited for static and rotational IMRT techniques?
4.5.1 Prostate cancer
Statistically, prostate cancer is one of the most commonly diagnosed and cause of death 
of cancer of men worldwide (Jemal et al. 2010). As the prostate is located next to several 
vital organs inside the human body such as bladder and rectum, the better the sparing 
of OAR during the radiotherapy course, the better the treatment will be.
Vassiliev et al. (2007) studied the feasibility of using the FFF linac for IMRT of 
prostate cancer. They created IMRT prostate plans using 6  FF, 6  FFF, 18 FF and 
18 FFF beams of a Varian linac. They found that all created plans with FFF beams 
were clinically accepted. In addition, as the dose rate increased, the number of MUs 
was reduced by factor of 2  and 2.6 for 6  and 18 MV FFF beams, respectively. They 
concluded, that this reduction would reduce the out-of-field doses to normal tissues.
Zwahlen et al. (2012) performed 7 VMAT treatment plans of prostate cancer with 6  
FF, 6  FFF, 10 FF and 10 FFF beams. The dose rate was 600 MU/min for FF beams and 
1200 MU/min for FFF beams. They found that the conformity and homogeneity inside 
the PTV were similar for all beams. The 10 FFF beams gave slightly better bladder
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sparing (2.3%) as well as reducing the whole body dose. In addition, they found by using 
a single arc and FFF beam, the treatment time was reduced by 35±10( 2SD)%.
Alongi et al. (2013) evaluated the possibility of using a hypo-fractionated SBRT 
prostate cancer (35 Gy in 5 days) with 1 0  MV FFF-VMAT. The evaluation of 40 patients 
after 1 1  months follow-up showed that 26/40 patients were at low-risk and the other 11  
patients were with intermediate-risk according to NCCN (National Comprehensive Can­
cer Network) criteria. They concluded that this techniques was feasible and tolerated in 
an acute setting but longer follow-up was required to assess the late toxicity and outcome.
Lechner et al. (2013) compared the IMRT and VMAT quality for prostate cancer 
created by the FF and FFF photon beams using Pareto optimal front concept L They 
found that the use of the FFF beams increased the total number of MUs and the total 
time of VMAT plan increasd by 22%. However, the use FFF beam was found to reduce 
the time of IMRT plan by 18% and reduce the Vs^y by 5 %. They concluded that the 
advantages of the FFF beams can be clearer with smaller tumour sites.
4.5.2 Breast cancer
It is well known that breast cancer is one of the most common cancers that can lead to 
death in women worldwide (Jemal et al. 2010). To study the effect of removing the FFF 
on breast treatment outcome, Spruijt et al. (2013) carried out a clinical investigation 
on unfiattened beams for left breast radiotherapy as the left breast irradiation gives a 
certain dose to the heart compared to the right breast irradiation. They performed 10 
plans for left breast with different IMRT techniques (i.e. step and shoot, dynamic, hybrid 
and electronic tissue compensator) using FF and FFF beams. To verify these plans for 
out-of-field dose, measurements were carried out using an ionisation chamber and simple 
cube phantom. For all IMRT techniques, the deviation in PTV coverage, homogeneity 
and conformity between the two beams was within 3 %. The doses to OARs such as heart 
and ipsilateral lung were similar for both beams. The delivery time of FFF plans was 
found to be 31% less than of FF one. Measurements of out-of-field doses were significantly 
higher than calculated with treatment planning system. They concluded that all IMRT 
modalities with and without FF were clinically acceptable but the planning system was
^Pareto optimal front concept: is the compromise solution of several objectives that differ with each 
other and enhance any one of them can decline somewhat one of the other.
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not capable in obtaining an accurate out-of-field calculations.
Subramaniam et al. (2 0 1 2 ) studied the potential of using FFF-VMAT for chest wall 
radiotherapy after mastectomy. They compared 1 0  plans created using 3D-CRT, VMAT 
and FFF-VMAT. They found that the PTV coverage was similar for all techniques. 
However by using FFF-VMAT, the total heart dose was reduced by about 4 .5  and 15 Gy 
compared with VMAT and 3D-CRT, respectively. They concluded that the FFF-VMAT 
produced acceptable plans with the potential of reducing the dose to the adjacent OAR.
4.5.3 Lung cancer
Zhang et al. (2011) performed 15 plans of lung SBRT treated with 3D-CRT, coplanar 
VMAT with FF and non-coplanar VMAT with and without FF. They found that the 
VMAT plans produced better conformity and mean dose than 3D-CRT especially for 
FFF-VMAT. For example the conformity index was 1.44, 1.23, 1.22 and 1.19 for 3D- 
CRT, coplanar VMAT with FF and non-coplanar VMAT with and without FF plans, 
respectively. Again the total MUs were found to be higher for N-FFF-VMAT as the linac 
was calibrated to produce the same dose per MU for all treatment modalities.
Navarria et al. (2013) assessed the feasibility of using FFF-VMAT for SBRT lung 
cancer. 8 6  and 46 patients underwent SBRT with FF 3D-CRT and FFF-VMAT, respec­
tively. The results obtained showed similar dose conformity to target but treatments with 
FFF-VMAT had a significant reduction in the dose to ipsilateral lung and in beam-on 
time. The beam-on time reduced from about 8  min using FF 3D-CRT to less than 2 
min when FFF-VMAT was used. They concluded that SBRT lung cancer with FFF- 
VMAT produced safer high dose delivery with shorter treatment time regarding early 
radio-biological respond than FF 3D-CRT.
Ong et al. (2013) studied the impact of using the FFF beam with VMAT SBRT lung 
cancer at different rates. They analysed the treatment of 7 tumours with motion less than 
20 mm. The 10 FFF beam with two different dose rates of 400 and 2400 MU/min was 
used for the irradiation. In addition, a controllable phantom with sinusoidal longitudinal 
motion and GafChromic films were used for treatment verification. They found that the 
maximum dose deviation for 2400 MU/min dose rate plans was less than 5  and 3 % when 
measurements were combined under 2  arcs and 2  and 3  different initial breathing phases, 
respectively. They concluded that by using the higher dose rate and the combination of
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2  arc irradiation and >  2  initial breathing phases, VMAT SBRT lung cancer plans could 
be produced with an acceptable level.
Nakagawa et al. (2014) studied the impact of using the FFF beam in VMAT for lung 
cancer on delivery time. They found that the delivery time decreased from 202.7±2.3 s 
to 904:2.1 s when the FFF beam was used. They also found that the FF and FFF beams 
produced similar dose distribution.
4.5.4 Oesophageal cancer
Nicolini et al. (2 0 1 2 ) studied the potential of using a RabidArc® with or without FF 
for oesophageal cancer against 3D-CRT and IMRT. Plans with different modalities were 
created using 6  MV beam for 10 patients. The results showed that VMAT has similar 
PTV coverage as IMRT and better than 3D-CRT. the mean lung dose was 18.3, 12.2, 
11.3 and 10.8 Gy for 3D-CRT, IMRT, FF-VMAT and FFF-VMAT, respectively. They 
concluded that the RapidArc® plans was compared to IMRT with slightly better OAR 
sparing especially without FF . Moreover, the FFF-VMAT gave the potential of reducing 
the treatment time and reduce the dose to normal tissues.
4.5.5 Nasopharyngeal cancinoma
Zhuang et al. (2013) assessed the role of FFF-VMAT in treating the nasopharyngeal can­
cinoma. Plans of 10 patients were created with IMRT, FF-VMAT and FFF-VMAT. The 
results obtained showed no difference in the PTV coverage but the FFF-VMAT had the 
lowest conformity and homogeneity indexes in the PTV and the highest mean dose com­
pared with the other techniques. The delivery time was almost the same for FF-VMAT 
and FFF-VMAT but 70% less than the delivery time for the IMRT. They concluded that 
the FF-VMAT was the best option for treating the nasopharyngeal cancinoma.
4.5.6 Head and neck cancer
Lechner et al. (2013) compared the IMRT and VMAT quality for six Head and neck 
cancer patients created by the FF and FFF photon beams using Pareto optimal front 
concept. They found that the use of the FFF beams substantially increased the total 
number of MUs. The total time of VMAT plan with the FFF beam increasd by 16%
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while it decreased by only 4% in the IMRT plan. The Vscy was almost the same for both 
beams.
4.5.7 Brain m étastasés
Stieler et al. (2013) investigated the potential of the 6 FFF beam in Intensity modulated 
radiosurgery of brain métastasés. They created VMAT and IMRT plans of 15 patients 
with and without a FF. They found that both beams produced similar PTV coverage 
with the same total number of MUs. However, the mean treatment time in 6 FFF plans 
reduced by 51.5%.
Based on all studies described above, it can be concluded that radiotherapy treatment 
with a FFF beam can give for most cases same tumour coverage with same or slight 
improvement on OAR sparing and with significant reduction in delivery time. However, 
these improvements depend on several factors such as treatment type, tumour size, total 
number of MUs, number of segmentations and beam energy. In addition, it can be noted, 
that treatments with FFF beam energy higher than 10 MV have not been fully examined 
even for the 18 MV beam which it was carried out by Vassiliev et al. (2007).
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Chapter 5 
M onte Carlo study of Varian Clinac 
with and w ithout a flattening fllter
The Monte Carlo (MC) method is an excellent tool used in radiotherapy and dosimetry 
applications. Basically, it uses the information of the probability distributions leading 
the individual interactions of particles (e.g. electrons, photons, neutrons etc.) in materi­
als to simulate the random path of individual particles by using a good random number 
generation source. This method estimates a good approach of the true average distribu­
tion of particles which have energies from 0.001 MeV up to 50 MeV (Limit Theorem) by 
increasing the number of particle histories simulated (in the order of 1 0 -^ 1 0  ^ to simulate 
radiotherapy treatment planning). MC simulation is achieved by (Mayles et al. 2007):
1 . Choosing the particle energy, direction and initial position.
2 . Choosing the distance to the first interaction area and transferring the particle to 
this area.
3. Choosing the type of interaction (Coulomb force, Compton scattering, photo-electric, 
etc.)
4. Choosing the direction, energy, etc. of secondary particles
5. Transferring the scattered particle until it skips out from the geometry or it reaches 
pre-fixed cut-off energy.
6 . Scoring the deposited dose, energy, fiuence etc. in the area of concern.
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7. Repeating steps 1 -6  for a large number of particles until the statistical uncertainty 
reduced to a suitable value.
Two MC codes^ere used in this project ’’FLUKA” developed by (CERN, Switzer- 
land) (Ferrari et al. 2005) and ’’BEAMnrc/DOSXYZnrc” developed by (National Re­
search Council, Canada) (Rogers et al. 2001, Walters et al. 2005). Each code has advan- 
tages and limitations compared with other codes.
The advantages of FLUKA over other codes such as BEAMnrc are its possibility to 
model not only linac heads and/or phantoms but also to simulate detectors, treatment 
rooms, imaging devices, other types of accelerator (e.g. cyclotrons) and more. Addition­
ally, it can simulate the interaction and transportation in m atter of about 60 different 
particles in addition to photons, electrons and positrons such as protons, neutrons and ol 
particles. Therefore, the photoneutron production from high energy linacs can be simu­
lated accurately using this code which is not included in BEAMnrc/DOSXYZnrc (Ferrari 
et al. 2005).
The advantages of BEAMnrc/DOSXYZnrc compared to FLUKA are that it can model 
dynamic radiotherapy treatments such as IMRT and VMAT with only one simulation 
while in FLUKA this has to be carried out by a large number of simulations beam by beam 
(or even sub-beam by sub-beam). In addition, BEAMnrc code can read phase-space files 
(e.g. TrueBeam phase-space files) which are available sometimes from manufacturers 
(e.g. Varian) as an alternative from giving the linac head specification (Rogers et al. 
2001, Walters et al. 2005). To reduce the time required to finish all MC simulations 
and decrease the uncertainty to acceptable levels, three different computers (a University 
desktop with 4 cores, a personal laptop with 8  cores and a University server computer 
with 16 cores) were used. All these computers have UNIX operating systems.
This chapter covers all studies carried out (during my PhD project) to study the 
effect of the FF removal on dosimetric properties and treatment outcome of the Varain 
Clinac. This includes the dosimetric properties of the 15FFF photon beams, the neutron 
production inside treatment rooms housing FFF linacs at different energies, the quality 
of MVCBCT images by using the unfiattened 6  MV photon beam (6 FFF) with a copper 
target, studying the feasibility of the 15FFF photon beam in IMRT for prostate cancer 
and finally, studying the effect of mixing two FFF photon energies on treatment out­
comes which can be considered as the simple form of the prospective energy modulated
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radiotherapy (EMRT) using FEE linacs.
The reason of modelling the Varian Clinac without a EE although TrueBeam is the 
only Varian linac available commercially, which operates without a EE, is that the head 
specification of TrueBeam above the Jaws is only available as phase space files, therefore 
any simulation to any beam without a EE at energies apart from 6  and 10 MY will not 
be accurate. In addition, these phase space files do not contain any information about 
neutron production from high energy photons and neutron interactions with matter. All 
studies listed above are described in the following sections:
5.1 The physical characteristics of the 15 M V unflat­
tened beam of the Varian Clinac
In this section, the effect of removing the EE from the 15 MV photon beam of a Varian 
Clinac on beam characteristics including the neutron level has been studied.
5.1.1 M aterials and m ethods 
M C param eters
The fiattened (X) and unfiattened (FEE) beams of the 15 MV Varian Clinac were simu­
lated using ELUKA. The actual geometry of the 15 MV Varian Clinac head used in the 
simulation was obtained from the Varian manufacturer. Figure 5.1 illustrates the geom­
etry of the Varian linac head simulated using ELUKA. The energy of incident electron 
beam that hits the target was set to 15 MeV and its diameter was set to 3 mm. The 
’’PHOTONUC” card (a simulation parameter in ELUKA) was turned on to activate the 
photoneutron reaction. The electron and photon cut-off energies were set to 700 and 50 
keV, respectively. The interaction length for the inelastic interaction of photon-nucleus 
was set to 0 .0 2  using the LAM-BIAS” card to enhance the efficiency of photoneutron 
production.
A 40 X 40 X 40 cm^ water phantom was simulated at 100 cm from the source. The 
jaws and MLC was fixed to form a 10 x 1 0  cm^ field-size at the phantom surface. The 
water phantom was divided into voxels in order to calculate the photon dose, neutron 
fluence and neutron dose-equivalent. The voxel size in photon calculations was set to
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F igure 5.1: The simulated geometry of the 15 MV Varian Cline with flattening filter by
FLUKA.
0.5 X 0.5 X 0.25 cm^ and to 1 x  1 x  1 cm^ in neutron calculations. The number of 
histories was set to 2 billion in each setup (FF and FFF modes) to reduce the statistical 
uncertainty to an acceptable level.
M C validation
To validate these simulations, the calculated PDD curve of the FF beam on the central 
axis of the water phantom was compared with data obtained from the Royal Surrey 
County Hospital (RSCH). Figure 5.2 shows the PDD curves of the 15 MV FF beam 
simulated and obtained from the RSCH. The difference between them was less than 2 % 
at all points.
The F D D , Beam  Profile and out-of-field dose
The PDDs for both configurations were calculated in a water phantom. The statistical 
uncertainty for all points was less than 1%. The beam profiles for both beams FF and 
FFF were calculated using MC simulation in the water phantom at The out-of-field 
doses at à.^ax from the edge of the field to the edge of the phantom were also calculated 
after normalising both beams to give the same dose at dmax- The statistical uncertainty of
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F igure 5.2; The PDD curves of the 15 MV Varian linac FF beam simulated using MC and 
obtained from the RSCH for a 10 x 10 cm^ field-size in a water phantom.
peripheral dose was less than 0.5% inside the field and less than 3.5% up to the phantom 
edge.
D ose rate
The difference in dose rates for 15X and 15FFF beams was calculated at dmax in the 
central axis of the water phantom. The result obtained was compared with that for the 
15 MV Siemens linac calculated by Chofor et al. (2011).
N eutron fluences and neutron dose-equivalent
The neutron fluences in air and in the phantom for both beams were calculated. The 
neutron fiuence in air was obtained at 1 cm above the phantom at three positions: the 
isocentre, the field edge and the phantom edge. The neutron fiuence and neutron dose- 
equivalent in the phantom were calculated along the central axis of the phantom in 
order to calculate the depth at maximum neutron fiuence and study the change in dose- 
equivalent, when the FF is removed, after normalising both beams to give the same 
photon dose at dmax- The statistical uncertainty for all neutron calculations was less 
than 1 0 %.
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The effect o f field size on the out-of-field dose and neutron production
The 15X and 15FFF beams of the 15 MV Varian Clinac for different ffeld-sizes (4x4, 
10x10, 20x20, 30x30, 40x40 cm^ ) were simulated. All MC settings (i.e. electron and 
photon cut-off energies, ’’PHOTONUC”, ”LAM-BIAS” , voxel size, etc.) were kept the 
same. However, the size of the water phantom was increased to 50x50x40 cm^ to cover 
ffeld-sizes up to 40x40 cm^.
The jaws and MLC were used to form the field size to model the clinical set-up since 
all treatments used the MLC to shape the tumour contour. Three dosimetric properties 
were calculated for both FF and FFF beams for comparison. The out-of-field dose was 
calculated for each field size as a function of the distance from the field edge for both 
conventional and FFF beams. Neutron fluences in air for both beams for each field-size 
were calculated at two different locations: the isocentre and 5  cm from the field edge. 
In addition, the neutron dose equivalent at the phantom surface, Hq, was calculated for 
both beams (FF and FFF).
5.1.2 Results and discussion  
P D D s in the central axes and surface dose
The PDDs for 15X and 15FFF beams are shown in figure 5.3 . The results obtained show 
no change in dmax which was found for both of them to be 2.75±0.13 cm and it agreed 
with the dmax obtained at the RSCH which was 2.80di0.03 cm. We can also see that 
the FFF beam undergoes slightly faster fall-off after dmax and that arises again from the 
softness of the FFF X-ray spectrum compared with that of the FF. The surface doses at 
a 2.5 mm inside the phantom for the FFF beam were found higher than those for the FF 
one. The difference between the two was about 18.7±0.4%.
Wang et al. (2012) found that the difference for a 10x10 cm^ field-size between the 
FF and FFF at 2  mm depth was 10.5±0.1% and 16.0±0.2% for 6  MV and 10 MV beams, 
respectively. They concluded that the difference between them was clinically insignificant. 
However, it can be seen that the difference between the FF and FFF increases with beam 
energy and it might be insignificant for one treatment fraction dose but if we consider 
the total dose from all fractions the difference can add up to an extra dose to the patient 
surface which might be substantial.
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F igu re 5.3: PDDs of the 15 MV FF and FFF beams for a 10x10 cm^ fîeld-size in a water
phantom.
D ose rate
Figure 5.4 shows the depth doses per primary electron for 15X and 15FFF beam s in 
the water phantom . The dose rate of the 15FFF beam  was found to be 4.864=0.09 tim es 
higher than that for the 15X beam. This result is different from that calculated by Chofor 
et al. (2011) for the 15 M V Siemens linac since they found it to  be 3.96 tim es higher. 
This is a result of the difference in the FF com position in a Varian (Tungsten) and a 
Siemens (Steel) linacs and the exact beam  nom inal energy.
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F ig u r e  5 .4 : Depth dose on the central axis per primary electron for FF and FFF beams. 
Beam  profiles and out-of-field doses
The beam profiles and out-of-field doses for both the FF and the FFF beams are shown 
in figures 5.5 and 5.6. From figure 5.5, we can see the falling in the flatness of the FFF 
beam which results from the removal of the FF. This result does not have any problems 
with dose calculations since new techniques have been introduced such as IMRT. From 
figure 5.6, it can be seen that the out-of field dose for the FFF beam from the edge of the 
field to the edge of the phantom was reduced. The average reduction at all points was 
about 44.0±0.5%. This reduction is due to the decrease in head scatter. Also, it can be 
seen in the same figure that the reduction in out-of-field dose at < 3  cm from the field 
edge is more than that in distance > 3 cm and that agrees with the result obtained by 
Kry et al. (2010) (see section 4.1.7).
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F igure 5.5: Beam profiles after the normalisation for a 10x10 cm^ field-size of the 15 MV
beam with and without FF.
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F igure 5.6: The difference in out-of-field doses from the edge of the field to the edge of the
phantom for FF and FFF beams.
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Neutron fluence in air
The neutron fluences at 1 cm above the phantom in three different locations for both 
beams were calculated as seen in figure 5.7. The neutron fluence of the 15X beam at the 
isocentre was (10.5:L0.5) x 10  ^n cm-^Gy"^ and it was close to that obtained by Kry et al. 
(2005) which was (9.2±0.6)xl0G n cm'^Gy-:^ and that obtained by Howell et ah (2006)
which was (9.4i0.3)xl0® n cm ^Gy The neutron fluence of the FFF beam was found 
to be (2.5±0.1)xl0® n cm -^G y'b  Therefore, neutron fluence was reduced by 77±3%. 
This result is greater than that obtained by Chofor et al. (2011) since they found the 
neutron strength for a Siemens linac was reduced by 71%. The reason for this is because 
the FF for the Siemens linac is made of steel which has lower photoneutron cross-section 
compared with the tungsten FF of the Varian linac.
15X
15FFF1 2 -,
1 0 -
o
" F - — —  -
X (cm)
F igu re 5.7: Neutron fluence in air at the isocentre, the edge of the field and the edge of the
phantom.
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N eutron fiuence and dose-equivalent in phantom
The neutron percentage depth fluences for the FF and FFF beams were calculated as 
seen in figure 5.8. Both beams have the same slopes as removing the FF affects only the 
number of neutrons created and not the neutron fluence distribution. From the results, 
the depth at maximum neutron fluence (dmax-n) for both beams was found to be 2 .0 T 0 .5  
cm and that agrees with the result obtained by Martmez-Ovalle et al. (2 0 1 1 ) since they 
found the dmax~n to be 2.31±0.07 cm in an ICRU tissue equivalent phantom (p = 1  g 
cm ^). In addition, the neutron dose-equivalent was calculated in the water phantom for 
both beams as seen in figure 5.9. From this figure, it can be found that the surface neutron 
dose-equivalent for the FF beam was 2.11±0.05 mSv Gy“  ^ and is close to that obtained 
by Golnik et al. (2004) which was 2.9T1.3 mSv Gy~^. The neutron dose equivalent of 
the 15X was about 77% higher than that of the 15FFF which was 0.48±0.01 mSv Gy“  ^
due to the decrease in the number of neutrons produced per Gy.
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F igu re 5.8: Percentage depth neutron fluences in the phantom for the FF and FFF beams.
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F igu re 5.9: The neutron dose-equivalent in the phantom for the FF and FFF beams.
The effect of field size on the out-of-field dose and neutron production
Results obtained from MC simulations showed that the out-of-field dose with the absence 
of the FF depends on beam field size. The percentage reduction with the FF removal 
for field sizes from 4x4- 40x40 cm^ at a 3 cm distance from the field edge is presented 
in table 5.1. Clearly, the out-of-field decreases with field size. This reduction is due to 
the decrease in beam scatter by the Jaws and MLC by the FF removal. The relative 
reduction in out-of-field dose with and without a FF was found to be proportional to the 
field-size,(see figure 5.10), by the following equation:
O F r e la t iv e  =  a F (5.1)
Where, the OFreiative is the relative reduction in out-of-field dose by the FF removal, 
FZ is the field size, a and b are fitting constants and were found to be 28.2±1.6 and 
O.lOiO.Ol, respectively. The R^ for the fitting equation was found to be 0.977.
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Table 5.1: Reduction in out-of-field dose by FF removal for different field sizes at a 3 cm
distance from the field edge.
4 x 4  cm^ 10x10 cm^ 20x20 c i jF 30x30 cm2 40x40 cm2
Reduction in
out-of-field dose 37.5±4.0 47.3±4.0 52.14:4.0 60.1±4.0 61.64:4.0
(%)
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F igure 5.10: The reduction in out-of-field dose as a function of field size at a 3 cm distance
from the field edge by removing the FF .
It is also worth mentioning that the reduction in out-of-field dose with the FF removal 
was obtained with all field-sizes even for distances larger than 5  cm from the field edge. 
For example, the dose at 10 cm from the field edge for a 20x20 cm^ field size was 1.2 
and 0.7% with and without a FF, respectively. This differs from what was reported by 
Kry et al. (2010) as they found that the out-of-field dose increased in this region due to 
an increase in patient scatter. They concluded that the FFF beam is only suitable for
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treatment with field sizes less than 4x4 cm^. This disparity in findings may arise from 
the difference in beam normalisation as they normalised both beams to have the same 
dose at the edge of the field size not at the beam centre (as shown in figure 5 .1 1 ). Thus, 
both beams do not have the same dose at dmax-
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1-E-05 -
—  ' iS cm FFF
'IBosnFFS ' 1.E-C6-
1.E -07-
1.E-G9
-50 -1C 10 :
Distance frcmi Central Axis (cm)
so
F igu re 5.11: Peripheral dose in arbitrary units for 18 MV beams with and without a FF at 5 
and 15 cm depth in a water phantom normalised to give the same dose at the field edge (Kry
et al. 2010).
With regard to neutron calculations, neutron fluences for different field sizes at the 
isocentre and 5 cm from the field edge are listed in table 5 .2 . The Hq at the isocentre 
for the 15X and 15FFF beams is shown in table 5.3. It can be seen from both tables 
that the maximum neutron fiuence and dose equivalent for the conventional beam was 
obtained at field size 30x30 cm^ which agreed with what was obtained by G arnica- Garza 
(2005). However, they stated that as the field size increases the neutron fiuence increases 
whereas in this work the neutron fiuence decreases after a field size greater than 30x30 
cm^. The reason for this is because the maximum size simulated in their study was 30x30 
cm while in this work the maximum field size was 40x40 cm^. The same behaviour was 
obtained for the FFF beam. However, the neutron fiuence and dose equivalent of the 
FFF beams were significantly lower than with FF. This reduction enlarged with field size 
at both locations. For example, the reduction in neutron fiuence by the removal of the 
FF was 71.O i l .4% and 83.O i l .7% for 4x4 and 40x40 cm^ field sizes, respectively.
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T able 5.2; Neutron fluence in air (xlO® n cm '^jat isocentre and 5 cm from fleld edge for 
diflFerent field sizes for 15 MV flattened and unflattened beams. The uncertainty was less than
2%.
4 x 4  cm^ 10 x 1 0  cm^ 2 0 x 2 0  cm^ 3 0 x 3 0  cm^ 4 0 x 4 0  cm^
X  FFF X  FFF X FFF X  FFF X  FFF
isocentre 4.20 1.20 10.5 2.50 15.8 3.40 18.9 3.40 17.4 3.10
5 cm from field edge 2.40 0.80 4.60 1.30 8.80 1.60 15.8 3.00 15.4 2.30
T able 5.3: Neutron dose equivalent on the central axis at the surface of phantom for different
fleld sizes of 15 MV flattened and unflattened beams. The uncertainty was less than 2%.
4 x 4  cm^ 1 0 x 1 0  cm^ 2 0 x 2 0  cm^ 3 0 x 3 0  cm^ 4 0 x 4 0  cm^
X  FFF X FFF X FFF X  FFF X  FFF
H o  (mSv G y -i)  0.86 0.24 2.15 0.49 2.97 0.64 3.45 0.63 3.14 0.56
5.2 Neutron fluence in treatm ent rooms housing FFF  
linac
As mentioned before, neutrons produced by high energy linacs give unwanted extra dose 
to the patient which can increase the risk of causing secondary cancers. These neutrons 
increase the shielding cost of the treatment room housing this machine which prevents 
staff from receiving higher doses than the dose limit agreed by national and international 
organisations (IRR 1999). This section describes the methods used in this work to cal­
culate the neutron fiuence at different locations inside a treatment room housing a FFF 
linac. It was carried out, first, in order to estimate the total neutron fiuence and neutron 
dose equivalent produced by these types of linacs and compared them with what were 
produced by a conventional linac. Second, in order to have a clearer idea about the effect 
of nominal energy of the FFF beam on photoneutron production.
5.2.1 M aterials and m ethods
Several simulations were performed. A treatment room housing a linac with different 
photon beam energies (10, 15 and 18 MV) with and without FF were modelled using 
FLUKA to calculate the neutron fiuence and Hq at the isocentre as well as the neutron
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fluence and neutron strength (Q) at two different locations: inside the treatment vault 
at a distance 1 m from the isocentre and inside the maze at distance 6 .2  m from the 
isocentre. The treatment vault design was modelled with the same dimensions of the 
treatment room layout in ’’Appendix 1” of the Health Building Note no. 5 4  (2006). In 
addition, concrete with density 2.35 g cm“  ^ was used as the material of the treatment 
room wall as stated in the Health Building Note no. 54 (2006). Figure 5.12 shows a cross 
sectional view of the modelled treatment room at a plane crossing the isocentre.
Location 2
Location 1
Isocentre •
Figure 5.12: Cross-sectional view of a plane crossing the isocentre of the modelled concrete 
treatment room including locations where neutron calculations were performed.
The MC parameters (except the beam energy) were kept the same as in section 5.1.1.
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MC validation
These simulations were validated by comparing the Dio (dose at depth 10 cm) and dgo 
(depth at relative dose 80%) of conventional beams (1 0 , 15 and 18 MV) with those 
published in BJR supplement 25 (BJR 1996). Table 5.4 lists the Dio nnd dgo calculated 
using the MC technique and published in BJR supplement 25 of the 10, 15 and 18 MV 
conventional beams for a 10x10 cm^ field size. As can be seen in Table 5 .4 , the variations 
in BJR supplement 25 and the MC results were less than 2%.
T able 5.4: Dio B-nd dgo calculated using MC technique and published in BJR supplement 25 
of the 10, 15 and 18 MV conventional beams for a 10x10 cm^ field size in a water phantom.
Dio(%) [MC] Dio(%) [BJR-25] dgo (cm) [MC] dgo (cm) [BJR-25]
lOMV 72.6±1.5 73.0 7.9±0.1 8.0
15 M V 77.6±1.6 77.0 9.2±0.1 9.1
18 M V 79.5±1.6 79.0 9.84:0.1 9.7
5.2.2 R esults and discussion  
N eutron fiuence in air
The neutron fiuence for 10,15 and 18 MV fiattened and unfiattened beams at the isocentre 
and the other two locations are listed in table 5.5. It can be seen from this table that 
the neutron fiuence at the iso centre for the 15X beam is larger than what was obtained 
in section 1 . This results from the increase in the neutron scattering dose due to the 
treatment room as well as the water phantom. To ensure this hypothesis is correct, a 
MC simulation of the 15X beam was carried out in the same treatment room but without 
a water phantom. The result obtained showed that the neutron fiuence decreased to 
1.1x10^ n cm“ .^
It should be noted that the neutron fiuence decreased with all beams when the FF 
was removed. The reduction was 54.44:1.0%, 764:1.5% and 754:1.5% for 1 0 , 15 and 18 
MV beams, respectively. The maximum reduction was obtained for the 15 MV beam due 
to FF compositions made totally from tungsten (the (y,n) reaction threshold for is 
6.19 MeV). The FF was made from copper (for the 10 MV photon beam) and two layers
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T able 5.5: Neutron fluences (xlO® n cm"^) at different locations in the treatment room for 
10, 15 and 18 MV photon beams with and without a FF. The values in square brackets are 
the normalised fluence values to isocentre for each beam.
10 M V 15 M V 18 M V
X FFF X FFF X FFF
iso centre 0.314:0.01 0.14±0.01 14.0±0.1 3.40±0.03 18.5±0.1 4.60±0.02
[1] [1 ] [1] [1] [1] [1]
Location 1 0.16±0.01 (5.5T0.3) X 10-2 7.8±0.1 1.40±0.02 10.4±0.7 1.90±0.01
[0.52] [0.39] [0.56] [0.41] [0.56] [0.41]
Location 2 (1.8 ±0.3) X10-2 (6.3±0.8)x 10-3 0.60±0.02 0.13±0.01 0.80T0.03 0 .2 0 ± 0 .0 1
[0.06] [0.05] [0.04] [0.04] [0.04] [0.04]
of steel and tantalum (for the 18 MV beam). The (7 ,n) reaction thresholds for 
and are 10.85, 1 1 .2  and 7.58 MeV, respectively (Chadwick et al. 2 0 0 0 ).
It can also be seen from this table that the ratio between the neutron fluence at the 
isocentre and other locations is constant regardless of the beam energy. For example, the 
ratio between the first location and the isocentre was found to be approximately 0 .5 5  and 
0.40 with and without a FF at all beam energies, respectively.
The neutron strength at these locations for all beams can be calculated using 
equations 3.7 and 3.8. The neutron strengths for all beams at these locations are shown 
in table 5.6. It can be seen that the calculated for flattened beams at different locations 
is approximately equal, particularly for 15 and 18 MV beams as the uncertainty increases 
for the 10 MV beam due to the lower photoneutron production.
It can be seen for unfiattened beams that the is approximately constant regardless 
of the location but it has slightly higher value at the isocentre than the other two locations 
as the energy increases compared with flattened beams. These results are consistent with 
the production mechanism of photoneutron theory (see section 3 .5 .1 ) which indicates that 
direct neutrons, dominant at the high energy region, are produced in the same direction 
as the photons which generated them. Consequently, a larger amount of fast neutrons are 
emitted towards the isocentre because the FF removal reduces the photon scattering in 
the linac head and increases the number of photons that travel straight forward. However, 
equation 3.7 and 3.8 can still be valid for unflattened beams as an approximation.
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The reduction in for the 18 MV photon beam, obtained by removing the FF, was 
found to be (78.4±1.4)% in this work and agrees with what was obtained by Kry et al.
(2008). They found that the reduction in neutron strength by the FF removal with closed 
jaws was (81±5)%.
Table 5.6: Neutron strengths (x 10^ )^ at different locations in the treatment room for 10, 15 
and 18 MV photon beams with and without a FF.
1 0  M V 15 M V 18 M V
X FFF X FFF X FFF
isocentre 0.034±0.001 0.014±0.001 1.60±0.02 0.340±0.003 2.05±0.01 0.508±0.003
location 1 0.030±0.002 O.OlOiO.OOl 1.40±0.02 0.250±0.003 1.80±0.01 G.340±0.002
location 2 0.044±0.007 0.015±0.002 1.50±0.07 0.30±0.01 1.90±0.06 0.38±0.01
^ A v e r a g e 0.036±0.003 0.014±0.001 1.50±0.04 0.31±0.01 1.90±0.03 0.41±0.01
N eutron dose equivalent
The calculated values of the neutron dose equivalent of FF and FFF beams at the surface 
of the phantom on the central axis for different energies are listed in table 5.7. The 
calculated dose equivalent for conventional beams in this work agreed well with published 
data. For example, Zanini et al. (2004) found that the neutron dose equivalent at 3 cm 
from the isocentre for a 10x10 cm^ field size was 3.3T0.3 mSv Gy~^. The percentage 
reduction in neutron dose equivalent when the FF was removed is the same as in fiuence. 
This is important as the decrease in neutron dose equivalent will have a significant impact 
on reducing the possibility of secondary induced cancers.
Table 5.7: Neutron dose equivalent at different locations in the treatment room for 10, 15 
and 18 MV photon beams with and without a FF.
10 M V 15 M V 18 M V
X FFF X FFF X FFF
H q (mSv G y -i)  0.030±0.005 0.020±0.003 2.20±0.09 0.54±0.02 3.10±0.07 0.80±0.01
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N eutron spectra
The neutron spectra for 18X and 18FFF beams at these three locations are shown in 
figure 5.13. Table 5.8 lists the ratio of fast to thermal neutron energy peaks for 18X and 
18FFF beams energy at these three locations. It can be seen that despite the reduction 
in number of neutrons produced, both beams have thermal and fast peaks at the same 
energies. Moreover, the reduction in the fast neutron peak by moving from the iso centre 
to other locations is higher than that in the thermal neutron region which agreed with the 
literature and it is due to the neutron scattering by the concrete walls of the treatment 
room. From table 5.8, the ratio of fast to thermal neutrons for the 18 FFF beam is 
higher than that for the 18X beam. These results agreed, again, with the theory of the 
production mechanism of photoneutrons.
T able 5.8: The ratio of fast to thermal neutron energy peaks for the 18X and 18FFF beams
at different locations in the treatment room.
Isocentre Location 1 Location 2
18X 2.3±0.1 2.4±0.1 0 .2 0 ± 0 .0 1
18FFF 2.7±0.1 2 .2 ± 0 .1 0.40±0.02
With reference to the data listed above and the results obtained by Kry et al. (2009) 
and Jank et al. (2014) (see section 4.4), the reduction in photon scattering and neutron 
fiuence can reduce the amount of photon and neutron leakage from the treatment room. 
Thus, it can reduce the annual dose to staff if these types of linac are housed in existing 
treatment rooms or can reduce the total amount of treatment room shielding required, 
which reduces the installation cost. This conclusion needs further investigation by calcu­
lating the average workload for each beam energy per week. The calculation is required 
due to first, the increase in dose rate by the FF removal which could increase the number 
of patients treated per week and second, the increase in total MUs used per treatment 
course which has been reported by several studies (Cashmore et al. 2 0 1 1 , Zhan et al. 
2 0 1 2 ). Having obtained these data, the researcher can use them to calculate the thick­
ness of primary and secondary barriers required using the equations reported in NCR? 
151 (NCR? 2005).
Table 5.9 summarises the neutron fluence in-field calculated in this work and other
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F igure 5.13: The neutron spectra inside the treatment room for (a) the 18X beam at 
different locations (b) 18FFF beam at different locations (c) 18X and 18FFF at isocentre and
(d) 18X and 18FFF at the other two locations.
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works for the fiattened and unfiattened beams at different energies.
Table 5.9: Summary table of the neutron fiuence (xlO® n cm^) in-field calculated in this 
work and other works (where possible) for the fiattened and unfiattened beams at different
energies.
10 M V  
X FFF
15 M V  
X FFF
18 M V  
X FFF
This work 0.31±0.01 0.14±0.01 1 4 .0 ± 0 .r 3.404:0.03 18.54:0.1 4.60±0.02
Other works 0.55±0.02'’ 9.2±0.6^ 17.04:1.4'' 2.14:0.2'^
a: T h e value decrease to  1 1 .0 ± 0 .2  XlO® n cm^ w ith ou t a w ater phantom , 
b: (Kry et al. 2005), c lin ical filed  size.
c: (Zanini et al. 2004), 3 cm  from  th e  isocentre in a lO x  cm^ field  size, 
d: (K ry e t al. 2008), closed  jaw s.
5.3 M odelling M VCBCT with FFF linac and differ­
ent target materials
As mentioned in section 4.3, severai groups and individuais have been investigating the 
effect on MVCBCT image quaiity by using unfiattened beams with different target ma­
terials and sizes. In this work, it was suggested to use a copper target for the imaging 
mode using a 6  MV FFF beam since the former is already present inside the head of 
most Varian linacs to be used with either the 8  or 10 MV photon beam.
5.3.1 M aterials and m ethods 
M C param eters
The 6  MV Varian Clinac was simulated using FLUKA (Ferrari et al, 2005). Five different 
targets were simulated without a FF. Ail configurations are listed in table 5.10. The 
incident electron beam hitting the target was simulated as a pencil beam of energy 6  
MeV and a diameter 3 mm. A 40 x 40 x 40 cm^ water phantom was simulated at a 
source to surface distance (SSD) of 100 cm. The water phantom was divided into voxels 
in order to calculate the percentage depth dose as well as the entrance dose along the 
central axis. The voxel size was set to 0.5x 0.5 x 0.25 cm^. The photon and electron
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Table 5.10; Target configurations used in this simulation.
W ith a FF Varian 6  MV original target (tungsten target ~  0.1 cm)
Varian 6  MV original target 
Varian copper target (~  0.5 cm)
W ithout a FF Copper target (0.25 cm)
Carbon target (1  cm)
Carbon target (2  cm)
cut-off energies were set to 1 0  and 511 keV respectively. The number of histories was set 
to 1 x 1 0  ^ primary electrons to reduce the statistical uncertainty to less than 2 %.
MC validation
To validate the simulation, the PDDs of the FF beam in the central axis of the water 
phantom were compared with PDDs published in BJR-supplement 25 (BJR 1996). Fig­
ure 5.14 shows the PDD curves of the simulated 6  MV FF beam and that obtained from 
BJR-supplement 25 (BJR 1996). The difference between them was less than 2 % at all 
points.
Photon spectra, electron contam ination and entrance dose
The photon spectra for all configurations were calculated in air at the isocentre. The 
ratio of low energy photons (10-150 keV) in each spectrum was compared with that for 
the conventional beam. The photon average energies for all setups were calculated. The 
electron contamination on the patient plane in each setup was obtained by calculating 
the ratio of the total number of electrons to photons at the isocentre. In addition, the 
entrance dose was calculated at a depth 0.5 cm from the phantom surface on the central 
axis.
Image quality
In order to calculate the improvement in image quality by using the Varian copper target, 
two simulations for the conventional and the copper target beams were performed. Both 
beams with a 2 0 x 2 0  cm^ field-size were simulated to irradiate two cylindrical bones of 2  
cm diameter placed inside a water phantom with 5 cm thickness at 100 cm from the target.
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F ig u r e  5 .1 4 : The PDD curves of the conventional 6  MV Varian linac beam simulated 
(squares) and obtained from BJR-suplement-25 (circles) for a 10 x 1 0  cm^ field-size in a water
phantom.
The images were obtained by scoring the photon fiuence 1 0  cm below the phantom. Since 
changing the target and removing the FF affects the dose rate, the number of incident 
electrons for the new setup was reduced to obtain an image with the same dose as in the 
conventional setup. The local contrast (LC) for both images was calculated using the 
following equation (Flampouri et al. 2 0 0 2 ):
— Iw\
(5.2)h  +  Iw
where A and 7^ are the photon fiuence in a region of interest in bone and water 
respectively.
5.3.2 Results and discussion
Photon spectra, electron contam ination and entrance dose
The average energy of photon spectra for copper targets is between the average energy 
obtained using the original Varian targets and the carbon targets; see Figure 5.15. In 
addition, the low photon ratio increased in using the copper target compared with use of
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the original target (tungsten target). It was further found that by using a thin target (0.25 
cm copper or 1 cm carbon) the number of primary electrons at the isocentre increased 
sharply. The entrance dose also increased when the FF was removed and also increased 
as the thickness or Z of the target decreased. Table 5.11 summarises the calculated 
parameters for each configuration.
E (MeV)
FF
FFF
C u -0 .5cm
Cu-0.25cm
C-lcm
C-2cm
F igu re 5.15: The photon spectra in air for all configurations at the isocentre.
Table 5.11: The average photon energy, low energy photon ratio, electron contamination 
ratio and the entrance dose for all configurations.
FF FFF Cu(0.5) Cu(0.25) C ( 1  cm) C ( 2  cm)
Average photon energy (MeV) 2.5T0.1 2 .1T 0 .1 1.9T0.1 1 .8 T0 .1 1 .6 T0 .1 1 .2 T0 .1
10-150keV photons ratio(%) 0.33T0.02 1.03T0.05 2.39T0.12 3.55T0.18 6.1T0.3 5.16T0.23
Electron contamination ratio (%) 0.090T0.005 0.25T0.01 0.060T0.003 6.17T0.31 41.1±2.1 0.030T0.002
Entrance dose (%) 83.0T1.7 96.3T1.9 86.1T1.7 99.2T2.0 96.2T1.9 87.9T1.8
Image quality
The acquired images obtained by the conventional and the copper target beams are shown 
in Figure 5.16. It should be noted that the image acquired by the copper target beam 
has the better quality compared to that acquired by the conventional beam. The LC has 
improved by 31±6%. Clearly, this value will reduce if a thicker phantom is used. This 
modification is suggested to be useful for repositioning patients who undergo radiotherapy
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treatment for lung or head and neck cancers. This modification points to provision of a 
simple and low cost technique for acquiring MVCBCT images with better quality, being 
perhaps most important for developing countries.
(^) (b)
F igure 5.16: The acquired images of two cylindrical bones of 2  cm diameter placed inside a 
water phantom of 5 cm thickness at a distance 100 cm from the target by (a) the conventional
beam and (b) the copper target beam.
5.4 Using high energy FFF beams in IMRT for prostate 
cancer
Briefly, the use of IMRT provides better PTV coverage and OAR sparing than 3D-CRT 
(ICRU 2010). However, IMRT is still delivered with a photon beam < 10 MV in most 
radiotherapy sites. This results from the increase in patient scatter due to the increase in 
total monitor units (MUs) due to the use of a modulation scaling factor to produce the 
same photon dose to the tumour and the increase in neutron dose to the patient which 
was reported to be about 6  times higher than that for conventional treatment (Hussein 
et al. 2 0 1 2 , Naseri & Mesbahi 2 0 1 0 , Stathakis et al. 2007).
The risk of neutrons to produce secondary cancers was estimated to be 2 .2 % and 5 .1 % 
for 15 and 18 MV beams, respectively. However, It was reported that the 15 MV beam is 
preferred when the PTV is close to the OAR even in head and neck cancer cases (Followill 
et al. 2007). In addition, a recent study by Hussein et al. (2 0 1 2 ) showed that the use 
of the 15 MV photon beam in IMRT of prostate cancers produced better organ sparing 
but a slight increase in rectum normal tissues complication probability from 3 % to 3 .6 % 
compared with the 6  MV photon beam for 6  and 15 MV, respectively. On the other
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hand, the introduction of FFF beams re-initiates the interest of using higher energies in 
IMRT (for more details see section 4.5.1).
The aim of the present work was to compare IMRT plans for prostate cancer created 
using the 6  and 15 MV photon beams with and without a FF with regard to PTV 
coverage, OAR sparing, dose to normal tissue and neutron dose using Monte Carlo (MC) 
technique.
5.4.1 M aterials and M ethods 
Prostate plan
In order to study the feasibility of the 15FFF photon beam in IMRT for prostate treat­
ment, four IMRT plans of an arbitrary prostate cancer case; two step-and-shoot (SnS) 
and two dynamic (DYN) using both 6  and 15 MV beams were created by the treatment 
planning system (TPS) at the Royal Surrey County Hospital (RSCH), Guildford, UK. 
These plans were produced using the Varian Eclipse TPS version 10.0.42 (Varian Medi­
cal Systems, Palo Alto, CA, USA). Figure 5.17 shows the size (width and depth) of the 
patient modelled in this work. It should be mentioned that the volume of the PTV is 
150 cm^.
24 cm
t
F igu re 5.17; A CT slice illustrate the depth and width of the patient modelled in this work.
The PTV is shown as a red circle in this slice.
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M C param eters
IMRT plans, obtained from the RSCH, were exported in a DICOM format to be used 
in our MC simulations. The exported plans were simulated using the code BEAMnr- 
c/DOSXYZnrc (Rogers et al. 2001, Walters et al. 2005) for verification and evaluation. 
Other four plans were simulated with the same plan configurations as those created by 
the TPS but without a FF. The total number of beam segmentations (sub-beams) in SnS 
IMRT plans of 6  and 15 beams was 6 6  while it was 499 and 510 for DYN IMRT plans of 
6  and 15 MV beams, respectively.
All DYN IMRT plans were modelled by performing a MC simulation for each beam 
in the treatment plan (the total number of beams in all plans was 5 ) then combining 
output files because the maximum number of segmentations (sub-beams) that BEAMnrc 
can model per simulation is 265. The CT slices, with a voxel size O.lxO.lxO.5 cm^ 
were used to create the ”*.egsphant” file using the ’’ctcreate” code (enclosed as part of 
BEAMnrc/DOSXYZnrc code) to be read in DOSXYZnrc. The voxel size of the created 
MC phantom was 0.36x0.36x2.5 cm^. The number of histories was chosen to reduce the 
uncertainty to less than 2 %.
A code written using MATLAB (Appendix A) was used to read all plan parameters, 
as seen in figure 5.18, from the Radiotherapy (RT) plan files such as the MLC leaves 
positions, jaws opening, gantry angle, treatment table angle and collimator angle for 
each beam segmentation then generate the MLC opening sequences. Jaws opening and 
control points files to be read in BEAMnrc and DOSXYZnrc. The BEAMnrc modelled 
accelerator was compiled as shared library to be used with DOSXYZnrc source number 
2 1  ’’synchronized BEAM treatment head simulation”.
Transformation between the gantry (Og ) ,  collimator { 9 c )  and treatment table (Ot )  angles 
to DOSXYZnrc MC angles [theta, phi and phicol), as seen in figure 5.19, was performed 
by using a set of transformation equations, derived by Zhan et al. (2012), as follows:
theta = cos“ ^ (-  sin 9t  sin 9g) (5 .3 )
phicol =  ^  -  -  t an~^( — (5 .5 )
z  COS 6 t
It is noteworthy to mention that, the positions of MLC leaves should be reversed to
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Q  sequerK:efiles_creater
File Tools
-Sequence and Control Points Files Greater 
Treatment Planning plan file Open
Score Plan Isocentre Distance (cm)
Select Treatment Modality 
#  VMAT
O Dynamic IMRT 
OStep&ShootIMRT 
Save MLCs Sequence File As 
Save Jaws Sequence File As
Save Control Point File As
0.0
Save
Save
Save
Create
F igu re 5.18: The interface of the Matlab code used to read the RT plan file and generate 
required MC files for BEAMnrc/DOSXYZnrc code.
match the MLC leaves positions in BEAMnrc (i.e. the MLC leaves in the (-x) direction 
of DICOM plan file are the leaves in (-f-x) in BEAMnrc code and vice versa). Figure 5.20 
shows two slices before and after the isocentre of a MC plan modelled with the same order 
and reversed order of MLC positions comparing to the same slices of TPS plan. After 
the simulations finished, The RT structure, ”*.egsphant” and resulted three dimensional 
dose distribution file ”*.3ddose” were imported to the MATLAB code (figure 5.21) to 
calculate the dose in each region of interest specified in the RT structure file such as 
the PTV, rectum and bladder then extract the required plan assessment parameters for 
evaluating the MC plans. The calculated assessment parameters in the PTV, rectum and 
bladder are listed in table 5.12. It should be noted that the prescribed dose in modelled 
prostate cancer case was 74 Gy to prostate target volume.
The assessing parameters were chosen on what was recommended or calculated in 
an example in the ICRU report number 83 (ICRU 2010). In addition, the bladder and 
rectum were chosen in our assessment because they are the most common organs in which
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Y2
X2
^ dsource
theta
(b)(a)
F igure 5.19: Coordinate system definition in the DICOM plan file (a) and DOSXYZnrc (b)
(Walters et al. 2005, Zhan et al. 2012).
secondary cancers are induced (Bostrom & Soloway 2007). The assessing parameters were 
defined in section 2.3.2. Figure 5.22 summarises the whole process of obtaining the MC 
plan assessment parameters.
Table 5.12: Calculated parameters in the PTV, rectum and bladder which was used for plan
evaluation.
PT V Rectum Bladder
Mean dose Mean dose Mean dose
D V H D V H D V H
D2 , Dgg D 2 , D50 , D q 8 D 2 , -D50? D q 8
H I U20Gy, V jo G y V 2 0 G y , V ro G y
C l
CN
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€
(e) (f)
Figure 5.20: Comparison between two TPS slices before (a) and after (b) the isocentre and 
the same slices modelled using the same (c and d) and reversed (e and f) order of MLC
positions in the DICOM plan file.
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F igure 5.21: The interface of the Matlab code used to calculate plan assessing parameter at 
any region of interest specified in RT structure file.
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F igu re 5.22: Flowchart of MC plan evaluation process.
IMRT plans validation
All MC IMRT plans were compared with those obtained from RSCH by com paring the  
mean dose and DVH at the P T V , rectum  and bladder as well as the dose at the isocentre 
for both MC and hospital plans.
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N eutron calculations
In order estimate the neutron dose equivalent from a full plan using the 15 MV FFF beam, 
two 15 MV SnS IMRT plans of a prostate cancer (the same plan that was modelled using 
BEAMnrc) with and without a FF were simulated using FLUKA as BEAMnrc does not 
support modelling neutron interactions. Since FLUKA cannot model full treatment in 
one run, 6 6  simulations were carried out to model each segmentation (MLC position) of 
the 15X and 15FFF SnS IMRT plans then combining all simulations together to obtain 
the final results. In addition, the SnS IMRT plan of the prostate case was modelled 
in a 40x40x30 cm^ water phantom instead of using patient CT images for simplicity 
and to reduce the total time required to finish all simulât ions. The voxel size was set to 
0.5 X 0.5 X 0.5 cm . The DYN IMRT plans were not simulated as the total number of 
simulations to be carried out for each plan is 510 simulations which is difficult to achieve. 
The electron and photon cut-off energies were both set to 5  MeV to reduce the time of 
each simulation because the lowest photoneutron production threshold of linac materials 
is for tungsten W at 6.19 MeV (Chadwick et al. 2000). The statistical uncertainty in 
neutron calculations was less than 5 % for all voxels.
5.4.2 Results and discussion  
IM RT Plans verifications
The MC calculated plans agreed well with the TPS IMRT plans. The dose distribution 
in a CT slice at the isocentre of the TPS and MC dynamic IMRT plans using the 6 X 
beam is shown in figure 5.23. The dose at the isocentre and mean dose within the PTV 
for the TPS and MC dynamic and step and shoot IMRT plans using the 6 X and 15X 
beams are listed in table 5.13. The percentage differences in dose calculations between 
MC and TPS were less than 2 % for all plans.
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m
(a) (b)
F igure 5.23: The dose distributions in a CT slice at the isocentre of the TPS and MC 
Dynamic IMRT prostate cancer plans using: (a) 6 X-TPS and (b) 6 X- MC. The ’’MMCTP” 
software was used for plan visualization (Alexander et al. 2007).
Table 5.13: The dose at the isocentre and mean dose in the PTV for 6 X and 15X dynamic 
(DYN) and step and shoot (SnS) IMRT plans calculted using MC and TPS. The uncertainty
was less than 2 %.
D Y N 6 X
MC TPS
DYN15X
MC TPS
S n s e x
MC TPS
SnSlSX
MC TPS
Dose at Isocentre (%) 103.1 101.1 101.7 100.1 1 0 1 .1  1 0 0 .1 101.0 99.9
M ean dose in PT V  (%) 98.3 97.9 97.7 97.9 98.0 98.4 98.0 98.1
Evaluation of IMRT plans
The calculated evaluation parameters of the the PTV, rectum and bladder for the Dy­
namic and Step and Shoot IMRT plans using 6 X, 6 FFF, 15X and 15FFF beams are 
summarised in table 5.14. The DVHs of the PTV, rectum and bladder for 6 X, 6 FFF, 
15X and 15FFF MC Dynamic IMRT plans are shown in figure 5.25.
It can be seen from table 5.14 and figure 5.25 that the 6 X, 6 FFF and 15X plans are 
found to be clinically acceptable according to ICRU recommendations, where the mean 
dose in the PTV was within 95% and 107% (ICRU 2010). The deviation in the mean 
dose and D50 in the PTV between these plans was found to be within 2.0%. The His 
of dynamic plans for these beams is slightly better than those of step and shoot plans 
because the number of sub-beams (MLC segmentation) in dynamic plans is substantially
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larger. The mean dose mean dose of the 6 FFF plans (dynamic and step and shoot) within 
the rectum and bladder is slightly lower than those of the 6 X plans but they are still 
somewhat higher than those of the 15X. In addition, the 6 FFF beam seems to reduce the 
volume that received 70Gy within the rectum and bladder compared with the 6 X and 
15X plans.
# #
# m
(c) (d)
Figure 5.24; The dose distribution in a CT slice at the isocentre of the MC Step and shoot 
IMRT prostate cancer plans using: (a) 6X, (b) 6FFF, (c) 15X and (d) 15FFF. The 
’’MMCTP” software was used for plan visualization (Alexander et al. 2007).
On the other hand, the IMRT plans created using the 15FFF beams were found to 
be not acceptable clinically in this study as they did not produce sufficient coverage 
to the PTV . This is due to the profile sharpness of the 15FFF beam and the IMRT 
plans were created without optimisations (i.e. MLC sequences). Even though the 6 FFF 
IMRT plans were created also without optimisations, these plans were accepted as the 
6 FFF beam has lower profile sharpness than the 15FFF beam (see figure 5.28) and 
therefore it can approximately be considered uniform for small and medium tumours
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Table 5.14: The calculated evaluation parameters of the PTV, rectum and bladder for the 
MC DYN and SnS IMRT plans using 6X, 6 FFF, 15X and 15FFF beams. The uncertainty was
less than 2 %.
SnS D Y N
6 X 6 FFF 15X 15FFF 6 X 6 FFF 15X 15FFF
PT V
M e a n  d o s e  (%) 98.0 97.2 98.0 89.7 98.3 96.6 97.7 88.9
D2 (%) 104.8 105.2 104.8 103.9 103.4 102.9 102.7 1 0 1 .1
%  (%) 99.0 98.1 99.0 90.6 99.5 97.7 99.2 90.6
%  (%) 8 8 .0 8 6 .2 87.4 74.8 89.0 87.0 88.9 73.4
H I 0.17 0.19 0.18 0.32 0.15 0.16 0.14 0.45
C l 1.04 1.05 1.03 1 .0 0 1.05 1.03 1.04 1 .0 0
O N 0.34 0.29 0.37 0 .1 0 0.42 0.24 0.34 0.04
Rectum
M e a n  D o s e  ( % ) 38.2 37.6 37.2 32.3 38.9 38.4 38.0 32.8
Dg (%) 95.0 93.7 94.3 86.9 95.1 93.6 95.2 88.17
%  (%) 27.0 26.7 25.8 2 2 .2 27.8 27.6 26.6 2 2 .8
Dgg (%) 5.2 5.1 4.6 3.1 5.6 5.2 4.8 3.15
UzOGy (%) 49.8 48.7 46.6 39.9 52.9 51.9 49.2 41.1
UrOGy (%) 3.3 2.5 3.2 0 .1 4.2 2 .6 4.1 0 .0
Bladder
M e a n  d o s e  (%) 33.4 32.7 32.2 26.8 33.4 32.9 32.2 26.6
Dg (%) 96.8 95.4 96.8 84.8 96.9 95.5 96.6 84.7
A o  (%) 2 0 .6 2 0 .0 19.9 15.6 20.7 19.9 2 0 .0 15.5
%  (%) 2.5 2.5 1.5 1 .2 2.5 2.5 1 .6 1 .2
UzOGy ( % ) 45.6 44.2 45.7 39.3 45.6 44.2 45.7 39.2
UroGy ( % ) 5.9 4.1 5.2 0 .2 5.8 3.4 4.8 0 .2
Total M Us 451 471 708 556
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Figure 5.25: DVH of (a) PTV, (b) rectum and (c) bladder for 6 X, 6 FFF, 15X and 15FFF
MC Dynamic IMRT plans.
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Figure 5.26: The beam profile of the 6 FFF and 15FFF photon beams for a 10x10 cm^ at
1.5 cm depth in a water phantom.
(i.e. the width of tumour is less than 10 cm). To optimise the 15FFF plans, the TPS 
needs to be re-commissioned to be able to calculate the optimised MLC sequences. This 
needs the FF to be removed from the linac and re-commissioning the TPS system by 
measuring the PDDs, beams profiles and output factors for different field sizes then 
imported them the TPS. However, this is difficult to be carried out in a busy radiotherapy 
department at the hospital and I think it needs to be performed on a linac dedicated 
only for research. Another method that can be used to optimise the TPS is carrying out 
several MC simulations to obtain these data (PDDs, beam profiles, etc.) for different 
field sizes then import them to the TPS. However, This method is time consuming and 
more important can not used with Varian Eclipse TPS, but rather with other TPSs such 
as Elekta Pinnacle TPS (Elekta Ltd, Crawley, UK).
N eu tro n  calcu lations
The calculated neutron dose equivalent for 15X and 15FFF MC Step and shoot IMRT 
prostate plan carried out on a water phantom are depicted in figure 5.27. As can be 
seen in this figure, neutrons deposit their energy within the first few centimetres from 
the phantom or patient surface which agreed with literature (Kry et al. 2009, Martmez- 
Ovalle et al. 2011). The maximum neutron dose equivalent for the 15X IMRT plan was 
found to be 9.1i0.3 fiSv MU L This is equivalent to 2.1T0.1 mSv Gy~^ as the total
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number of MUs in this plan was 471 to deliver 2  Gy to isocentre for each radiotherapy 
fractionation. This result agreed with what was obtained by Hussein et al. (2 0 1 2 ) as they 
found the neutron dose equivalent of IMRT for prostate cancer using Polyallyl-diglycol- 
carbonate detector, a neutron track etch detector, to be 2.04:0.3 mSv Gy~^. The neutron 
dose equivalent decreases sharply with the FF removal . The maximum dose equivalent 
for the 15FFF plan was found to be 2.4±0.1 //Sv MU“  ^ (0.56±0.02 mSv Gy“ )^ which 
is equivalent to a 71.3% reduction per MU. The result obtained of the 15FFF plan is 
still valid although the non-optimised plan was used in this study as the neutron dose 
does not change significantly by changing the MLC shape. Since most prostate cancer 
patients receive in general a total dose of 75 Gy in 30-40 fractions, the total neutron 
dose equivalent of the 15FFF plan is 42 mSv rather than 158 mSv in the case of 15X 
plan. Prom these results, the lifetime risk of neutrons to induce secondary fatal cancers 
in the general population is found to be 0.8% and 0.2% for 15X and 15FFF IMRT plans 
respectively, these values can increase to 1 .2 % and 0 .3 % by including the total risk of 
inducing secondary cancers (fatal and non-fatal) in the general population. These values 
were calculated according to what was reported in the NCRP report 116 supposing the 
lifetime risk of radiation to induce fatal or secondary cancer per Sv in general population 
is 5% or 7.3%, respectively (NCRP 1993).
15 20 25 30
X (cm )
10 15 20 25
X(cm)
(a) (b)
Figure 5.27: The neutron dose equivalent for SnS IMRT prostate plan modelled on a water
phantom using (a) 15X and (b) 15FFF.
Prom figure 5.24, it can be seen that the 6  MV plan gives substantially higher dose to 
normal tissues within the first few centimetres of patient surface in-field direction. For
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example, the mean dose within the first 5 cm the left- posterior beam at the isocentre 
CT slice was decreased from 68.8±9.2(1SD)% for 6 X plan to 56.0±7.4(1SD)% for 15X 
plan. This means that the patient, within this region, is receiving an extra 9  Gy by using 
the 6 X beam which is significantly higher than what the patient receives in the 15X plan 
even by adding the neutron dose. Moreover, the mean dose to normal tissues, Dnormah 
which can be calculated using the following equation was found to be 8 .4 % and 7 .8 % in 
the 6 X and 15X plans respectively.
7-v ^ 2 B ody ^ v o x e l Y 2 p T V  ^ v o x e l{ '^ )
------------- (5.6)
Where, Y^Body ^voxei{i) is the sum of the dose in each voxel in the patient body, Y2ptv  ^voxeiif) 
is the sum of the dose within the PTV , Npody is the total number of voxels in the patient 
body and Nppv  is the total number of voxels within the PTV.
Prom these results, I believe that the use of the 15 MV beam for IMRT plans of 
prostate cancer should not be discarded as it might give better treatment outcomes. If 
the linac is re-configured to be used in the 15FFF photon, this might produce extra OAR 
sparing and lower dose to normal tissues besides imparting significantly lower neutron 
dose to patient.
5.5 The dosimetric effect of combining two FFF beams 
in IMRT for prostate cancer
A number of studies have reported several advantages of flattening filter free (FFF) 
photon beams such as the improvement in beam stability. In contrast with flattened 
photon beam where the slight change in beam position and energy severely affects the 
beam flatness and symmetry, the FFF photon beam proves to have less dependent on 
these parameters (Cashmore 2008, Georg et al. 2 0 1 1 ).
Georg et al. (2011) outlined that the FFF photon beam is more stable than the 
conventional beam and it could open the door to energy modulated radiotherapy (EMRT).
Akino et al. (2013) reported that the FFF beam of the Siemens A rtiste™  linear 
accelerator (Siemens, Erlangen, Germany) was stable even for low monitor units (>  2  
MU). The linearity in dose delivery was found to be within ± 2 %.
On the other hand, few studies have addressed the potential of using a mix of two
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flattened photon beams in radiotherapy of different cancer sites. Lief et al. (2008) used a 
mix of 6  and 15 MV flattened photon beams to increase the dose to the superficial region 
for treating a large intact breast cancer.
Park et al. (2 0 1 1 ) studied the feasibility of using a mix of 6  and 15 MV flattened 
photon beams in IMRT for a prostate cancer. They found that the Vjocy in the rectal 
wall was 16.7%, 17.9% and 16.3%, for 6  MV, 15 MV and a mix of 6  and 15 MV photon 
beams, respectively. The mean dose in the femoral head was found to be 31.7, 26.3 and 
26.2 Gy, respectively.
In addition, Pokharel (2013) investigated the effect of mixing 6  and 16 MV flattened 
photon beams in VMAT for prostate cancer. He obtained similar PTV coverage as in 
the single 6  MV VMAT plan. The mean dose in the rectum and bladder were reduced 
by 3.7% and 8.4%, respectively, in mixed-beams VMAT plan. However, the mean dose 
to the femoral head increased by 0 .8 %.
To my knowledge, no one has studied the effect of mixing unflattened photon beams on 
treatment outcomes. The aim of the present work is to assess the use of two unflattened 
photon beams in treatment outcomes by comparing IMRT plans for a prostate cancer 
created using the flattened 6  MV (6 X), unflattened 6  MV (6 FFF) and a mix of 6 FFF 
and 15FFF (6_15FFF) photon beams with regard to PTV coverage, OAR sparing, and 
surface dose using the Monte Carlo (MC) technique. This work is a preliminary study as 
no optimisation of the 6 FFF and 15FFF plans were carried out.
5.5.1 M aterials and m ethods
The two dynamic IMRT plans of the prostate cancer case, modelled in the previous 
section, using both 6  and 15 MV beams were employed in this study. This IMRT plan 
was performed with 5 beams (posterior, left posterior, left interior, right interior and right 
posterior photon beams). The plans were then modelled using BEAMnrc/DOSXYZnrc 
and the evaluation parameters were extracted using the MATLAB code (see section 5 .4 .1  
for the detailed explanation for the process).
The 6_15FFF plan was modelled by having three 6 FFF beams (posterior, left interior 
and right interior photon beams) and two 15FFF beams (left posterior and right posterior 
photon beams). Figure 5.28 shows a schematic diagram of the modelled 6_15FFF plan. 
The calculated assessment parameters in the PTV, rectum and bladder are also the same
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15FFF
6FF
Figure 5.28: Figure 1: A schematic diagram of the photon beam energies and directions
used in the 6_15FFF plan.
as listed in table 5 .1 2 .
W^ith regard to the patient entrance dose received during the total treatment course, 
the mean dose in-field within the first few centimetres from the patient’s surface was 
likewise calculated in the left-posterior beam within the first five centimetres from the 
patient’s surface for the three plans.
5.5.2 R esults and discussion
The calculated evaluation parameters of the PTV, rectum and bladder and the total MUs 
for the three IMRT plans using 6 X, 6 FFF and 6_15FFF photon beams are summarised 
in table 5.15. It can be seen from this table that all plans were found to be clinically 
acceptable according to ICRU recommendations (ICRU 2010). The deviation in the mean 
dose and D50 in the PTV between these plans was found to be within 2.2%. The 6 X plan 
provides the best conformity and homogeneity within the PTV, but the 6_15FFF plan 
gives better conformity within the PTV than the 6 FFF plan.
Although the 6 FFF plan reduces the dose to the rectum and bladder compared with 
the 6 X plan, the 6-15FFF plan provides the lowest dose to both OAR with a significant 
decrease (44.9%) in the D50 within the bladder. This reduction results to the substantial
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decrease in head scatter and therefore in out-of-field dose. It should be noted that the 
mean dose of the 6_15FFF plan within the tumour itself (within the GTV) is 9 9 .7 %. In 
addition, both HI and CN improved within this region to 0.20 and 0.48. This means 
that the decrease in dose only occurs at the margin added to the GTV to take into 
account the uncertainty in positioning the patient and change in tumour shape. Thus, 
this result might be considered as a positive thing especially with the improvement in 
imaging modalities before and during the treatment course.
Table 5.15: The calculated evaluation parameters of the PTV, rectum and bladder for the 
MC IMRT plans using the 6X, 6FFF and (6_15)FFF photon beams. The uncertainty was less
than 2 %.
6 X 6 FFF 6_15FFF
P T V
M e a n  d o s e  (%) 98.3 96.6 96.1
D2 (%) 103.4 102.9 106.5
%  (%) 99.5 97.7 98.4
%  (%) 89.0 87.0 71.7
H I 0.15 0.16 0.36
C l 1.05 1.03 1.04
C N 0.42 0.24 0.37
R ectum
M e a n  D o s e  ( % ) 38.9 38.4 35.9
1)2 (%) 95.1 93.6 95.0
%  (%) 27.8 27.6 25.4
Dgg (%) 5.6 5.2 6.04
V 2Q G y (%) 52.9 51.9 45.7
FroGy (%) 4.2 2 .6 2 .0
Bladder
M e a n  d o s e  (%) 33.4 32.9 25.3
D2 (%) 96.9 95.5 90.7
%  (%) 20.7 19.9 11.4
%  (%) 2.5 2.5 2.5
UzOGy ( % ) 45.6 44.2 35.9
UrOGy ( % ) 5.8 3.4 0.7
The mean dose within the first 5 cm of the left- posterior beam for a slice crossing
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the isocentre was found to be 68.8±9.2(1SD)%, 72.3±9.5(1SD)% and 58.7±7.7(1SD)% 
for 6 X, 6 FFF and 6_15FFF plans, respectively. Figure 5.29 shows the dose distribution 
in a CT slice at the isocentre of the MC dynamic IMRT plans using 6 X, 6 FFF and 
photon beams. The results obtained, as clearly seen in this figure, show that 
the 6 X and 6 FFF plans give substantially higher dose to normal tissues within the first 
few centimetres of the patient s surface in-field direction. The increase in the mean dose 
within the first 5 cm from the patient’s surface in the left-posterior beam at the iso centre 
CT slice in 6 X and 6 FFF plans was found to be 10.1% and 13.6%, respectively, compared 
with the 6-15FFF plan. This means that the tissues, within this region, receive 7.5 and 
10 Gy extra dose by using the 6 X or 6 FFF photon beam, respectively.
On the other hand, the production of photoneutrons by using energies >10 MV raises 
concerns of adding extra dose to the patient. As found in the previous section the 
neutron dose from the 15FFF IMRT was estimated to be 2.4di0.1 //Sv MU“ L Thus, the 
estimated total neutron dose, received during a full treatment course, in the 6_15FFF 
plan is 24.2±0.3 mSv per 74 Gy as the total number of MUs in both 15FFF beams was 
272. This value increases the risk by neutrons to induce secondary fatal cancer in the 
general population by only 0.12% according to the NCRP report 116 (NCRP 1993).
From these preliminary results. It can be demonstrated that combining two unflat­
tened photon beams could provide better treatment outcome by providing lower dose to 
OAR as well as reducing the patient surface dose. Further investigation should be carried 
out on FFF linac at different energies, different treatment cases and optimised TPS for 
FFF beams.
95
M. A. Najem CHAPTER 5. MONTE CARLO STUDY OF VARIAN CLINAC
(c)
F igure 5.29: The dose distribution in a CT slice at the isocentre of the MC dynamic IMRT 
prostate cancer plans using: (a) 6 X, (b) 6 FFF and (c) 6.15FFF photon beams. The 
’’MMCTP” software was used for plan visualization (Alexander et al. 2007).
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Chapter 6 
M onte Carlo study of Varian 
TrueBeam w ith and w ithout a 
flattening filter
Varian Medical Systems titled their recent linac, which can operate w ith/without a FFF, 
as ’’TrueBeam”. TrueBeam has photon energies of 4, 6 , 8 , 10, 15, 18 and 20 MV com­
pared to other linacs, which, mostly, have only two photon energies. Only 6  and 10 MV 
photon modes in this linac, so far, can operate with/without a FF (Hrbacek et al. 2011). 
Moreover, TrueBeam can produce dose rates from 250 to 2400 MU min~^ whereas con­
ventional linacs can only produce dose rates up to 600 MU min~^. This improvement in 
dose rate can be useful for several treatments such as SBRT (Georg et al. 2011).
Several researchers have investigated and measured the dosimetric properties of True­
Beam linacs (Chang et al. 2 0 1 2 , Glide-Hurst et al. 2013, Hrbacek et al. 2 0 1 1 ). However, 
only a small number of MC simulations were performed to study these properties due to 
access limitations to the geometrical configuration information of the Varian TrueBeam 
linac head, which was released in 2 0 1 1  as phase-space files (Constantin et al. 2 0 1 1 , Gete 
et al. 2013). This version of the phase-space files was scored on a cylindrical surface 
instead of planar surface, which needs to be modified to be read in BEAMnrc code. This 
problem was then resolved in the Varian second version of TrueBeam phase-space files 
released in 2013 as they were scored on a planar surface.
On the other hand, as mentioned in chapter 4, several studies have reported interesting 
results of using unflattened photon beams for several treatments such as prostate cancer
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(Vassiliev et al. 2007).
The aim of the present work was first, to calculate the dosimetric properties for 
the 6 X, 6 FFF, lOX and lOFFF photon beams based on Varian TrueBeam 2”  ^ version 
phase-space files and compare them with measurements. Second, to assess four VMAT 
treatment plans performed with the same photon beams in terms of PTV coverage and 
organs at risk (OAR) sparing.
6.1 M aterials and methods
6.1.1 Dosim etric Properties
M C param eters
Several MC simulations were performed using phase-space files obtained from Varian as 
radiation sources using BEAMnrc in order to calculate the dosimetric quantities with and 
without FF for the 6  MV and 10 MV photon beams. The calculations were performed 
by setting the jaws to produce a 1 0 x 1 0  cm^ field size at the isocentre. MC results scored 
as new phase-space files and used for the irradiation of a 30x30x30 cm^ water phantom 
created using DOSXYZnrc . The water phantom was divided into voxels with a voxel 
size of 0.5x0.5x0.25 cm^ up to 3 cm depth and 0.5 x 0.5x1 cm^ up to the maximum 
depth of 30 cm. The electron and photon cut-off energies were set to 0.7 and 0.01 MeV, 
respectively. The number of histories in each simulation was set to produce an uncertainty 
less than 2 % at all points.
The effect o f field size
In order to calculate the differences in the dosimetric properties with and without FF for 
different field sizes, several MC simulations were performed with lOX and lOFFF beams 
with field sizes from 2x2 to 40x40 cm^. The size of the water phantom was increased to 
50x50x30 cm^ to cover all field sizes.
Calculated param eters
Five dosimetric properties were calculated for each photon beam mode. The percentage 
depth doses (PDDs) for each energy mode were calculated at the central axis. The
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entrance dose at the central axis was calculated at depth 2.5 mm from the phantom 
surface for a 10x10 cm^ field size. The change in dose rate when the FF was removed 
was calculated on the central axis at dmax- The beam profile and the out-of-field dose 
for all photon energies for a 10x10 cm^ as well as for each field size in the case of lOX 
and lOFFF beams across the central axis at dmax were also calculated. The out-of-field 
dose was calculated at a distance 3 cm from the edge of the phantom as Diallo et al.
(2009) had reported that about 66% of secondary cancers occur between the edge of the 
treatment field and 5 cm.
MC validation
All calculated results were compared with measured data obtained from University Col­
lege London Hospital (UCLH), London, UK.
6.1.2 VM AT Plan
Two VMAT inverse plans using the 6X and 6FFF beams for a prostate cancer case 
were created by the treatment planning system (TPS) at UCLH. These plans were then 
exported in DICOM” format to be used in MC simulations. The steps used for modelling 
these plans from the plans exported in ” DICOM” format are the same used for modelling 
IMRT plans in section 5.4.1. The voxel size of the created MC phantom using ” ctcreate” 
was 4x4x2.5 cm^. The total number of segmentations in the modelled plans was 178. 
Figure 6.1 shows the size (width and depth) of the patient modelled in this work. The 
volume of the PTV is 77 cm^.
Since the TrueBeam machine at UCLH is equipped with high definition MLC produc­
ing a maximum field size of 22x32 cm^ in dynamic mode, the ’’SYNCHDMLC” (a MC 
component) was used to accurately model this type of MLC. Another two MC plans for 
lOX and lOFFF beams were created with the same VMAT hospital plan set-ups of the 
6FF and 6FFF beam, respectively. These plans were created as preliminary study plans 
in order to investigate the feasibility of using photon beam energies higher than 6 MV 
and to evaluate their impact on treatment outcome as VMAT plans at UCLH are only 
created using 6 MV photon beam energy. The calculated assessment parameters in the 
PTV, rectum and bladder are the same parameters as listed in table 5.12.
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22.5 cm
F igure 6.1: A CT slice illustrate the depth and width of the patient modelled in this work.
The PTV is shown as a red circle in this slice.
VM AT plans validations
The MC VMAT plans generated using TrueBeam phase-space files of the 6X and 6FFF 
beams were compared to those obtained from UCLH by comparing the mean dose and 
DVH at the PTV, rectum and bladder as well as the dose at isocentre for both MC and 
hospital plans.
6.2 Results and discussion
6.2.1 Dosim etric properties 
D ose rate
The calculated dose rates of the 6FFF and lOFFF beams were found to be 2.20±0.04 
and 3.20±0.06 higher than that of the 6X and lOX beams, respectively. The value of 6 
MV beams agreed with the literature as Hrbacek et al. (2011) found it to be 2.26±0.02. 
However, my finding for the 10 MV beams was less than what has been published as it 
was found to be about 4.03i0.04 (Hrbacek et al. 2011). The reason for that is because the 
linac is set to produce a maximum dose rate for 6 and 10 MV conventional photon beams 
to 600 MU/min while in the FFF mode this dose rate can increase to 2400 MU/min in 
the case of lOFFF beams. In MC simulations the dose rate is not limited and therefore
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the lOX beam produces higher dose rate than that of the 6X beam.
PD D s at the central axis
Plot of the MC calculated and measured PDDs for all photon beams are shown in fig­
ure 6.2. Results showed good agreement between the simulated and measured PDDs. For 
example, the Dio (dose at 10 cm depth) for the calculated and measured 6X beam were 
found to be 66.7il.3%  and 66.6i0.7%, respectively. The FFF beams have a somewhat 
faster fall-off after due to the softness of the FFF X-ray spectrum compared with 
that of the FF beams. Table 6.1 shows the beam quality indices Dio and dgo (the depth 
at 80% dose) for the calculated and measured 6X, 6FFF, lOX and lOFFF beams.
1 0 0 -
■ 6X-MC
•  6FFF-MC
- A 10X-MC
▼ 10FFF-MC
------ 6X-UCLH
------ 6FFF-UCLH
-------10X-UCLH
------ 10FFF-UCLH
2 0 -
0  5  1 0  1 5  2 0  2 5  3 0
Depth (cm)
Figure 6.2: The MC calculated and measured PDDs of the 6X, 6FFF, lOX and lOFFF 
photon beams for a 10x10 cm^ field size in a water phantom.
T able 6.1: The calculated (MC) and measured beam quality indices of 6X, 6FFF, lOX and 
lOFFF photon beams for a 10x10 cm^ field size.
6X 6FFF lOX lOFFF
MC Measured MC Measured MC Measured MC Measured
Dio (%) 66.7±1.3 66.64:0.7 63.1±1.3 63.8±0.6 73.6±1.5 73.14:0.7 72.14:1.4 71.24:0.7
dgo (cm) 6.54:0.5 6.5±0.1 6.0±0.5 6.1±0.1 8.24:0.5 8.2±0.1 7.84:0.5 7.64:0.1
1 0 1
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E n tran ce  dose
Since the FFF beams have a softer X-ray spectrum than the FF beams, this results in an 
increase in the entrance dose which increases the patient surface dose. Table 6.2 shows 
the calculated and measured entrance doses for 6X, 6 FFF, lOX and lOFFF beams on 
the central axis for a 10x10 cm^ field size at 2.5 mm depth from the phantom surface. 
It can be seen that the rise in the entrance dose due to the removal of the FF increases 
with beam energy and was found to be 16.74:0.3% and 21.14:0.4% for the calculated 6 
and 10 MV beams, respectively. The percentage differences between the calculated and 
measured entrance doses were found to be within 2.0% for all photon beams and modes 
under investigation.
T able 6.2: The calculated and measured entrance dose for 6X, 6FFF, lOX and lOFFF beams 
at 2.5 mm depth from the phantom surface on the central axis for a 10x10 cm^ field size.
MC (%) Measured (%) Absolute difference (%)
6X 60.5 62.0 1.5
6FFF 70.6 69.0 1.6
lOX 47.9 46.1 1.8
lOFFF 58.0 56.5 1.5
B eam  P rofile
Figure 6.3 shows the plot of the MC calculated and measured beam profiles of all photon 
beams for a 10x10 cm^ field size and the calculated beam profiles for different field sizes 
varying from 4x4 to 40x40 cm^ for the lOX and lOFFF photon beams. It can be seen in 
figure 6.3(a) that the calculated profiles are in good agreement with measurements. The 
lOFFF beam had a sharper profile than the 6FFF beam given that the higher electron 
beam energy, the more forward the emitted X-rays (Mayles et al. 2007). In Figure 6.3(b), 
it can be seen that as the field size increases, the beam profile flatness decreases. There­
fore, several authors have reported that the standard definition of penumbra becomes 
meaningless and should be replaced by the definition suggested by Ponisch et al. (2006).
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Figure 6.3: (a) The calculated and measured beam profiles at d m a x  of the 6X, 6FFF, lOX 
and lOFFF beams for a 10x10 cm^ field size, (b) The calculated beam profiles of lOX and
lOFFF for different field sizes.
Out-of-field dose
Tables 6.3 and 6.4 outline the calculated and measured out-of-field doses of all beams 
for a 10x10 cm^ field size and the calculated out-of-field doses of lOX and lOFFF beams 
for different field sizes. Good agreement has been achieved between the calculated and 
measured results, where the maximum percentage difference was within 0.2%. It was 
observed that the out-of-field doses of 6 and 10 FFF beams were lower than that of 6 and 
10 conventional beams. The out-of-field dose was reduced by 30.4±0.6% and 44.84:0.9% 
for 6 and lOFFF beams, respectively, with a 10x10 cm^ field size.
Similarly, for the same field size the out-of-field dose was decreased for the lOFFF 
beam compared to the lOFF beam by up to 76.3% for a 40x40 cm^ field size. In addition, 
the out-of-field doses of lOX beam were found to increase with increasing field size. It 
is worth mentioning that the reduction in the calculated and measured out-of-field doses 
for both 6 and lOFFF beams was obtained for all beam energies and field-sizes even at 
distances larger than 5 cm form the field edge. This again differs from what was reported 
by Kry et al. (2010). The decrease in out-of-field dose has a significant impact on reducing 
the secondary induced cancers especially for pediatric patients as it was reported that 
the risk of secondary induced cancer in pediatric patients is 66% within the first five 
centimetres from the edge of treatment field (Diallo et al. 2009).
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T able 6 .3 . The measured and calculated out-of-field dose at a distance 3 cm from the field 
edge of the 6X, 6FFF, lOX and lOFFF beams for a 10x10 cm^ field size at d^^T.
MC (%) Measured (%) Absolute difference (%)
6X 2.3 2.5 0.2
6FFF 1.6 1.7 0.1
lOX 2.9 2.8 0.1
lOFFF 1.6 1.5 0.1
T able 6.4: The calculated out-of-field dose (%) at a distance 3 cm from the field edge of the 
lOX and lOFFF beams for different field sizes d m a x -
4x4 cm^ 10x10 cm^ 20x20 cm2 30x30 cm2 40x40 cm2
lOX 1.0 2.9 5.0 7.2 7.6
lOFFF 0.6 1.6 2.1 2.2 1.8
6.2.2 VM AT Plan evaluation  
Plan verification
The MC calculated plans agreed well with the TPS VMAT plans as can be seen in 
figure 6.4. The absolute percentage differences between the MC calculated and TPS 
plans for the 6X and 6FFF beams (as shown in table 6.5) were less than 1.5% at the 
isocentre and mean dose within regions of interest. The MC and TPS calculations of the 
DVH for the PTV, rectum and bladder of 6X and 6FFF VMAT plans are illustrated in 
figure 6.5. Minor variations between the MC and TPS calculated DVHs were observed. 
These differences in DVH values were due to the differences in the voxel size of the 
CT images used for the TPS (1x1x2.5 mm^) and MC (4x4x2.5 mm^) calculations. 
Even though the voxel size of the CT images used for the MC plans was larger than 
that used by the TPS, MC calculations produced accurately 3D dose distribution which 
can be hardly obtained by using the existing dosimetric instruments (e.g. ion chamber or 
thermoluminescence dosimeters (TLDs)). Therefore, the MC treatment plan calculations 
could be used as a tool for TPS quality assurance and treatment planning verification.
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Table 6.5: The dose at the isocentre and mean dose in the PTV, rectum and bladder for 6X 
and 6FFF VMAT plans calculted using MC and TPS. The uncertainty was less than 2%.
6X 6FFF
MC Measured Absolute Diff. MC Measured Absolute Diff.
Dose at Isocentre (%) 9&8 98.6 0.2 99.2 99.9 0.7
Mean dose (%)
P T V 98.2 98.6 0.4 9&8 98.6 0.2
R e c t u m 68.3 69.3 1.0 68.5 69.2 0.7
B l a d d e r 37.1 36.2 0.9 36.7 36.1 0.6
m ü
m #
(c) (d)
F igure 6.4: The dose distribution in a CT slice at the isocentre of the TPS and MC VMAT 
prostate cancer plans using: (a) 6X-TPS, (b) 6X-MC, (c) 6FFF-TPS and (d) 6FFF-MC  
beams. The ’’MMCTP” software was used for plan visualization (Alexander et al. 2007).
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Figure 6.5: The DVH of PTV, rectum and bladder for (a) 6X and (b) 6FFF VMAT prostate 
cancer plans calclated usng MC techniques and TPS.
E valua tion  of p lans
AU calculated MC VMAT plans were found to be clinically acceptable according to ICRU 
recommendations, where the mean dose in the PTV was within 9 5 % and 107% (ICRU 
2 0 1 0 ). Table 6 . 6  and figure 6 . 6  show that the PTV coverage and OAR sparing were 
almost similar for all plans. The deviation in the mean dose and D50 in the PTV between 
all plans and the 6 X plan was found to be within 1.5%. The non-optimised lOX plan 
had the lowest HI and highest CN values (best values) where the non-optimised lOFFF 
plan had the highest HI and the lowest CN values. However, the non-optimised lOFFF 
plans had the lowest mean dose within the rectum and bladder. In addition, the use 
of the lOFFF beam significantly reduced the Vyocy for both the rectum and bladder by 
69.1±1.4% and 60.5±1.2%, respectively. This is due to the profile sharpness of lOFFF 
beam.
Results obtained for the 10 MV plans in this study supported what were obtained 
by Zwahlen et al. (2012) where they found that the lOFFF beam provides better OAR 
sparing than other beams. It was also demonstrated that treating patients using VMAT 
with higher energy than 6  MV with or without FF can produce clinically acceptable 
results and might give better PTV coverage and/or OAR sparing. Moreover, changing 
only the beam energy of the treatment plans without applying an optimisation did not 
have a great impact on the overall outcomes of the treatment plan. Further investigations
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Table 6.6: The calculated evaluation parameters of the PTV, rectum and bladder for the 
MC VMAT plans using 6X, 6FFF, lOX and lOFFF beams. The uncertainty was less than 2%.
6X 6FFF lOX lOFFF
PT V
M e a n  d o s e  ( % ) 98.2 9&8 99.4 96.7
Dg (%) 101.6 102.1 102.0 100.7
%  (%) 97.9 98.5 99.1 96.6
Dgg (%) 93.6 93.5 94.6 8&9
H I 0.08 0.09 0.07 0.11
C l 1.41 1.25 1.31 1.10
C # 0.20 0.32 0.39 0.13
Rectum
M e a n  D o s e  ( % ) 68.3 68.5 67.1 63.4
D2(%) 95.5 96.3 96.6 94.2
-P50 (%) 68.3 69.0 68.5 6&8
D98 (%) 20.7 21.3 19.8 18.0
V 2Q G y (%) 95.8 95.8 95.4 94.7
UroGy (%) 10.6 13.0 13.8 3.2
Bladder
M e a n  d o s e  (%) 37.1 36.7 36.2 33.7
Dg (%) 99.1 98.6 99.5 95.3
%  (%) 19.0 17.6 19.6 17.0
%  (%) 2.4 2.6 1.6 1.5
V 2 0 G y  ( % ) 45.4 45.1 45.2 44.0
UrOGy ( % ) 11.9 11.0 11.3 4.7
Total M Us 428.5 479.5 428.5 479.5
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Figure 6.6: The DVHs of the PTV, rectum and bladder for 6X, 6FFF, lOX and lOFFF MC
VMAT plans.
should be carried out in order to ascertain whether replanning a treatment by only 
changing the beam energy without an optimisation would be clinically acceptable. The 
total MUs was increased with the FFF beams by a factor of 1.12. However, similar or 
even lower (in case of lOFFF) dose to normal tissues can still be found.
The neutron dose, when using 10 MV beams, was not discussed in this work as the 
photoneutron production is considered negligible, especially for a lOFFF beam as was 
found for the Varian Clinac in section 5.2.2 to be 0.020±0.003 mSv Gy~L
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Conclusion and recom m endations
Two MC codes, FLUKA and BEAMnrc/DOSXYZ, have been used in this project in order 
to study the effect of the FF removal from the linac head on the dosimetric properties 
of photon beams and radiotherapy outcomes. Both codes have been used to model two 
types of medical linacs which are Varian Clinac and Varian TrueBeam.
In C h a p te r  4 the literature was reviewed. It was found that FFF linacs produced several 
advantages compared with conventional linacs. The advantages are:
•  Increase in dose rate which is useful for SBRT and treatments requiring control of 
organ motions as well as reducing the beam-on and/or treatment time.
• Decrease in out-of-field dose and neutron dose which has a significant impact on 
reducing the risk of secondary induced cancers as well as on reducing the shielding 
cost in term of building new treatment rooms.
•  The softness in X-ray spectra which improves the MVCBCT images quality.
Only one disadvantage was found which is the increase in entrance dose. Other factors 
such as the biological effect of FFF beams due to the increase in dose rate and FFF beam 
energy on treatment outcome are still under investigation and they require more studies 
and follow-up.
As discussed in C h a p te r  5, the dosimetric properties of the unflattened beam for a 
15 MV Varian Clinac 21000 linac with emphasis on the photoneutron production were 
calculated using FLUKA. It was found that the dose rate for the unflattened beam was 
increased 4.86 times compared with the flattened one. This increase could be useful in
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a number of treatment cases such as SBRT lung cancer. Obviously, the removal of the 
FF reduces the out-of-field dose, where it was found reduced, in this work, by 44%. The 
neutron fiuence and neutron dos-equivalent were also reduced by 77%. These reductions 
have a significant impact on decreasing the probability of induced secondary cancer. The 
photon surface dose was found to be about 13% higher than the fiattened beam. The 
increase in surface dose from all treatment fractions might increase the patient surface 
dose and that needs further investigation.
By increasing the field size of the 15FFF photon beam, the reduction in out-of-field 
dose, neutron fiuence and neutron dose equivalent enlarged. The reduction was due to 
the decrease in head scatter. The neutron level inside the treatment room decreased with 
the FF removal at all energies. However, the amount of reduction varied with energy due 
to the dissimilarity in FF compositions.
The decline in neutron dose equivalent and neutron fiuence using the FFF beam, 
which were up to 76%, has a significant impact on the outcome of radiotherapy treat­
ment as reported by Followill et al. (2007) that the risk of neutrons to induce secondary 
cancers is about 2.2% and 5.1% for 15 and 18 MV beams, respectively. In addition, 
the reduction in neutron fiuence, found in this work, and radiation scatter inside the 
treatment room, found in other studies, can decrease the annual dose received by staff 
for existing treatment rooms or reduce the shielding cost when new treatment rooms are 
built. Of course, more research is needed to calculate the total workload of these types 
of linacs as the enlargement in dose rate and decrease in treatment time could increase 
the number of patients treated and therefore the weekly workload. Having carried out 
these calculations, the amount of shielding required can be more accurately estimated.
With regard to portal imaging, the effect of using a copper target to acquire MVCBCT 
images was studied. It was found that the low energy photon ratio was increased by a 
factor of 7.2 when the copper target was used as a replacement for the conventional 
target. The image quality for a simple phantom made of two cylindrical bones with 2 
cm diameter placed inside 5 cm thickness water phantom was improved by 31%. As a 
consequence, the quality of MVCBCT images can be improved with a simple and low 
cost modification of the Varian copper target and the use of FFF beam.
With reference to IMRT plans for prostate cancer treatment, the plans created by the 
6X, 6FFF and 15X photon beams passed the acceptance criteria. Dynamic IMRT plans
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offered slightly better dose homogeneity within the PTV than the step and shoot IMRT 
plans but can be considered negligible. The 15X plan had the lowest mean dose within the 
rectum and bladder compared with the 6X and 6FFF plans but the 6FFF plans had the 
lowest V'jQGy The 15FFF plans did not provide enough coverage to the PTV and therefore 
did not meet the acceptance criteria because they were not optimised. The optimisation 
process required re-commissioning of the TPS to be able to calculate the optimised MLC 
sequences. This process was difficult to be achieved in a busy radiotherapy department.
Neutron doses from a step and shoot IMRT using the 15X and 15FFF beams were 
calculated. Having the FF been removed, the neutron dose equivalent decreased by 
71.3%. This reduction reduced the estimated risk of inducing secondary cancers from 
1.2% to 0.3%. It was found that neutrons deposited most of their energy within few 
centimetres from the phantom surface. Comparing the 6X and 15X plan with tacking 
into account the neutron dose, the 6X plans provided significantly higher in-field dose 
within a few centimetres from the patient surface as well as slightly higher mean dose to 
normal tissues. The estimated extra dose in this region during the total course of prostate 
cancer treatment was found to be 9 Gy. Thus, the IMRT using the 15X beam should be 
included as one of the possible option of prostate cancer treatment. If the TPS had been 
optimised to include dose calculations of the 15FFF beam, the knowledge whether the 
15FFF beam could provide better treatment outcomes would have been ascertained.
Combining 6 and 15FFF beams in IMRT was introduced and assessed using MC 
techniques. An IMRT plan for prostate cancer was modelled using 6X, 6FFF and 6_15FFF 
photon beams. All plans produced sufficient PTV coverage and OAR sparing and were 
clinically acceptable. The 6-15FFF plan gave a significant sparing of the rectum and 
bladder. It also reduced the dose to the patient’s surface. The neutron dose produced 
in this plan can be considered negligible. To conclude, this technique can be considered 
as a prototype for the EMRT technique which can open the door towards the optimum 
photon radiotherapy.
As already explained in C h a p te r  6, the calculated dosimetric properties for 6 and 10 
MV beams with and without a FF using the second version of Varian TrueBeam phase- 
space files were in good agreement with measurements. Beam dose rate for unfiattened 
beams was increased by a factor of 2.3 and 3.2 at photon beam energy 6 and 10 MV, 
respectively. The out-of field dose decreased for FFF beams and the amount of reduction
111
M. A. Najem__________ CHAPTER 7. CONCLUSION AND RECOMMENDATIONS
varied as a function of beam energy and field size. However, the surface dose was increased 
when the FF was removed.
With respect to VMAT plans evaluation, all plans, generated using the MC technique, 
produced similar PTV coverage and OAR sparing and were clinically acceptable. The 
MC plans were in good agreement with TPS. Small variations in DVHs calculations 
between the MC and TPS plans were found as a result of the differences in voxel size of 
CT images used for MC and TPS calculation. The lOX VMAT plan provided the best 
homogeneity and conformity within the PTV. On the other hand, the lOFFF VMAT plan 
gave the best OAR sparing with a significant reduction in the Wocy by 69.1% and 60.5% 
in rectum and bladder, respectively. References to these results, the use of 10 MV beams 
for VMAT plans should not be discarded as they might give better treatment outcomes.
From the current study on Varian Clinac and TrueBeam, it can be concluded that the 
unflattened beam can enhance the outcomes of existing radiotherapy techniques such as 
IMRT and VMAT. Therefore, FFF linacs can provide a step forward toward the optimum 
results of Radiotherapy treatments.
Table 7.1 summarises the dosimetric characteristics of Varian Clinac and TrueBeam 
unflattened photon beams at different energies calculated which were calculated in this 
work where possible.
T able 7.1: Summary table of the dosimetric characteristics of Varian Clinac and TrueBeam 
unflattened photon beams at different energies compare to flatten beams.
Varian Clinac Varian TrueBeam
Beam energy (MV) 6 10 15 18 6 10
increase in dose rate 2.30±0.05“ - 4.86±0.095.50±0.11“ 2.20T0.04 3.20±0.06^
increase in entrance dose 1 6 . 1 ± l . r ' ^  -  18.7±0.4‘^ 40.0±2.8“’‘= 16.7T0.3® 21.1T0.4®
decrease in out-of-field dose 15.0±0.8“’^  - 48.3±0.5-^ 43.0±2.2“’^  30.4±0.6-^ 44.8±0.9-^
decrease in neutron contamination N/A 54.4T1.0 76.0T1.5 75.0F1.5 N/A
a: (V assiliev  et al. 2006a).
b: Hrbacek e t al. (2011) found it to  b e 4 .0 3 ± 0 .0 4 . See section  6.2.1 for d etails, 
c: ca lcu la ted  a t 3 mm  d epth  on th e  central axis, 
d: ca lcu la ted  at 2 .5  mm  d ep th  on  th e  central axis, 
e: ca lcu la ted  a t 4 cm  from field ed ge at 10 cm  depth, 
f: ca lcu la ted  at 3 cm  from field  ed ge a t d m a x  ■
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7.1 Recommendations
This work studied only the photon beam characteristics of FFF linacs including the dose 
rate, beam profiles, out-of-field dose, entrance dose and neutron dose. The portal imaging 
using the FFF beam was briefly investigated. In addition, IMRT and VMAT treatment 
plans for prostate cancer were modelled and evaluated using the MC technique and a 
MATLAB code written by the author.
As future work, it is recommended that the following points based on my work and 
literature should be followed:
1. Studying the biological effect of FFF beams on different cancerous and normal cells 
in vitro as this area still needs further investigation as there are some contradictions 
in the literature.
2. Studying the biological effect of FFF beams in vivo. This can be achieved by per­
forming a statistical analysis after several years of following-up patients undergoing 
radiotherapy treatments using FFF beams. The study should take into account the 
beam energy, dose rate, dose per fraction, total dose, treated site and patient age 
and sex.
3. Measuring the neutron fiuence and neutron dose equivalent from FFF linacs for 
different linac models and energies and compare them with simulations.
4. Carrying out several MC simulations for different types of treatment room design, 
shielding material, wall thicknesses at different FFF beam energies and for various 
linac models. The purpose of these simulations is to calculate the total photon 
and neutron (in case of using high energy) fluences inside an outside the treatment 
room. After carrying out these calculations, validating them with measurements 
and estimating the total workload per week of these linacs, the researcher should 
work on calculating the total amount of radiation leakage from treatment rooms 
and the required thickness of primary and secondary shielding using the equations 
reported in NCRP report 151 (NCRP 1993).
5. Re-performing the same calculations of IMRT prostate plans after re-optimising 
the TPS. This can be achieved in two possible ways. The first one is by removing 
the flattening filter from the linac head then re-commissioning it to obtaining the
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PDD, beam profiles, etc. Then, importing these data to the TPS. Or, it can be 
done by calculating all these parameters (PDD, PD, etc.) using MC simulations 
then import these data to the TPS.
6. Studying different cancer cases such as (lung, brain, breast, etc.) at different linac 
energies with and without a FF to find out what is the better beam energy for each 
case and whether the FFF beam can add any improvement.
7. Performing full step and shoot and dynamic IMRT and VMAT plans using photon 
beams higher than 10 MV with and without a FF on a voxelised phantom based on 
CT images of a real patient in order to calculate the neutron dose that the patient 
receives during a full radiotherapy course. This study needs supercomputers, which 
are available in some research centres, to be achieved as current MC codes, which 
include photoneutron interactions, do not support modelling dynamic cases. How­
ever, the recent improvement in FLUKA (the new version) allows users to import 
CT images of patients (in DICOM format) and convert them to voxelised phantoms 
readable in FLUKA.
8. Investigating the feasibility of EMRT after optimising the TPS for different beam 
energies, beam direction and cancer sites as the preliminary results, obtained in this 
project, showed several advantages of mixing several FFF photon beams in terms 
of OAR sparing and reducing the superficial dose to the patient.
9. Producing new recommendation guidelines for quality control (QC) and quality 
assurance (QA) of linacs operating with/without a FF especially for those have 
several photon and electron modes. These guidelines are important due to the 
increase in time required to carry out all daily, monthly, etc. tests to cover all beam 
energies. For example, the daily linac worming up and QC for Varian Clinac, which 
has two photon energy modes and several electron modes, takes approximately 30 
min. W ith regard to TrueBeam, which has seven photon beams and eight electron 
beams, the time required to carry out these tests is longer. Consequently, this 
increase in QA and QC duration and could affect the number of patients treated 
every day and/or increase staff working hours.
10. Modifying the MATLAB code to include 3D-CRT plans and other assessing param-
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eters such as normal tissue complication probability (NTCP) and tumour control 
probability calculations. In addition, to be able to read plans from various TPS, 
apart from Eclipse, including XiO, Pinnacle, MIM, Leksell and Accuray as well as 
reading different exported plans format such as RTOG and CADPLAN.
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A. The MATLAB code
A .l  Create MC sequences files for step& shoot IMRT plans
1 % F u n c t io n  to  r e a d  t h e  h o s p i t a l  T re a tm e n t  P lan  f i l e  (V a r ia n
E c l i p s e )  of  Step&Shoot
2 % IMRT p lan  e x p o r t e d  in dicom fo rm a t  and c r e a t e  th e  MLC
p o s i t i o n s  , Jaws P o s i t i o n s
3 % and C o n t r o l  P o i n t s  f i l e s  to  be used in BEAMnrc/DOSXYZmc i n p u t
f i l e s
4  %
5 % Author  : Maan A Najem
6 % Date :  2 9 /1 1 /2 0 1 3
7 % D epar tm en t  of  P h y s ic s
8 % U n i v e r s i t y  of  S u r rey
9 % G u i ld fo rd  , UK
10 % G o p y r ig h t  : M.A.NAJEM(2013)
11 %
12
13 f u n c t i o n  [Beam.Weight  C o n t r o L p o i n t s b e a m  G o n t r o l . p o i n t s
number_of_beams MLC MUnew]=MCSnSIMRTPLAN_Parameters( f i l e n a m e  , 
d s o u r c e )
14
15 %import  RT_Plan f i l e
16 RT_Plan=dicominfo  ( f i l e n a m e  ) ;
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17
18 %  n u m b e r  o f  b e a m s
19
20 n u m b e r _ o f _ b e a m s = R T _ P l a n . F r a c t i o n G r o u p S e q u e n c e  . I t e m _ l  .
N u m b e r O f B e a m s  ;
21
22 %  i n i t i a l  v a l u e s  t o  s p e e d  u p  t h e  p r o c e s s
23 G o n t r o l_ p o i n t s b e a m = z e r o s  ( number_of_beams , 1 ) ;
24 G an t ry _ A n g le = z e ro s  ( number_of_beams ,1) ;
25 C o l l i m a t o r _ A n g l e = z e r o s  ( number_of_beams , 1 ) ;
26 T a b l e _ A n g l e = z e r o s  ( n u m b e r _ o f _ b e a m s  , 1 ) ;
27
28 JawY_Openning=zeros  (number_of_beams , 2 ) ;
29 JawX_Openning=zeros  (number_of_beams , 2 ) ;
30 JawY_OpeningUpLeft=zeros  ( number_of_beams , 1 ) ;
31 J a w Y _ O p e n i n g U p R i g h t = z e r o s  ( n u m b e r _ o f _ b e a m s  , 1 ) ;
32 J a w Y _ O p e n i n g D o w n L e f t = z e r o s  ( n u m b e r _ o f _ b e a m s  , 1 ) ;
33 J a w Y _ O p e n i n g D o w n R i g h t = z e r o s  ( n u m b e r _ o f _ b e a m s  , 1 ) ;
34 JawX_OpeningUpLeft=zeros  ( number_of_beams , 1 ) ;
35 JawX_OpeningUpRight=zeros  (number_of_beams , 1 ) ;
36 JawX_OpeningDownLeft=zeros (number_of_beams , 1 ) ;
37 JawX_OpeningDownRight=zeros (number_of_beams , 1 ) ;
38
39 %  t h e  n u m b e r  o f  l e a v e s
40 n _ o f _ M L C l e a v e s = 2 * R T _ P l a n . B e a m S e q u e n c e  . I t e m _ l  .
B e a m L i m i t i n g D e v i c e S e q u e n c e  . I t e m _ 3  . N u m b e r O f L e a f J a w P a i r s  ;
41
42 %  T h e  i s o c e n t r e  p o s i t i o n
43
44 I s o C e n t r e = R T _ P la n . BeamSequence . I te m _ l  . G o n t r o lP o i n t S e q u e n c e  
I te m _ l  . I s o c e n t e r P o s i t i o n / l O ;
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46 I s o C e n t r e _ X = I s o C e n t r e  ( 1 )
47 I s o C e n t r e _ Y = I s o C e n t r e  ( 2 )
48 I s o C e n t r e _ Z = I s o C e n t r e  (3)
49
50 % The s o u rce  Jaw d i s t a n c e
51 JawY_PostionUp =  2 8 .16;
52 JawY_PostionDown =  35.93;
53 JawX_Post ionUp =  36.88;
54 JawX_PostionDown =  44.68;
55
56 Beam_Weight=zeros (number_of_beams , 1) ;
57 c= z e ro s  (number_of_beams +  l  ,1) ;
58 W e ig h t_added=0;
59 j a w f a c t o r = z e r o s  (number_of_beams , 1) ;
60
61 fo r  i 1 =1: number_of_beams
62 % C o n t ro l  p o i n t s  per  beam
e v a l  ( [ ’ C o n t r o i_ p o in t s b e a m  ( i l  ) =R T _P lan . BeamSequence . I tem_ 
’ n u m 2 s t r ( i l )  ’ . N u m b e rO fC o n t ro lP o in t s  ; ’ ] ) ;
64 % G an try  a n g le s
e v a l  ( [ ’ G a n t ry .A n g le  ( i l  )=R T _P lan . BeamSequence . I tem_ ’
num 2st r  ( i l )  ’ . C o n t r o lP  o in t  Sequence  . I te m _ l  . G a n t ry  Angle
66 % C o l l i m a t o r  a n g le s
ev a l  ( [ ’ Col l i  m a t  o r -A n g le  ( i 1 )=R T _P lan . BeamSequence . I tem_ ’
n u m 2 s t r ( i l )  ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l . 
Beam Lim it ingD ev iceAngle  ; ’ ] ) ;
68 % Tab le  Angles
e v a l  ( [ ’ T  a b le .A n g le  ( i 1 )=R T_P lan . BeamSequence. I tem_ ’ 
num 2st r  ( i l  ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l . 
P a t i e n t S u p p o r t A n g l e  ; ’ ]) ;
70 %Jaws openn ing  from here  :
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ev a l  ( [ ’ JawY_Openning(i l  ) = R T _ P la n . BeamSequence. I tem_ ’ 
n u m 2 s t r ( i l  ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l . 
B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m . 2 .
L e a f J a w P o s i t i o n s / l O ;  ’ ]) ;
e v a l  ( [ ’ JawX.Openning ( i l  , : ) = R T . P l a n . BeamSequence . I t e m .  ’ 
num 2st r  ( i l  ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m . l .
Le a f  J a w P o s i t i o n s / l O ;  ’ ]) ;
75 JawY.OpeningUpLeft  ( i l  )= (Jaw Y _ O p en n in g ( i l  ,2)  *
Ja w Y .P o s t io n U p ) / lO O ;
7 6
77 JawY.OpeningUpRight ( i l  )= ( J a w Y .O p e n n in g ( i l  , 1 )*
Jaw Y .P o s t io n U p ) / lO O ;
7 8
79 JawY.OpeningDownLeft ( i l  )= ( J a w Y .O p e n n in g ( i l  , 2 ) *
JawY.Post ionDown) /lOO;
8 0
81 J aw Y .O pen ingD ow nRigh t( i l  )= ( J a w Y .O p e n n in g ( i l  ,1)  *
Jaw Y.Pos t ionD own)/ lO O ;
8 2
83 JawX.OpeningUpLeft  ( i l  ) = ( Ja w X .O p en n in g ( i l  , 2 )*
Jaw X .P o s t io n U p ) / lO O ;
8 4
85 JawX.OpeningUpRight  ( i l  ) = ( J a w X .O p e n n in g ( i l  , 1 )*
J a w X .P o s t io n U p ) / lO O ;
86
87 JawX.OpeningDownLeft  ( i 1 ) = ( JawX.Openning ( i l  ,2)  *
JawX .Pos t ionD ow n)/ lOO ;
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89 JawX_OpeningDownRight( i l  )= (Jaw X _O penn ing ( i l  , 1 )*
Jaw X .Pos t ionD ow n)/ lO O ;
90 %to here
91 % Beam weigh t
92 e v a l ( [  ’Beam.Weight ( i l  )=R T_P lan . F ra c t io n G ro u p S e q u e n c e  .
I t e m . l  . R eferencedBeamSequence  . I t e m .  ’ n u m 2 s t r ( i l )  
BeamMeterset  ; ’ ] ) ;
93
94 W e i g h t . added=W eight_added+Beam.W eight  ( i l ) ;
95 %c ( i l  + l )= c  ( i l  )+G o n t  r o i . p o i n t  sb eam  ( i l  ) ;
96 j a w f a c t o r  ( i l  )= W e ig h t . a d d e d  ;
97 e n d
99 G o n t r o I . p o i n t s = s u m (  G  o n t  r o i . p o i n t  s b e a m  ) ;
00
01 r a w S u b B e a m _ w e i g h t = z e r o s  ( C o n t r o l . p o i n t s  , 1 ) ;
02
M L C = z e r o s  ( C o n t r o l . p o i n t s  , n . o f . M L C l e a v e s  ) ; 
b = l ;  
d = l ;
07 % M L C  l e v e s  p o s i t i o n s  a t  i s o c e n t r e
08 f o r  i 2  = 1 : n u m b e r . o f . b e a m s
09
112
e v a l  ( [ ’MLC(b , : ) = r e s h a p e  ( R T . P l a n . BeamSequence. I t e m .  ’ 
n um 2st r  (12 ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
B e a m L i m i t in g D e v i c e P o s i t i o n S e q u e n c e . I t e m .3  .
Leaf  J a w P o s i t i o n s  , 1 , n .o f .M L C le av es  ) ; ’ ] ) ;  
ev a l  ( [ ’rawSubBeam.weight  ( b ) = R T .P l a n . BeamSequence. I t e m .  ’ 
n u m 2 s t r (  12 ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
C u m u la t iv e M e te r s e tW e ig h t  ; ’ ]) ;
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113 b = b + C o n t ro l_ p o in t s b e a m  ( i2 ) ;
114
115 fo r  i3 = 1 : (  C o n t r o L p o i n t s b e a m  ( i2 ) —1)
116
e v a l  ( [ ’MLC(d+i3 r e s h a p e  ( R T . P l a n . BeamSequence. I tem_ ’ 
num 2st r  (12 ) C o n t r o l P o i n t S e q u e n c e  . I t e m .  ’ num 2st r  ( 13 
+1) ’ . B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m . l  .
Lea f  J a w P o s i t i o n s  , 1 , n .o f .M L C le av es  ) ; ’ ] ) ;
119
127
ev a l  ([ ’rawSubBeam.weight  (d+13 ) = R T . P l a n . BeamSequence . I t e m .  
num 2st r  ( 12 ) C o n t r o l P o i n t S e q u e n c e  . I t e m .  ’ num 2st r  (13 
+1) ’ . C u m u la t iv e M e te r s e tW e ig h t  ; ’ ] ) ;
end
d=d+C ont  r o i . p o i n t  sb eam  ( 12 ) ;
%eval  ( [ ’ G a n t ry .A n g le  ( i ) = R T .P I a n . BeamSequence . I t e m . l  . 
G o n t r o lP o i n t  Sequence  . I t e m .  ’ n u m 2 s t r ( i )  ’ . G an t ryA ngle
129 end
130 % Sub beams w e ig h ts
131 SubBeam.weight=rawSubBeam.weight  ;
132
133
134 %Create  th e  BEAMnrc Step and Shoot  mic s e q u en ce s  f i l e
135
136 t i t l e  =  ’Step&Shoot IMRT MLCs p o s i t i o n s ’ ; % f i l e  t i t l e
137 s t r i n g l = ’ , ’ ;
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138
139
140
141
MLCfileName =  ’MLCSnSIMRT. sequence  ’ ;
f i l e  name 
f id  =  fopen (MLCfileName , ’w ’ ) ; 
l e f t _leaves=MLC(:  ,60: —1:1) ;
l e f t  MLCs 
R i g h t _Leaves=AlLC(: ,120:  —1:61) ; 
r i g h t  MLCs
% MLC sequence
% Open th e  f i l e  
% s t o r e  th e
% s t o r e  th e
143
145
147
149
151
l e f t  . l e a v e s  l = l e f t  . l e a v e s / l O ;
l e f t . I e a v e s 2 = (  l e f t . l e a v e s  1 *50 .86)  / lO O .  ;
R i g h t .L e a v e s  l = R i g h t . L e a v e s / l O ;
R i g h t . L e a v e s 2 = ( R i g h t .L e a v e s  1 *50 .86)  / lOO. ;
MUnev^zeros ( C o n t r o l . p o i n t s  ,1) ;
b e a m f a c to r = 0 ;
f l = 0 ;
152 for  i4 = 1 : n u m b e r .o f .b e a m s
153
156
for  i 5 = l : (  C o n t r o l . p o i n t  sb eam  ( i4 ) )
MUnew( i 5 + f l  ) = ( ( Beam.Weight  ( i4 ) / sum( Beam.Weight  ) ) * 
SubBeam.weight  ( i 5 + f l  ) ) + b e a m f a c to r  ;
160
162
end
beamfactor=MUnew( i5 + f  1 ) ; 
f l = f l + C o n t r o l . p o i n t s b e a m  ( i4 ) ;
end
138
M. A. Najem______________  Appendix A
166
167 i f  f id  ~= —1
168
170
173
176
177
179
f p r i n t f  ( f i d  , ’% s \ r \ n ’ , t i t l e )  ; % P r i n t  th e  t i t l e
f p r i n t f  ( f i d  , ’% d \ r \ n ’ , C o n t r o l . p o i n t s  ) ;
175 for  i6 =  1:num ber_of .beam s
178 for  i7 =  l: C o n t r o l  . p o i n t s
180 MU=MUnew( i7 ) ;
181 f p r i n t f  ( f i d  , ’% i \ r \ n ’ ,MU) ;% p r i n t  th e  MU w iegh t  f a c t o r
and c e a t e  new l i n e
182
183 fo r  j = l : ( n . o f . M L C l e a v e s / 2 )
184
188 f p r i n t f  ( f i d  , %  \  l e f t . l e a v e s  2 ( i7  , j ) )  ; % p r i n t  th e
lower  l e f t  c lo s e d  MLCs p o s i t i o n
186 f p r i n t f  ( f i d  , ’% s s t r i n g l  ) ; % p r i n t
187 f p r i n t f  ( f i d  , ’% d’ , R i g h t . L e a v e s 2 ( i 7  , j ) )  ; % p r i n t  th e
lower  r i g h t  c lo s e d  MLCs p o s i t i o n
188 f p r i n t f  ( f i d  , ’% s s t r i n g l  ) ; % p r i n t
189 f p r i n t f  ( f i d  , ’% d \ r \ n ’ ,1) ; % p r i n t  th e
number of  l e a v e s  (a lw ays  =  l ,  l e a f  by l e a f )  and c e a t e  
new l i n e
190
191 end
139
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end
end
197 f c l o s e ( f i d ) ;  % Close th e  f i l e
199 end
201 % C re a te  th e  jaw s  s e q u e n s e s  f i l e
202 Jaw sf i leN am e =  ’JawsSnSIMRT. sequence  ’ ; % Jaws
o p in in g  f i l e  copy what  is i n s i d e  and p u t  i t  in BEAMnrc i n p u t  
f i l e
203 t i t l e j a w  =  ’Step&Shoot IMRT Jaws p o s i t i o n s  ’ ; % f i l e  t i t l e
204 % s t r in g 2  =  ’Y ’ ;
205 % s t r in g 3  =  ’X ’ ;
206
207 f id J a w s  =  fopen  ( Jawsf i leNam e , ’w ’ ) ; % Open th e
f i l e
208 i f  fid J a w s  — 1
209
210 f p r i n t f  ( f i d  , ’% s \ r \ n ’ , t i t l e j a w )  ; % P r i n t  t h e  t i t l e
211
212 f p r i n t f  ( f i d  , ’% d \ r \ n ’ ,number_of_beams)  ; % p r in t  t h e
number of  f i e l d s  ( n .o f .M L C le a v e s )
213
214
215 %Write Y JAWs p a r a m e r t e r s
216 MU.Jaws=zeros (n u m b e r .o f .b e a m s  , 1 ) ;
217 for  18 = l :n u m b e r_ o f .b e a m s
218 MU.Jaws( 18 ) = j a w f a c t o r  (18 ) /sum (Beam .W eigh t)  ;
219
f p r i n t f  ( f id J a w s  , ’% . 2 f \ r \ n  ’ ,MU.Jaws(i8 ) ) ;
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221 f p r i n t f  ( f id Ja w s , Jaw Y .Pos t ionU p)  ;
222 f p r i n t f  ( f id J a w s , s t r i n g l  ) ;
223 f p r i n t f  ( f id Jaw s W , JawY.Post ionDown) ;
224 f p r i n t f  ( f id Jaw s , s t r i n g l  ) ;
225 f p r i n t f  ( f id Jaw s W , JawY.OpeningUpLeft  ( i8 ) ) ;
226 f p r i n t f  ( f id Jaw s s t r i n g l  ) ;
227 f p r i n t f  ( f id Jaw s JawY.OpeningDownLeft  ( i8 ) ) ;
228 f p r i n t f  ( f id J a w s s t r i n g l  ) ;
229 f p r i n t f  ( f id Jaw s , JawY.OpeningUpRight  ( i8 ) ) ;
230 f p r i n t f  ( f id Jaw s '%s ' s t r i n g l  ) ;
231 f p r i n t f  ( f id Jaw s ’% f \ r \ n  ’ , JawY.OpeningDownRight  (
233 %Write Y JAWs p a r a m e r t e r s
234 f p r i n t f  ( f id J a w s Jaw X .Pos t ionU p)  ;
235 f p r i n t f  ( f id Jaw s s t r i n g l  ) ;
236 f p r i n t f  ( f id Jaw s JawX.Post ionDown) ;
237 f p r i n t f  ( f id Jaw s s t r i n g l  ) ;
238 f p r i n t f  ( f id Jaw s JawX.OpeningUpLeft  ( i 8  ) ) ;
239 f p r i n t f  ( f id Jaw s s t r i n g l  ) ;
240 f p r i n t f  ( f id Jaw s JawX.OpeningDownLeft ( i8 ) ) ;
241 f p r i n t f  ( f id Jaw s s t r i n g l  ) ;
242 f p r i n t f  ( f id Jaw s JawX.OpeningUpRight ( i8 ) ) ;
243 f p r i n t f  ( f id Jaw s s t r i n g l  ) ;
244 f p r i n t f  ( f id Ja w s ’%f \  r \ n  ’ , JawX.OpeningDownRight ( i
245 end
246 f c l o s e  ( f i d J a w s ) ; % Close th e  f
248 end
250 % Create th e  C o n t r o l  p o i n t s  of DOSXYZnrc (copy what is in
pu t  i t  in 
%dosxyz i n p u t  f i l e
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252 C o n t r l P o i n t f i l e N a m e =  ’C t r l P o i n t S n S I M R T . t x t ’ ; % Jaws
o p in in g  f i l e  copy what is  i n s i d e  and pu t  i t  in BEAMnrc i n p u t  
f i l e
253 s t r i n g 4 =  ’ , ’ ;
254
255 MU_contlpoint=zeros (n u m b er .o f .b ea m s*2 , 1) ;
256 G a n t ry .A n g le l= z e ro s  (n u m b er .o f .b ea m s*2 , 1) ;
257 G o l l im a to r .A n g le l= z e r o s  (num ber .of .beam s *2 , 1) ;
258 T a b le .A n g le l= z e ro s  (num ber .of .beam s *2 ,1) ;
259 fo r  19 = l : n u m b e r . o f . b e a m s
260
261 M U .c o n t lp o in t  (2*19 )=MU.Jaws( 19 ) ;
262 M U .c o n t lp o in t  (2* 19+l)=MU.Jaws(  19 ) ;
263 G a n t r y .A n g l e l  (2*19 - l ) = G a n t r y . A n g l e  ( 19 ) ;
264 G a n t r y .A n g l e l  (2* 19 ) = G a n t r y .A n g le  (19)  ;
265 C o l l i m a t o r . A n g l e l  ( 2 * 1 9 - l ) = C o l l i m a t o r _ A n g l e  (19 ) ;
266 G o l l i m a t o r . A n g l e l  (2* 19 ) = C o l l i m a t o r . A n g l e  (19)  ;
267 T a b l e .A n g l e l  (2*19 - l ) = T a b l e . A n g l e  ( 19 ) ;
268 T a b l e .A n g l e l  (2*19 ) = T a b le .A n g le  ( 19 ) ;
270
281
end
M U .c o n t lp o in t  (end)  =  [] ;
274 t h e t a = z e r o s  ( n u m b e r .o f .b e a m s  *2 ,1 )  ;
275 p h i c o l = z e r o s  ( n u m b e r .o f .b e a m s  *2 ,1 )  ;
276 p h i= z e ro s  ( n u m b e r . o f . b e a m s *2 ,1) ;
277 r a w p h i= z e ro s  ( n u m b e r .o f .b e a m s  *2 ,1) ;
278 r a d G a n t r y .A n g le = d e g 2 r a d  ( G a n t r y .A n g l e l  ) ;
279 r a d T a b l e .A n g l e = d e g 2 r a d  ( T a b l e . A n g l e l  ) ;
280 r a d C o l l i m a t o r . A n g l e = d e g 2 r a d  ( G o l l i m a t o r . A n g l e l  ) ;
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282 f o r  i l 0  =  l : n u m b e r _ o f _ b e a m s * 2
283
284 t h ê t a  ( i lO )= ra d 2 d e g  ( a c o s ( - s i n  ( r a d T a b l e . A n g l e  ( i lO ) ) * s in  (
r a d G a n t r y . A n g l e  ( i lO ) ) ) ) ;
285
286 p h i c o l  ( i l O ) = r a d 2 d e g ( 1 . 5 * p i - r a d C o l l i m a t o r _ A n g l e  ( i l 0 ) -
a t a n 2 ( - ( c o s  ( r a d G a n t r y .A n g le  ( i l O )  ) * s i n  ( r a d T a b l e .A n g l e  ( 
i lO ) ) ) , ( COS ( r a d T a b l e .A n g l e  ( i lO ) ) ) ) ) ;
287
288 rawphi ( ilO )=rad2deg ( a t a n 2 ( - c o s  (radGantry .Angle  ( i lO ) ) ,(
COS ( r a d T a b l e .A n g l e  ( i lO ) ) * s in  ( r a d G a n t r y .A n g l e  ( i lO ) ) ) ) )
289 i f  r aw phi  ( i lO )<0
290 phi  ( i lO )=360+rawphi  ( i lO ) ;
291 e l s e
292 phi  ( i 10 )= raw ph i  ( i 10 ) ;
293 end
e n d
298 f i d C t r l P o i n t =  f o p e n  ( G o n t r l P o i n t f i l e N a m e  , ’w ’ ) ; %
O p e n  t h e  f i l e
299
301
i f  f i d C t r l P o i n t  ~ =  —1
f o r  i l l = l : n u m b e r _ o f _ b e a m s * 2
304 f p r i n t f  ( f i d C t r l P o i n t  , ’%.3f ’ , I s o C e n t r e . X )  ;
305 f p r i n t f  ( f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
306 f p r i n t f  ( f i d C t r l P o i n t  , ’%.3f ’ , I s o C e n t r e . Y )  ;
307 f p r i n t f  ( f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
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308
309
313
314
315
316
317
320
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f p r i n t f
f i d C t r l P o i n t  , ’%.3f ’ , I s o C e n t r e . Z  ) ; 
f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
f i d C t r l P o i n t  , ’%.2f ’ , t h ê t a  ( i l  1 ) ) ; 
f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
f i d C t r l P o i n t  , ’%.2f ’ , p h i ( i l l ) )  ; 
f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
f i d C t r l P o i n t  , ’%.2f ’ , p h i c o l  ( i l  1 ) ) ; 
f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
f i d C t r l P o i n t  , ’% . l f  ’ , d s o u rc e )  ; 
f i d C t r l P o i n t  , ’%s ’ , s t r i n g 4  ) ;
323 f p r i n t f  ( f i d C t r l P o i n t  , ’% . 2 f \ r \ n ’ , M U .c o n t lp o in t  ( i l  1 ) ) ;
327
329
end
f c l o s e  ( f i d C t r l P o i n t )  ; % Close t h e  f i l e
end
330 % The End of  F u n c t io n
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A.2 Create MC sequences files for Dynam ic IMRT plans
1 % F a c t i o n  to  r e a d  th e  h o s p i t a l  T re a tm e n t  P lan  f i l e  ( V a r i a n )  of
Dynamic IMRT
2 % p lan  e x p o r t e d  in dicom fo rm a t  and c r e a t e  th e  MLC p o s i t i o n s  ,
Jaws P o s i t i o n s
3 % and C o n t r o l  P o i n t s  f i l e s  to  be used in BEAMnrc/DOSXYZnrc i n p u t
f i l e s
4  %
5 % Author  : Maan A Najem
6 % Date :  2 9 /1 1 /2 0 1 3
7 % D epar tm en t  of  P h y s ic s
8 % U n i v e r s i t y  of  S u r rey
9 % G u i ld fo rd  , UK
10 % C o p y r ig h t :  M.A.NAJEM(2013)
11 %
12
13 f u n c t i o n  [ l e f t . l e a v e s  Beam.Weight n .o f .M L C le av es
C o n t r o L p o i n t s b e a m  C o n t r o l . p o i n t s  n u m b e r .o f .b ea m s]  =  
MCDYNIMRTPLAN_Parameters(filename , d s o u rc e )
14
15 %import  R T .P lan  f i l e
16 R T .P la n = d ic o m in fo  ( f i l e n a m e  ) ;
17
18 % number of  beams
19
20 n u m b e r .o f .b e a m s = R T .P l a n . F r a c t io n G ro u p S e q u e n c e  . I t e m . l  .
NumberOfBeams ;
22 %  i n i t i a l  v a l u e s  t o  s p e e d  t h e  p r o c e s s
24 C o n t r o l . p o i n t s b e a m = z e r o s  ( n u m b e r . o f . b e a m s  , 1 ) ;
25 G a n t r y _ A n g l e = z e r o s  ( n u m b e r . o f . b e a m s  , 1 ) ;
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26 C o l l im ato r_A ng le= zeros  (number_of_beams , 1 ) ;
27 Table_Angle=zeros (number .of .beams , 1) ;
28 JawY.Openning=zeros (number.of .beams , 2 ) ;
29 JawX.Openning=zeros (number .of .beams , 2 ) ;
30 JawY.OpeningUpLeft=zeros ( number .of .beams , 1 ) ;
31 JawY.OpeningUpRight=zeros (number .of .beams , 1) ;
32 JawY.OpeningDownLeft=zeros (number .of .beams ,1) ;
33 JawY.OpeningDownRight=zeros ( number .of .beams , 1 ) ;
34 JawX_OpeningUpLeft=zeros (number .of .beams , 1) ;
35 JawX.OpeningUpRight=zeros (number .of .beams , 1) ;
36 JawX.OpeningDownLeft=zeros (number .of .beams , 1 ) ;
37 JawX.OpeningDownRight=zeros (number .of .beams , 1 ) ;
38
39 %number of l eaves
40 n .of .MLCleaves=2*RT.Plan . BeamSequence . I t e m . l  .
BeamLimit ingDeviceSequence . I tem .3  . NumberOfLeafJawPairs ;
41
42 % i so C e n t r e  p o s i t i o n s
43 I so C e n t re = R T .P Ia n . BeamSequence . I t e m . l  . C o n t ro lP o in tS equ en ce  .
I t e m . l  . I s o c e n t e r P o s i t i o n / l O ;
45 I s o C e n t r e . X = I s o C e n t r e  (1)
46 I s o C e n t r e _ Y = I s o C e n t r e  (2)
47 I s o C e n t r e . Z = I s o C e n t r e  (3)
48
49 % s o u rce  Jaws d i s t a n c e s  :
50 Jaw Y .Pos t ionUp =  28.16;
51 J awY.PostionDown =  35.93;
52 Jaw X .Pos t ionU p =  36.88;
53 JawX.PostionDown =  44.68;
54
65 % i n i t i a l  v a lu e s
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56 Beam_Weight=zeros  ( n u m b e r .o f .b e a m s  ,1)  ;
57 c= ze ro s  ( n u m b e r .o f .b e a m s  +  1 ,1) ;
58 Weight  . a d d e d =0;
59 j a w f a c t o r = z e r o s  (n u m b e r .o f .b e a m s  , 1) ;
62 fo r  i 1 = 1 :n u m b e r .o f .b e a m s
88 % number of c o n t r o l  p o i n t s
per  beam
8^ e v a l  ( [ ’ C o n t r o L p o i n t s b e a m  ( i l  ) = R T . P l a n . BeamSequence . I t e m .
’ n u m 2 s t r ( i l )  L N u m b e rO fC o n t ro lP o in t s  ;
65 % G antry  a n g le s
8® e v a l  ( [ ’ G a n t r y .A n g le  ( i 1 )=R T_PIan . BeamSequence . I t e m .  ’
num 2st r  ( i l )  ’ . C o n t r o l P  o in t  Sequence  . I t e m . l  . G an t ryA ngle
67 % G o l l im a to r  a n g le s
88 ev a l  ( [ ’ C o l l i m a t o r .A n g l e  ( i l  ) = R T . P l a n . BeamSequence . I t e m .  ’
n um 2st r  ( i l )  ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l . 
Bea m L im it ingD ev iceA ngle  ; ’ ]) ;
69 % Tab le  Angles
e v a l  ( [ ’ T a b le .A n g le  ( i 1 ) = R T . P l a n . BeamSequence . I t e m .  ’ 
n um 2st r  ( 1 1 ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
P a t i e n t S u p p o r t A n g l e ;  ’ ]) ;
71 % Jaws openn ing  from here  :
e v a l  ( [ ’ Jaw Y .O penn ing ( i l  ) = R T . P l a n . BeamSequence. I t e m .  ’ 
n u m 2 s t r ( i l  ) L C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m . 2 .
L eaf  J a w P o s i t i o n s / l O ;  ’ ]) ;
73
ev a l  ( [ ’Jaw X .O penn ing ( i l  ) = R T . P l a n . BeamSequence. I t e m .  ’ 
num 2str  ( i l  ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l . 
B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m . l  .
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Leaf J a w P o s i t i o n s / l O ;  ’ ]) ;
7 5
76 JawY.OpeningUpLeft ( i 1 ) = ( JawY.Openning( i l  ,2 )*
JawY.Post ionUp) /lOO;
7 7
78 JawY.OpeningUpRight ( i l )  =(  JawY.Openning ( i l  , 1 ) *
JawY.Post ionUp)/ lOO;
7 9
80 JawY.OpeningDownLeft ( i l  )=(JawY_Openning( i l  ,2 )*
JawY.PostionDown)/lOO;
81
82 JawY.OpeningDownRight ( i l  )= (JawY .Openning( i l  , 1 ) *
JawY.PostionDown) /lOO;
83
84 JawX.OpeningUpLeft ( i 1 ) = ( JawX.Openning( i l  ,2 )*
JawX.Post ionUp)/ lOO;
85
86 JawX.OpeningUpRight  ( i l )  = (  JawX.Openning ( i l  , 1 ) *
Jaw X .Pos t ionU p)  /lOO;
87
88 JawX.OpeningDownLeft ( i l  )= (Jaw X .O penn ing (  i l  , 2 ) *
JawX.Post ionDown) /lOO;
89
90 JawX.OpeningDownRight  ( i l )  = (  JawX.Openning ( i l  , 1 )*
JawX.Post ionDown) /lOO;
91 % to  here
92
93 % beam weigh t
94 e v a l ( [  ’Beam.Weight ( i l  ) = R T . P l a n . F r a c t io n G ro u p S e q u e n c e  .
I t e m . l . R eferencedBeamSequence  . I t e m .  ’ n u m 2 s t r ( i l )  ’ 
BeamMeterset  ; ’ ] ) ;
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96 Weight_added=Weight_added+Beam_Weight ( i l  ) ;
97 %c ( i l  + l )=c  ( i l  )+C ont ro l .p o in t  sbeam ( i l  ) ;
98 j a w f a c t o r  ( i l  )=Weight_added ;
99 end
100
101 C on tro l_po in ts=sum (  C o n t ro L p o in t s b e a m )  ; % t o t a l  number of
c o n t r o l  p o in t s
102 % i n i t i a l  v a lu e s :
103
104 rawSubBeam_weight=zeros  ( C o n t r o L p o i n t s  , 1 ) ;
105 MLC=zeros ( C o n t r o L p o i n t s  , n . o f .M L C le a v e s )  ;
106 b = l ;
107 d = l ;
108
199 % MLC le a v e s  p o s t i o n s  a t  i s o c e n t r e
110 fo r  i2 = l : n u m b e r . o f . b e a m s
111
^^ 2 ev a l  ( [ ’MLC(b , : ) = r e s h a p e  ( R T . P l a n . BeamSequence. I t e m .  ’
n u m 2 s t r (12) L C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m .3  .
Leaf  J a w P o s i t i o n s  ,1 , n .o f .M L C le av e s  ) ; ’ ]) ;
113 ev a l  ([ ’ rawSubBeam.weight  ( b ) = R T .P l a n . BeamSequence. I t e m .  ’
num 2st r  ( 12 ) ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m . l  . 
C u m u la t iv e M e te r s e tW e ig h t ;  ’ ]) ;
114
115 b = b + C o n t r o l . p o i n t s b e a m  ( 12 ) ;
116
117 fo r  13 =1:  ( C o n t r o L p o i n t s b e a m  ( 12 ) —1)
119
e v a l  ( [ ’MLC(d+i3 , : ) —r e s h a p e  ( R T . P l a n . BeamSequence . I t e m .  ’ 
n u m 2 s t r (12)  ’ . C o n t r o l P o i n t S e q u e n c e  . I t e m .  ’ n u m 2 s t r ( 13
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+1) ’ . B e a m L im i t in g D e v ic e P o s i t i o n S e q u e n c e  . I t e m . l  . 
L e a f J a w P o s i t i o n s  ,1 , n . o f . M L C l e a v e s ) ; ;
e v a l  ([ ’rawSubBeam.weight  (d+i3 ) = R T . P l a n . BeamSequence . I t e m .
’ n u m 2 s t r ( i 2 )  C o n t r o l P o i n t S e q u e n c e  . I t e m .  ’ n u m 2 s t r ( i 3  
+1) ’ . C u m u la t iv e M e te r s e tW e ig h t  ; ’ ] ) ;
end
125
d=d+C o n t  r o i . p o i n t  sb eam  ( i2 ) ;
end
132 SubBeam.weight=rawSubBeam.weight  ; % sub beams w e ig h t s
133
135 % Crea te  th e  BEAMnrc dynamic mlc s e q u en ce s  f i l e s  ( f i l e  per  beam
)
136
137 t i t l e  =  ’Dynamic IMRT MLCs p o s i t i o n s ’ ; % f i l e  t i t l e
138 s t r i n g l = ’ , ’ ;
139 % le f t . l e a v e s= M U ]( :  , 1 :6 0 )  ; % s t o r e  t h e  l e f t
MLCs
140 % Right .Leaves=M LC(: , 6 1 :1 2 0 )  ; % s t o r e  th e
r i g h t  MLCs
141
142 l e f t . l e a v e s ^ V l L C ( : ,60: —1:1) ; % s t o r e  th e
l e f t  MLCs
143 Right.Leaves=4VlLC(: , 1 2 0 : - 1 : 6 1 )  ; % s t o r e  th e
r i g h t  MLCs
150
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144
145 % c o v e r t  from mm to  cm
146 l e f t - l e a v e s  l = l e f t - l e a v e s / lO ;
147 R i g h t -Le ave s l = R i g h t -Leaves /1 0  ;
148
149 % c a l c u l a t e  t h e  l e a v e s  p o s i t i o n s  a t  MLC p lan
150 l e f t _ l e a v e s 2 = ( l e f t - l e a v e s  1 *50 .86)  / 1 0 0 .  ;
151 R ig h t_ L e a v e s 2 = ( R i g h t - L e a v e s i  *50 .86)  / lOO.  ;
152
153 MUnew=zeros ( C o n t r o l . p o i n t s  , 1 ) ;
154
155 f l = 0 ;
156
157 fo r  i4 =  l :n u m b e r .o f . b e a m s
158
159 fo r  i5 =1:  ( C o n t r o L p o i n t s b e a m  ( i4 ) )
160 
161
162 MUnew( i5 + f  1 )=SubBeam.weight  ( i 5 + f  1 ) ;
end
167 f l = f l + C o n t r o L p o i n t s b e a m  ( i4 ) ;
168
169 end
170
171 g l = 0 ;
172 fname= ’MLCI>ynIMRT%d. sequence  ’ ;
173 f i l e . w r i t e = ’w ’ ;
174 for  n = l : n u m b e r . o f . b e a m s
175
151
176
178
179
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ev a l  ( [ ’MLCfileName ’ n u m 2 s t r (n )  ’= s p r i n t f  (fname , n) ; ’ ] ) ;
% MLC sequence  f i l e  name
e v a l  ( [ f id  =  fopen  (MLCfileName ’ n u m 2 s t r (n )  ’ , f i l e . w r i t  e )
; ’ ] ) % Open th e  f i l e
181 i f  f id  ~= —1
182
183 f p r i n t f ( f i d  , ’% s \ r \ n ’ , t i t l e ) ;  % P r i n t  th e  t i t l e
184
186 f p r i n t f  ( f i d  , ' % d \ r \ n '  , C o n t r o L p o i n t s b e a m  (n)  ) ; % p r i n t  t h e
number of  f i e l d s  ( n .o f .M L C le a v e s )
187
189
193
195
197
200
for  i7 =  l: C o n t r o L p o i n t s b e a m  (n)
190 9MU=SubBeam_weight ( i ) ;
191 MU=MUnew( i7 + g l  ) ;
f p r i n t f  ( f i d ,  ’% d \ r \ n ’ ,MU) ;% p r i n t  th e  MU w iegh t  f a c t o r  
and c e a t e  new l i n e
for  j =l:(n_of_M LCleaves /2 )
f p r i n t f  ( f id  , ’% i ’ , l e f t _ l e a v e s 2  ( i 7 + g l , j ) )  ; % p r i n t  th e
lower  l e f t  c lo se d  MLCs p o s i t i o n  
f p r i n t f  ( f i d  , ’%s ’ , s t r i n g l )  ; % p r i n t  ’ , ’
f p r i n t f  ( f i d  , R i g h t _ L e a v e s 2 ( i 7 + g l ,  j ) )  ; % p r i n t  th e
lower  r i g h t  c lo se d  MLCs p o s i t i o n  
f p r i n t f  ( f i d  , ’%s ’ , s t r i n g l )  ; % p r i n t  ’ , ’
f p r i n t f  ( f i d  , ’% d \ r \ n ’ ,1) ; % p r i n t  th e
number of  l e a v e s  (a lw ays  =  l ,  l e a f  by l e a f )  and c e a t e
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n e w  l i n e
e n d
e n d
206 g l = g l + C o n t r o l _ p o i n t s b e a m  ( n )  ;
e n d
209
210 f c l o s e  ( f i d  ) ; %  C l o s e  t h e  f i l e
e n d
214 % Create  the  jaws sequenses  f i l e
215 JawsfileName =  ’JawsDynIMRT. sequence ’ ; % Jaws
op in ing  f i l e  copy what is i n s id e  and put  i t  in BEAMnrc in p u t  
f i l e
216 t i t l e j a w  =  ’Dynamic IMRT Jaws p o s i t i o n s ’ ; % f i l e  t i t l e
217 % st r ing2  =  ’Y ’ ;
218 % st r ing3  =  ’X ’ ;
219
220 f idJaws =  fopen (Jawsfi leName , ’w ’ ) ; % Open the
f i l e
221 i f  f idJaws ~= —1
222
223 f p r i n t f  ( f id  , ’% s \ r \ n ’ , t i t l e j a w  ) ; % P r i n t  the  t i t l e
224
225 f p r i n t f  ( f id  , ’% d \ r \ n ’ , num ber .o f .beam s)  ; % pr in t  the
number of f i e l d s  (n .of .M LCleaves)
226
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228
230
231
%Write Y JAWs p a r a m e r t e r s  
MU_Jaws=zeros ( number_of_beams , 1 ) ; 
fo r  18 = 1 : number_of_beams
MU_Jaws(18 ) = j a w f a c t o r  ( 18 ) /sum(Beam_Welght ) ;
f p r l n t f  ( f l d J a w s  , ’%.2 f \ r \ n ’ ,MU_Jaws( 18 ) ) ;
234 f p r l n t f  ( f ld Jaw s W , JawY_PostlonUp) ;
235 f p r i n t f  ( f ld Jaw s , s t r l n g l  ) ;
236 f p r i n t f  ( f ld Jaw s W , JawY_PostlonDown) ;
237 f p r i n t f  ( f ld Jaw s , s t r l n g l  ) ;
238 f p r n t f  ( f ld Jaw s W , JawY_OpenlngUpLeft ( 18 ) ) ;
239 f p r n t f  ( f ld Ja w s , s t r l n g l  ) ;
240 f p r n t f  ( f ld Jaw s '%f ' , JawY_OpenlngDownLeft ( 18 ) ) ;
241 f p r n t f  ( f ld Jaw s , s t r l n g l  ) ;
242 fp r ] n t f  ( f ld Jaw s , JawY_OpenlngUpRlght ( 18 ) ) ;
243 fp r ] n t f  ( f ld Jaw s , s t r l n g l  ) ;
244 f p r l n t f  ( f ld Ja w s ’%f \  r \ n  ’ , JawY_OpenlngDownRlght ( 1 8 ) )
246 %Wrlte Y JAWs p a r a m e r t e r s
247 f p r l n t f  ( f ld Jaw s , JawX_PostlonUp) ;
248 f p r l n t f  ( f ld Jaw s , s t r l n g l  ) ;
249 f p r l n t f  ( f ld J a w s , JawX_PostlonDown) ;
250 f p r l n t f  ( f ld Jaw s , s t r l n g l  ) ;
251 f p r l n t f  ( f ld Jaw s W , JawX_OpenlngUpLeft ( 18 ) ) ;
252 f p r l n t f  ( f ld Jaw s , s t r l n g l  ) ;
253 f p r l n t f  ( f ld Jaw s W , JawX_OpenlngDownLeft ( 18 ) ) ;
254 f p r l n t f  ( f ld J a w s , s t r l n g l  ) ;
255 f p r l n t f  ( f ld Jaw s W , JawX.OpenlngUpRlght ( 18 ) ) ;
256 f p r l n t f  ( f ld Jaw s , s t r l n g l  ) ;
257 f p r l n t f  ( f ld Jaw s ’% f \ r \ n ’ , JawX_OpenlngDownRlght (
258 end
259 f c l o s e  ( f l d J a w s ) ; % Close th e
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e n d
263 % Create  t h e  C o n t r o l  p o i n t s  of  DOSXYZmc (copy what is in s id e  ad
pu t  i t  in
264 %dosxyz i n p u t  f i l e
265 C o n t r l P o i n t f i l e N a m e =  ’C t r l P o i n t D y n I M R T . t x t ’ ; % Jaws
o p in in g  f i l e  copy what is i n s i d e  and pu t  i t  in BEAMnrc i n p u t  
f i l e
266 s t r i n g 4 =  ’ , ’ ;
267 s t r i n g n = ’ Beam number
268
269 t h e t a = z e r o s  (number_of_beams , 1) ;
270 p h i c o l = z e r o s  (number_of_beams , 1 ) ;
271 p h i = z e r o s  (number_of_beams , 1) ;
272 r a w p h i= z e ro s  ( number_of_beams , 1 ) ;
273 r a d C a n t ry _ A n g le = d e g 2 ra d  (G a n t ry _ A n g le )  ;
274 r a d T a b le _ A n g le = d e g 2 ra d  (T a b le_ A n g le )  ;
275 r a d C o l l i m a t  or _ A n g le= d eg 2 ra d (  C o l l i m a t o r  . A n g l e )  ;
276
277 for  i lO = l :n u m b er_ o f_ b ea m s
278
279 t h e t a  ( 110 )= rad 2 d eg  ( a c o s ( - s l n  ( r a d T a b l e .A n g l e  ( 110 ) ) * s ln  (
r a d C a n t r y .A n g l e  ( 110 ) ) ) ) ;
280
281 ph ico l  ( 1 1 0 ) = r a d2 d eg ( 1 . 5 *p l - r ad C o l l lm a t o r _A n g l e  ( 1 1 0 ) -
a t a n 2 ( - ( c o s  ( r a d C a n t r y . A n g l e  ( 110 ) ) * s l n  ( r a d T a b l e . A n g l e  ( 
110 ) )  ) , ( cos ( r a d T a b l e .A n g l e  ( 110 ) ) ) ) ) ;
282
283 raw phl  ( 110 )= rad 2 d eg  ( a t a n 2 ( - c o s  ( r a d C a n t r y  .A ngle  (110)  ) , (
cos ( r a d T a b l e .A n g l e  (110) ) * s ln  ( r a d C a n t r y . A n g l e  ( 1 1 0 ) ) ) ) )
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285
289
i f  raw ph i  ( i lO )<0
phi  ( i l 0 ) =360+rawphi  ( i 10 ) ;
e l s e
phi  ( i lO )= raw ph i  ( 110 ) ; 
end
end
292 f l d C t r l P o l n t =  fopen  ( C o n t r l P o l n t f l l e N a m e  , ’w ’ ) ; 
Open th e  f i l e
%
If f l d C t r l P o l n t  ~= — 1
295
296 fo r  1 1 1 = l :number_of_beams
297 f p r l n t f f l d C t r l P o l n t s t r l n g n  ) ;
298 f p r l n t f f l d C t r l P o l n t ’% i \ r \ n ’ , 1 1 1 ) ;
300 f p r l n t f f l d C t r l P o l n t '% .3f ’ , I s o C e n t r e . X  )
301 f p r l n t f f l d C t r l P o l n t s t r l n g 4  ) ;
302 f p r l n t f f l d C t r l P o l n t '% .3f ’ , I s o C e n t r e . Y  )
303 f p r l n t f f l d C t r l P o l n t s t r l n g 4  ) ;
304 f p r l n t f f l d C t r l P o l n t ’%.3f ’ , I s o C e n t r e . Z  )
305 f p r l n t f f l d C t r l P o l n t s t r l n g 4  ) ;
307 f p r l n t f f l d C t r l P o l n t '% . 2 f ’ , t h e t a ( 1 1 1 ) ) ;
308 f p r l n t f f l d C t r l P o l n t s t r l n g 4  ) ;
310 f p r l n t f f l d C t r l P o l n t '% . 2 f ’ , p h l ( l l l ) ) ;
311 f p r l n t f f l d C t r l P o l n t s t r l n g 4  ) ;
f p r l n t f
f p r l n t f
f l d C t r l P o l n t  , ’% . l f  ’ , d s o u rc e )  ; 
f l d C t r l P o l n t  , ’%s ’ , s t r l n g 4  ) ;
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315
316 f p r l n t f  ( f l d C t r l P o l n t  , ’%.2 f ’ , p h l c o l ( l l l ) ) ;
317 f p r l n t f  ( f l d C t r l P o l n t  , ’% s \ r \ n ’ , s t r l n g 4 )  ;
318
319 end
320
321 f c l o s e  ( f l d C t r l P o l n t  ) ; % Close th e  f i l e
322 end
323
324 % The End of  F u n c t io n
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A .3 Create MC sequences files for VM AT plans
1 m
2 % Func t ion  to read  the  h o s p i t a l  Trea tment  Plan f i l e  (V ar ian )  of
VMAT IMRT
3 % plan expor ted  in dicom format  and c r e a t e  the  MLC p o s i t io n s  ,
Jaws
4 % P o s i t i o n s  and C ontro l  P o in t s  f i l e s  to be used in BEAMnrc/
DOSXYZmc i n p u t
5 % f i l e s
6 Wo Author : Maan A Najem
7 Wo Date :  2 9 /1 1 /2 0 1 3
8 Wo Department of Physics
9 Wo U n iv e r s i ty  of Surrey
0 Wo Guildford  , UK
Wo C o p y r ig h t :  M.A.NAJEM(2013)
2 W
3 f u n c t i o n  MCVMATPLAN_Parameters( f i l en a m e  , d so u rce  )
4
5 %import RT.Plan f i l e
6
7 RT_Plan=dicominfo  ( f i l e n a m e  ) ;
8
9 % number of c o n t r o l  p o in t s
20 num ber_of_beams=RT_Plan . F r a c t io n  G roup  Sequence . I t e m . l  .
NumberOfBeams ;
21 r a w C o n t r o l _ p o i n t s = z e r o s  (number_of_beams , 1 ) ;
22 C o l l im a to r _ A n g le = z e r o s  ( number_of_beams , 1 ) ;
23 T a b le _ A n g le = z e ro s  (number_of_beams , 1 ) ;
24
25 for 10 = 1 :number_of_beams
26 6 v a l  ( [ ’ r a w C o n t r o l . p o l n t s  ( 10 )=R T _P lan . BeamSequence. I t e m .  ’ . . .
27 n u m 2 s t r (1 0 )  ’ . N u m b erO fC o n t ro lP o ln t s  ; ’ ] ) ;
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28 6 v a l  ( [ ’ C o l l i m a t o r . A n g l e  ( 10 )=R T_P lan . BeamSequence . I t e m .  ’ . . .
29 n u m 2 s t r ( 1 0 ) ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m . l .
Beam L lm l t lngD ev lceA ngle  ; ’ ]) ;
30 6 v a l  ( [ ’ T a b le .A n g le  ( 10 )= R T _ P lan . BeamSequence. I t e m .  ’ . . .
31 n u m 2 s t r ( 1 0 ) ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m . l  .
P a t l e n t S u p p o r t A n g l e  ; ’ ]) ;
32 end
33
34 C o n t r o l . p o ln t s= s u m (  r a w C o n t r o l . p o i n t s  ) ;
35 G a n t r y .A n g le = z e r o s  ( C o n t r o l . p o l n t s  , 1 ) ;
36 SubB eam .w elgh t= zeros  ( C o n t r o l . p o l n t s  , 1 ) ;
37
38 n . o f . M L Cleaves  = 2 $ R T .P la n . BeamSequence . I t e m . l  . . . .
39 Beam L lm l t lngD ev lceS equence  . I t e m .3  . Nnm berO fLeafJaw Palrs  ;
40 MLG=zeros ( C o n t r o l . p o l n t s  , n .o f .M L C le a v e s  ) ;
41 G a n t ry .A n g le  ( l ) = R T _ P l a n . BeamSequence. I t e m . l  . . . .
42 C o n t r o l P o l n t S e q u e n c e  . I t e m . l  . GantryA ngle  ;
43 I s o C e n t r e = R T . P l a n . BeamSequence . I t e m . l  . . . .
44 C o n t r o l P o l n t S e q u e n c e  . I t e m . l  . I s o c e n t e r P o s l t l o n  / lO ;
46 I so C e n t re .X = Iso C e n t re  (1)
47 I so C e n t re .Y = Iso C e n t re  (2)
48 I s o C e n t r e .Z = Is o C e n t re  (3)
50 Jaw Y .O penn lng=zeros  ( n u m b e r .o f .b e a m s  ,2) ;
51 Jaw X .O penn lng=zeros  ( n u m b e r .o f .b ea m s  ,2) ;
52 JawY.Pos t lonUp =  2 8 .16;
53 JawY.Post lonDown =  35.93;
54 JawX.Pos t lonUp =  36.88;
55 JawX.PostlonDown =  44.68 ;
56 j a w f a c t o r = z e r o s  (n u m b e r .o f .b e a m s  , 1 ) ;
57 w e lg h ta d d e d = 0 ;
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59 fo r  i j  = 1 : n u m b e r .o f .b e a m s
60 ev a l  ( [ ’ JawY.Openning(  ij ) = R T . P l a n . BeamSequence . I t e m .  ’
num 2st r  ( i j  ) . . .
61 ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m . l .
B e a m L lm l t ln g D e v lc e P o s l t l o n S e q u e n c e  . I t e m .2  . Lea f  J a w P o s l t l o n s  
/ l O ; ' ] ) ;
62 ev a l  ( [ ’ JawX.Opennlng(  Ij ) = R T . P l a n . BeamSequence. I t e m .  ’
num 2str  ( Ij ) . . .
63 ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m . l .
B e a m L lm l t ln g D e v lc e P o s l t l o n S e q u e n c e  . I t e m . l . Lea f  J a w P o s l t l o n s  
/ l O ; ' ] ) ;
64 JawY.OpenlngUpLeft  ( Ij )=(JawY_Opennlng(  Ij , 2) * Jaw Y .Pos t lonU p)
/lOO;
65 JawY.OpenlngUpRlght ( Ij ) = ( JawY.Opennlng ( Ij , 1) * Jaw Y .P os t lonU p)
/lOO;
66 JawY.OpenlngDownLeft(  Ij ) = ( Jaw Y .O penn lng(I j  ,2)  *
JawY.Post lonDown) / 1 0 0  ;
67 JawY.OpenlngDownRlght ( 1 j ) = ( JawY.Opennlng ( Ij , 1 ) *
JawY.Post lonDown) /lOO;
68 JawX.OpenlngUpLeft  ( Ij )= (Jaw X .O penn lng(  Ij , 2) * Jaw X .P os t lonU p)
/lOO;
69 JawX.OpenlngUpRlght  ( Ij ) = ( Jaw X .O penn lng( Ij , 1 )*  Jaw X .P os t lonU p)
/lOO;
70 JawX.OpenlngDownLeft  ( Ij )=(JawX_Opennlng(  Ij , 2 )*
Jaw X .Pos t lonD ow n)/ lOO ;
71 JawX.OpenlngDownRlght  ( 1 j ) = ( JawX.Opennlng ( Ij , 1 ) *
JawX.Post lonDown) /lOO;
72 e v a l  ( [ ’ m e t e r s e t  ( 1 j ) = R T . P l a n . F r a c t lo n G ro u p S e q u e n c e  . I t e m . l  .
ReferencedBeamSequence  . I t e m .  ’ . . .
73 n u m 2 s t r ( l j )  ’ . BeamMeterset  ; ’ ] ) ;
74 w e ig h ta d d e d = m e t e r s e t  ( 1 j )+ w e lg h tad d e d  ;
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75 j a w f a c t o r  ( ij  )= w e ig h tad d e d  ;
76 end
77
78 a l = 0 ;
79
80 for  ip =1: n u m b e r .o f .b e a m s
81
82 e v a l  ( [ ’M L C (  a l  + 1 ,  : ) — r e s h a p e  ( R T . P l a n . B e a m S e q u e n c e . I t e m .  ’
n u m 2 s t r  ( i p  ) . . .
83 ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m . l .
B e a m L l m l t l n g D e v l c e P o s l t l o n S e q u e n c e  . I t e m . 3  .
L e a f  J a w P o s l t l o n s  , 1 , n . o f . M L C l e a v e s  ) ; ’ ] ) ;
84 e v a l  ( [ ’ S u b B e a m . w e l g h t  ( r a w C o n t r o l . p o l n t s  ( I p  ) + a l  ) = R T . P l a n .
B e a m S e q u e n c e  . I t e m .  ’ . . .
33 n u m 2 s t r ( l p )  ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m . l .
C u m u l a t l v e M e t e r s e t W e l g h t  ; ’ ] )  ;
86 a l = r a w C o n t r o l . p o i n t s  ( I p  ) ;
87
88 e n d
89
90 a 2 = 0 ;
91
92 f o r  11 = 1 : n u m b e r . o f . b e a m s
93
94 f o r  1 =  2 : ( r a w C o n t r o l . p o l n t s  ( H  ) )
95
e v a l  ( [ ’ G a n t r y . A n g l e  ( l + a 2  ) = R T . P l a n . B e a m S e q u e n c e  . I t e m .  ’ 
n u m 2 s t r  ( 11 ) ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m .  ’ n u m 2 s t r  ( 1 ) 
’ . G a n t r y A n g l e  ; ’ ] ) ; 
e v a l  ( [ ’M L C (  l + a 2  , : ) = r e s h a p e  ( R T . P l a n . B e a m S e q u e n c e . I t e m .  ’ 
n u m 2 s t r  ( 11 ) ’ . C o n t r o l P o l n t S e q u e n c e  . I t e m .  ’ n u m 2 s t r  ( 1 ) 
’ . B e a m L l m l t l n g D e v l c e P o s l t l o n S e q u e n c e  . I t e m . l .
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Leaf  J a w P o s l t l o n s  , 1 , n .o f .M L C le a v e s  ) ; ’ ] ) ;  
e v a l  ( [ ’ SubBeam.welght ( l+a2 ) = R T . P l a n . BeamSequence. I t e m .  ’ 
n u m 2 s t r ( l l )  C o n t r o l P o l n t S e q u e n c e  . I t e m .  ’ n u m 2 s t r ( l )
’ . C u m u la t lv e M e te r s e tW e lg h t  ; ’ ] ) ;
e n d
102 a 2 = r a w C o n t r o l _ p o l n t s  ( 11 ) ;
103
104
105
e n d
106 r a w M U s = z e r o s  ( C o n t r o l . p o l n t s  , 1 )  ;
107 f a c t  o r  1 = 0 ;
108 a 4 = 0 ;
109 c = 0 ;
111 f o r  I s  = l : n u m b e r _ o f . b e a m s
113 for  I s l  = l : ( r a w C o n t r o l . p o i n t s  ( Is ) )
114
115 rawMUs( l s l + a 4 )  = ( ( m e t e r s e t  ( Is ) /sum( m e t e r s e t  ) ) *
SubBeam.welght  ( l s l + a 4 )  ) + f a c t o r l  ;
116
117 end
118
119 fac to r l= raw M U s(  l s l + a 4 )  ;
120 a 4 = r a w C o n t r o l . p o i n t s  ( Is ) ;
121
122 end
123
124 %Create  th e  BEAMnrc VMAT mlc se q u e n ce s  f i l e
125 t i t l e  =  ’VMAT MLCs P o s i t i o n s  ’ ; % f i l e  t i t l e
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126 s t r i n g l = ’ , ’ ;
127 MLCfileName =  ’MLCVMAT. s eq u en ce  ’ ;
f i l e  name
128 f id  =  fopen  (MLCfileName , ’w ’ ) ;
129 l e f t _leaves^V[LC(: ,60: — 1:1) ;
l e f t  MLCs
130 Right_Leaves=MLC(: , 1 2 0 : —1:61) ;
r i g h t  MLCs
131 l e f t  . l e a v e s  l = l e f t  . l e a v e s / lO ;
132 l e f t _ l e a v e s 2 = l e f t . l e a v e s  1 * 5 1 .0 /1 0 0 ;
133 R i g h t . L e a v e s l = R i g h t . L e a v e s / lO ;
134 R i g h t . L e a v e s 2 = R i g h t . L e a v e s l  * 5 1 .0 /1 0 0 ;
% MLC sequence
% Open th e  f i l e  
% s t o r e  th e
% s t o r e  th e
136 i f  f id  ~= —1
139
f p r i n t f  ( f i d  , ’% s \ r \ n ’ , t i t l e  ) ; % P r i n t  t h e  t i t l e
f p r l n t f  ( f id  , ’% d \ r \ n ’ , C o n t r o l . p o l n t s  ) ; % p r in t  th e  number
of  f i e l d s  ( n .o f .M L C le a v e s )
for  1=1: C o n t r o l . p o l n t s
143 MU=rawMUs ( i ) ;
f p r i n t f  ( f i d  , % \ r \ n ’ ,MU) ;% p r i n t  t h e  MU w iegh t  f a c t o r  
and ce a t e  new l i n e
147
149
for  j = l : ( n . o f . M L C l e a v e s / 2 )
f p r i n t f  ( f i d  , ’% d’ , l e f t . I e a v e s 2  ( i  , j ) )  ; % p r i n t  th e
lower  l e f t  c lo s e d  MLCs p o s i t i o n  
f p r i n t f  ( f i d  , ’%s ’ , s t r l n g l  ) ; % p r i n t  ’ , ’
f p r i n t f  ( f i d  , ’% d’ , R i g h t . L e a v e s 2 ( i  , j ) )  ; % p r i n t  th e  
lower  r i g h t  c lo se d  MLCs p o s i t i o n
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f p r i n t f  ( f i d  , ’%s ’ , s t r i n g  1 ) ; % p r i n t  ’ , ’
f p r i n t f  ( f i d  , ’% i \ r \ n ’ ,1) ; % p r i n t  th e
number of  l e a v e s  (a lw ays  =  l ,  l e a f  by l e a f )  and 
c e a t e  new l i n e
end
end
158 f c l o s e  ( f i d )  ; % Close th e  f i l e
159
160 end
161
162 %  C r e a t e  t h e  j a w s  s e q u e n s e s  f i l e
163 J a w s f i l e N a m e  =  ’J a w s V M A T . t x t ’ ; %  J a w s  o p i n i n g  f i l e
164 s t r i n g 2 = ’Y ’ ;
165 s t r i n g 3 =  ’X ’ ;
166 f i d  J a w s  =  f o p e n  ( J a w s f i l e N a m e  , ’w ’ ) ;  %  O p e n  t h e
f i l e
167 M U _ J a w s = z e r o s  ( n u m b e r . o f . b e a m s  , 1 )  ;
168 i f  f i d  J a w s  ~ =  —1
169
170 f o r  i i  = l : n u m b e r _ o f . b e a m s
171
172 %Write Y JAWs p a r a m e r t e r s
173 MU.Jaws( i i  ) = j a w f a c t o r  ( i i  ) /sum(sum( m e t e r s e t  ) ) ;
174 f p r i n t f  ( f i d J a w s  , ’% . 2 f \ r \ n  ’ ,MU.Jaws( i i  ) ) ;
175 % f p r i n t f  ( f id  Jaw s  , ’% s \ r \ n ’ , s t r i n g 2 ) ;
176 f p r i n t f  ( f id J a w s  , ’%d ’ , J aw Y .Pos t ionU p)  ;
177 f p r i n t f  ( f id Ja w s  , ’%s ’ , s t r i n g  1 ) ;
178 f p r i n t f  ( f i d J a w s  , ’%d ’ , JawY.Post ionDown) ;
179 f p r i n t f  ( f id Jaw s  , ’%s ’ , s t r i n g  1 ) ;
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180 f p r i n t f  ( f id Ja w s  , % ’ , JawY.OpeningUpLeft  ( i i  ) ) ;
181 f p r i n t f  ( f id Jaw s  , '%s ’ , s t r i n g l  ) ;
182 f p r i n t f  ( f id Ja w s  , , JawY.OpeningDownLeft ( i i ) ) ;
183 f p r i n t f  ( f id Jaw s  , '%8 ’ , s t r i n g l  ) ;
184 f p r i n t f  ( f id Ja w s  , , JawY.OpeningUpRight ( i i ) ) ;
185 f p r i n t f  ( f id Jaw s  , '%8 ’ , s t r i n g l  ) ;
186 f p r i n t f  ( f id Jaw s  , , JawY.OpeningDownRight ( i i ) ) ;
187 f p r i n t f  ( f id Ja w s  , ’% s \ r \ n ’ , s t r i n g l  ) ;
188 %Write Y JAWs p a r a m e r t e r s
189 % f p r i n t f  ( f id J a w s / % 8 \ r \ n ’ , S t r i n g s )  ;
190 f p r i n t f  ( f id Jaw s  , % ’ , Jaw X .Pos t ionU p)  ;
191 f p r i n t f  ( f id Jaw s  , % ’ , s t r i n g l  ) ;
192 f p r i n t f  ( f id Ja w s  , % ’ , JawX.Post ionDown) ;
193 f p r i n t f  ( f id Ja w s  , '%8 ' , s t r i n g l  ) ;
194 f p r i n t f  ( f id Jaw s  , , JawX.OpeningUpLeft  ( i i ) ) ;
195 f p r i n t f  ( f i d J a w s  , '%8 ’ , s t r i n g l  ) ;
196 f p r i n t f  ( f id J a w s  , % ’ , JawX.OpeningDownLeft  ( i i ) ) ;
197 f p r i n t f  ( f id Jaw s  , % ’ , s t r i n g l  ) ;
198 f p r i n t f  ( f id Ja w s  , % ’ , JawX.OpeningUpRight ( i i  ) ) ;
199 f p r i n t f  ( f id Jaw s  , '%8 ’ , s t r i n g l  ) ;
200 f p r i n t f  ( f id Ja w s  , W , JawX.OpeningDownRight ( i i ) ) ;
201 f p r i n t f  ( f id Ja w s  , ’% s \ r \ n  ’ , s t r i n g l  ) ;
202 end
203 f c l o s e  ( f id J a w s  ) ; % Close t h e  f
Appendix A
2 0 4
end
2 0 6
2 0 7
209
%Create  t h e  C o n t r o l  p o i n t s  of DOSXYZmc 
C o n t r l P o i n t f i l e N a m e =  ’C tr lPoin tVMAT. t x t  
s t r i n g 4 = ’ , ’ ;
r a d C a n t ry _ A n g le = d e g 2 ra d  ( G a n t ry .A n g le  ) ; 
r a d T a b l e .A n g l e = d e g 2 r a d  ( T a b le .A n g le  ) ;
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212 r a d C o l l i m a t o r _ A n g l e = d e g 2 r a d  ( C o l l i m a t o r . A n g l e )  ;
213 rawphi=zeros  ( C o n t r o l . p o i n t s  ,1) ;
214 ph i=zeros  ( C o n t r o l . p o i n t s  , 1 ) ;
215 a3=0;
216 th e t a = z e r o s  ( C o n t r o l . p o i n t s  ,1) ;
217 p h ic o l= z e ro s  ( C o n t ro l  . p o i n t  s ,1) ;
218
219 for i p l  =  1:number .of .beam s
220
222
fo r  ip2 =  l: r a w C o n t r o l . p o i n t s  ( i p l  )
223 t h e t a  ( i p 2 + a 3 ) = r a d 2 d e g ( a c o s ( - s i n  ( r ad T ab le .A n g le  ( i p l  ) )* s in
( r a d C a n t ry .A n g le  ( ip 2 + a 3 )  ) ) ) ;
224 p h i c o l  ( ip2+a3 )= rad 2 d eg  (1 .5*  p i —r ad  C o l l i m a t o r .  A ng le  ( ip 1 )—
a t a n 2 ( - ( c o s  ( r a d C a n t r y . A n g l e  ( ip2+ a3)  ) * s i n  ( 
r a d T a b l e . A n g l e  ( i p l ) ) )  , ( c o s (  r a d T a b l e . A n g l e  ( i p l ) ) ) ) )  ;
223 rawphi  ( ip2+a3 )=rad2deg ( a t a n 2 ( - c o s  ( r a d C a n t r y .A n g l e  ( ip2+a3
) ) 5 ( COS ( r a d T a b l e .A n g l e  ( i p l  ) ) * s in  ( r a d C a n t r y .A n g l e  ( ip 2 +  
a 3 ) ) ) ) ) ;
226
227 i f  r aw phi  ( i p 2 + a 3 )<0
228
229 phi  ( ip2+a3 )=360+rawphi  ( ip2+a3 ) ;
230
231 e l se
phi  ( ip2+a3 )=raw ph i  ( ip2+a3 ) ;
233
234 end
235
236
238
end
a 3 = r a w C o n t r o l _ p o i n t s  ( i p l  )+a3 ;
end
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239
240 f i d C t r l P o i n t =  fopen  ( C o n t r l P o i n t f i l e N a m e  , ’w ’ ) ; 
Open th e  f i l e
%
243
245
i f  f i d C t r l P o i n t  ~= —1
for  k = l :  C o n t r o l  . p o i n t s
246 f p r i n t f f i d C t r l P o i n t I s o C e n t r e . X ) ;
247 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
248 f p r i n t f f i d C t r l P o i n t I s o C e n t r e . Y ) ;
249 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
250 f p r i n t f f i d C t r l P o i n t I s o C e n t r e . Z  ) ;
251 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
252 f p r i n t f f i d C t r l P o i n t t h e t a ( k ) ) ;
253 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
254 f p r i n t f f i d C t r l P o i n t p h i ( k ) ) ;
255 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
256 f p r i n t f f i d C t r l P o i n t p h i c o l  (k)  ) ;
257 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
258 f p r i n t f f i d C t r l P o i n t d s o u r c e ) ;
259 f p r i n t f f i d C t r l P o i n t s t r i n g 4  ) ;
260 f p r i n t f f i d C t r l P o i n t  , ’% d \ r \ n  ’ ,rawMUs(k) )
261
end
264 f c l o s e  ( f i d C t r l P o i n t )  ; % Close th e  f i l e
266
267
end
The End of F u n c t io n
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A .4 Generate MC plan assessing parameters
1 % F u n c t io n  to  r e a d  * . e g s p h a n t ,  * .3 d d o se  and h o s p i t a l  ( V a r i a n )
t r e a t m e n t  p l a n n i g
2 % (TP) f i l e s  e x p o r t e d  in dicom fo rm a t  (CT s l i s e s  , RT S t r u c t u r e  ,
RT Dose and
3 % RT p l a n )  and c r e a t e  :
4
5 % 1. Monte Car lo  v o x e l i s e d  p h a n t o m / p h a t i a n t  s l i c e s .
6
7 % 2. Monte Car lo  3D Dose f i l e  n o r m i l i s e d  a c o r d in g  to  t h e  maximum
dose in
8 % h o s p i t a l  TP.
9
10 % 3. The r e g io n  of i n t r e r e s t  RIO such as PTV and OAR in o r d e r  to
c a l c u l a t e
11 % ROI Volume and D o se .
12
13 % 4. The DVHs fo r  each ROI fo r  a n a l y s i n g  th e  MC p l a n .
14
15 % 5. The a s s i s s i n g  p a r a m e t e r :  HI ,D2,D50,D98,  VJDGy, C l ,  CN, GI
16
17
19 % Author Name: Maan.A Najem Department of Phys ics  U n iv e r s i ty  of
Sur rey
20 % G u i ld fo rd ,  UK Date: (10th  of January  2014) Copyright  M.A.Najem
(2014)
24 f u n c t io n  [C T .S l ices  MCDose3D CumulativeDVH Nz Dmax] = 
P Ians _E v a lu t  ion (new)
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25 % read *. egsphan t  f i l e
26 [eg sphan t . fnam e  e g s p h a n t_ d i r ] =  u i g e t f i l e  ( ’ *. e g s p h a n t ’Open *.
egsphant  F i le  ’ ) ;
27 eg sp h an f i l en a m e = f  u l l f i l e  ( e g s p h a n t . d i r  , e g s p h a n t . f n a m e ) ;
28 r a w D a ta l= im p o r td a t a ( egsphanf i lename , ’ ’ ,6) ; % Im por t ing  the  *.
egsphant  f i l e
29
30 % read  * .3 d d o se  f i l e
31 [dose3d_fname d o s e 3 d _ d i r ] =  u i g e t f i l e  ( ’ * . 3 ddose ’ , ’Open * .3ddose
F i l e ’ ) ;
32 f i l e _ 3 d d o s e = f u l l f i l e  (d o s e 3 d _ d i r  , d o se3 d _ fn am e) ;
33 r a w D o s e l = i m p o r t d a t a ( f i l e _ 3 d d o s e )  ; % I m p o r t in g  th e  * .3 d d o se
f i l e
34 %import  R T .P lan  f i l e
35 [RTdose.fname R T d o se_ d i r ]=  u i g e t  f i l e  ( ’ * .d cm ’ , ’Open RT Dose F i l e ’ )
)
36 f i l e n a m e 4 = f  u 11 f i 1 e ( R T d o se .d i r  , RTdose.fname ) ;
37 % fi lenam e4  =  ’Data /RD.dcm ’ ;
38 R T .D o s e i n f o = d i c o m i n f o ( f i l e n a m e 4 )  ; % Read th e  in fo  of RT.Dose2.
dcm
39 RT.Dose=dicomread  ( f i l e n a m e 4  ) ;
40
41 [ RTplan .fnam e R T p l a n . d i r ] =  u i g e t  f i l e  ( ’ * .d cm ’ , ’Open RT P lan  f i l e ’ )
42 f i l e n a m e 6 = f u l l f i l e  ( R T p l a n . d i r  , RT p lan . fnam e)  ;
43 R T .P lan = d ico m in fo  ( f i l e n a m e 6  ) ;
44 n u m b e r .o f .b e a m s = R T .P l a n . F r a c t lo n G ro u p S e q u e n c e  . I t e m . l  .
NumberOfBeams; % C a c l u l a t i n g  th e  no. of beams
45 n u m b e r . o f . f r a c t i o n s = R T . P l a n . F ra c t lo n G ro u p S e q u e n c e  . I t e m . l  .
N u m b e rO fF ra c t io n sP la n n e d  ; % C a c l u l a t i n g  th e  no. of RT c o u r s e  
f r a c t i o n s
46 f r a c t i a l _ M U s = z e r o s  ( n u m b e r .o f .b ea m s  , 1) ;
169
M. A. Najem_________   Appendix A
47 f r a c t i a l _ d o s e = z e r o s  (number .of .beams , 1) ;
48 for n n = l :n u m b e r .o f .b ea m s
49
50 eval  ( [ ’ f r a c t i a l .M U s  (n n )= R T .P la n . F ract lonGroupSequence  . I t e m . l
. ReferencedBeamSequence . I t e m .  ’ num 2str (nn)  ’ .BeamMeterset
51 eval  ( [ ’ f r a c t i a l . d o s e  (n n )= R T .P la n . F rac t lonGroupSequence  .
I t e m . l  . ReferencedBeamSequence . I t e m .  ’ num 2str (nn)  ’ . 
BeamDose ; ’ ] ) ;
52 end
53
54 Total.MUs=sum( f r a c t i a l .M U s  ) ; % % C a c l u la t in g  the  t o t a l  MUs
55 absoluteDose=sum( f r a c t i a l . d o s e  ) * n u m b e r . o f . f r a c t io n s  ; %
C a c lu la t in g  the  p r e s c r i p t i o n  dose.
56
57 TPDosemaxraw=max( max ( max ( max (RT .Dose) ) ) ) *RT_Doseinfo .
D o s e G r id S c a l in g  ; % C a c l u l a t i n g  th e  max dose .
58 TPDosemax=double (TPDosemaxraw* 1 0 4 / a b s o lu t e D o s e  ) ;
59 raw D a ta2 = re sh a p e  ( t r a n s p o s e  ( r a w D a t a l . d a t a )  , s i z e  ( r a w D a t a l . d a t a  , 1) *
s iz e  ( r a w D a t a l . d a t a  ,2) , 1 ) ;  %Reshaping th e  im p o r te d  e g s p h a n t
f i l e  fo r  a n a l y s i s
60 raw D ose2=reshape  ( t r a n s p o s e  ( raw D ose l )  , s i z e  ( rawDosel  ,1) * s i z e  (
rawDosel  ,2) , 1 ) ;  % Rreshap ing  th e  im p o r t e d  Sddose f i l e  fo r
a n a l y s i s
61
62 rawData2 ( a r r a y f u n  ( ©isnan , r a w D a ta 2 ) ) = [ ] ;  % To d e l e t e  any NaN
v a lu e  in t h e  im p o r te d  e g s p h a n t  f i l e
63 rawDose2 ( a r r a y f u n  (@isnan ,rawDose2)  ) = [ ]  ; % To d e l e t e  any NaN
va lu e  in th e  im p o r te d  e g s p h a n t  f i l e
64
65 Nx=rawData2 ( 1 ) ; % C a l c u l a t i n g  th e  number of  x v o x e ls
66 Ny=rawData2 (2) ; % C a l c u l a t i n g  t h e  number of  y v o x e ls
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67 Nz=rawData2 (3) ; % C a l c u l a t i n g  t h e  number of z v o x e ls
68
69
70 X=rawData2  (4 :Nx+4) ; % C a l c u l a t i n g  th e  c o o r d i n a t e  of
of X v o x e ls
71 Y=rawData2 (Nx+5:Nx+Ny+5) ; % C a l c u l a t i n g  th e  c o o r d i n a t e  of
of y v o x e ls
72 Z=rawData2 (Nx+Ny+6 :Nx+Ny+Nz+6 ) ; % C a l c u l a t i n g  th e  c o o r d i n a t e  of
of z v o x e ls
73
Vx_size=10*(X(  s iz e  (X, 1) )—X ( l )  ) /N x;  % C a l c u l a t i n g  t h e  s i z e  of of
X voxel  in  mm
75 Vy_size=10*(Y(  s iz e  (X, 1) )—Y ( l )  ) /N y;  % C a l c u l a t i n g  th e  s i z e  of of
y voxe l  in mm
76 V z . s i z e  = 1 0 * (Z ( s i z e  ( Z , 1 ) )—Z ( 1 ) ) /Nz ; % C a l c u l a t i n g  th e  s i z e  of  of
z voxe l  in mm
77
78 % F o r t h e r  a n a l y s i s  of  th e  im p o r te d  e g s p h a n t  and 3ddose  f i l e s
form here  :
79 rawData3=rawData2  (Nx+Ny+Nz+7: s iz e  ( raw D a ta 2 ) ) ;
80 rawDose3=rawDose2 (Nx+Ny+Nz+7: s iz e  ( rawDose2 ) )  ;
81
82 rawData4=rawData3  (( s iz e  ( r a w D a ta 3 ) -(Nx*Ny*Nz)+ 1 ) : s i z e  ( raw D ata3 )  ) ;
83 rawDose4=rawDose3 ( 1 :Nx*Ny*Nz) ;
84
85 raw D a ta5 = re sh ap e  (rawData4 ,Nx,Ny,Nz)  ;
86 r aw D ose5=reshape  (rawDose4 ,Nx,Ny,Nz)  ;
87
88 r aw D ata 6 = p erm u te  ( rawData5 , [ 2  1 3 ] ) ;
89 rawDose6 = p erm u te  (rawDoseS , [ 2  1 3 ] ) ;
90
91 raw D ata7=1200*raw D ata6 /max(m ax(m ax(raw D ata6)  ) ) ;
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92 rawDose7=TPDosemax*rawDose6/max(max(max(rawDose6 (: , 2 : N z ) ) ) ) ;
93 % To he re
94 Dmax=uint32 (TPDosemax) ;
95 C T _ S l i c e s = u i n t l 6  ( raw D ata7)  ; % c r e a t i n g  th e  m a t r i x  of v o x e l i s e d
p h a n t o m / p a t i a n t  s l i c e s  in n i n t  16 fo rm a t  (same fo rm a t  of 
h o s p i t a l  TP CT s l i c e s )
96 MCDose3D=uint32 ( rawDose7) ; % c r e a t i n g  th e  m a t r i x  of  3D Dose a t
each v oxe l  in u n i t3 2  fo rm a t  (same fo rm a t  of  h o s p i t a l  TP RT 
Dose f i l e  )
97
98 [ c t s l i c e s . f n a m e  c t s l i c e s _ d i r ] = u i g e t f i l e  ( ’ * . d cm ’ , ’Open CT S l i c e s
F i l e s  ’ , ’ M u l t i S e l e c t  ’ , ’o n ’ ) ;
99 n _ o f_ p la n C T s l i c e s= le n g th  ( c t s l i c e s - f n a m e  ) ;
%RT_D oseinfo . NumberOfFrames ;
100 H C T s l i c e s = c e l l  ( n _ o f _ p la n C T s l i c e s  ,1) ;
101 c t s l i c e s _ d i r l  =  c e l l s t r  ( c t s l i c e s . d i r  ) ;
102 fo r  i =1: n _of . p l a n  C T  s l i ce s
103 H C T s l i c e s { i } = f u l l f i l e  ( c t s l i c e s . d i r  1 {1} , c t s l i c e s . f n a m e  { !} )  ;
104 end
105
106 i f  (new==l)
107 fo r  i l = l : n _ o f . p l a n C T s l i c e s  % Modify t h e  h o s p i t a l  TP CT s l i c e
i n f o r m a t i o n  to  a d a p t  th e  MC v o x e l i s e d  p h a n t o m / p a t i a n t  
d i m i n s i o n .
108 % f i l e n a m e l = s p r i n t f  ( ’CT ( % d ) ’ , i l ) ;  % C r e a t e  t h e  l i s t  of  CT
s l i c e s  ” User can change th e  name to  mache th e  name of  
h o s p i t a l  TP CT s l i c e s  names
109 % f o l d e r l = ’D a ta \R S C H \’ ; % C rea t  th e  d i r e c t o r y  where th e
h o s p i t a l  TP CT s l i c e s  is e x i s t  ” User can change th e  
d i r e c t o r y  to  mach th e  name of h is  f o l d e r ” 
no % F u l l f i l e n a m e l = f u l l f i l e  ( f o l d e r l  , f i l e n a m e l  ) ;
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111 e v a l  ( [ ’P l a n C T ’ n u m 2 s t r ( i l )  ’= d i c o m i n f o  ( H C T s l i c e s {  i l  } ) ; ’ ] )  ;
% Read t h e  i n f o  f o r  e a c h  CT s l i c e s
112 e v a l  ( [ ’P l a n C T ’ n u m 2 s t r ( i l )  ’ . I n s t a n c e N u m b e r = i l  ; ’ ] ) ;
% S o r t  t h e  CT s l i c e s
113 e v a l  ( [ ’P l a n C T ’ n u m 2 s t r ( i l )  ’ . I m a g e P o s i t i o n P a t i e n t
=  [ —230;  —2 3 0 ; 1 0 * Z (  i l  ) + (  V z . s i z e  ) / 2 ]  ; ’ ] ) ; % M o d i f y  t h e  i m a g e  
p o s i t i o n  t o  m a t c h  e a c h  MC s l i s e  p o s i t i o n
114 e v a l  ( [ ’P l a n C T ’ n u m 2 s t r ( i l )  ’ . S l i c e L o c a t i o n  =  ( 1 0 * Z ( i l  ) + (
V z - s i z e  ) / 2 )  ; ’ ] ) ; % M o d i f y  t h e  s l i c e  l o c a t i o n  t o  m a t c h  t h e  
MC s l i c e  l o c a t i o n
115 e v a l  ( [ ’P l a n C T ’ n u m 2 s t r ( i l )  ’ . R ow s=N x; ’ ] ) ; % M o d i f y  t h e
num ber v o x e l e s  i n  x  d i r e c t i o n  t o  m a tch  t h e  MC o n e
116 e v a l  ( [ ’P l a n C T ’ n u m 2 s t r ( i l )  ’ . C olum ns= N y ; ’ ] ) ; % M o d i f y  t h e
num ber v o x e l e s  i n  y  d i r e c t i o n  t o  m a tch  t h e  MC o n e
117 e v a l  ( [ P lan C T  ’ n u m 2 s t r ( i l )  ’ . P i x e l S p a c i n g  =  [ V x . s i z e  ; V y . s i z e  ] ;
’ ] ) ;  % M o d i f y  t h e  v o x e l e  s i z e  i n  x  and y  d i r e c t i o n  t o  
m a tch  t h e  MC on e
118 en d
119 i n f o = P l a n C T l  ; % i n i t i a l  d ico m  i n f o
120
121 % C r e a t i n g  t h e  MC s l i c e s  i n d ico m  f o r m a t
122
123 f o l d e r  2 = u i g e t  d i r  ( ’C: \  ’ , ’ S e l e c t  F o u l d e r  t o  S a v e  c r e a t e d  S l i c e s ’ ) ;
% C r e a t e  t h e  f o l d e r  w h ere  t h e s e  s l i c e s  w i l l  s a v e  i n
124 f o r  i 2 = l : N z
125 f i l e n a m e 2 = s p r i n t f (  ’ s l i c e _ % d . d c m ’ , i 2 )  ; % C r e a t e  t h e  ( i 2 )  MC
s l i c e  n am es
126 F u l l f i l e n a m e 2 = f u l l f i l e  ( f o l d e r 2  , f i l e n a m e 2 ) ;
127 e v a l  ( [ ’ in fo = P la n C T  ’ n u m 2 s t r ( i 2 )  ’ ; ’ ] ) ;  % s a v e  t h e  i n f o  o f
t h e  m o d i f i e d  ( i 2 )  h o s p i t a l  CT s l i c e  i n  t h e  v a r i a b l e  ” i n f o
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128 dicomwri te  ( C T .S l ices  ( : , : , i2 ) , Fu l l f i len am e2  , info ) ; % Create
the  ( i 2 )  MC s l i c e  dicom f i l e  with the  modif ied  ( i 2 )  
h o s p i t a l  CT s l i c e  info
129 end
130 end
131
132 % C rea t in g  the  ROI in the  MC s l i c e s  which then  w i l l  be used for
dose c a l c u l a t i o n
133 [R T s t ru c . fn a m e  R T s t r u c _ d i r ] =  u i g e t f i l e  ( ’ * . d c m ’Open RT S t r u c t u r e
Fi le  ’ ) ;
134 f i l e n a m e 3 = f u l l f i l e  ( R T s t r u c .d i r  , R Tstruc .fnam e)  ;
135 %filename3 =  ’Data /RS.dcm ’ ;
136 R T _ S t ru c tu r e = d ic o m in f o  ( f i l e n a m e 3 )  ; % Read th e  in fo  of
R T .S t ru c tu re  .dcm
137
138 N_of_ROI=sum( s t r u c t f u n  (@numel, R T . S t r u c t u r e  .
S t r u c t u r e S e t R O I S e q u e n c e ) )  ;
139 [ x l s f i l e n a m e  x l s f o l d e r ] =  u i p u t f i l e  ( ’ *. x l s ’ , ’ S e l e c t  *. x l s  f i l e  to
save a s s e s s i n g  p a r a m e t e r  f i l e  a s ’ ) ;  % MLC
sequence  f i l e  name
140 x l s f i l e  =  f u l l f i l e  ( x l s f o l d e r  , x l s f i l e n a m e  ) ;
141
142 fo r  i k = l : N . o f . R O I
143
144 ev a l  ( [ ’ROIJMame=RT_Structure . S t r u c tu r e S e tR O I S e q u e n c e  . I t e m .  ’
num 2str  ( ik ) ’ . ROIName ; ’ ] ) ;
145
146 ev a l  ( [ ’ R O I .n _ o f_ s l i c e s = s u m (  s t r u c t f u n  (@numel, R T . S t r u c t u r e  .
ROIContourSequence  . I t e m .  ’ num 2str  ( i k )  ’ . C o n to u r S e q u e n c e ) ) ; ’ ] ) 
; % c a l c u l a t e  th e
147 % number of  s l i c e s  of  d e s i r e d  ROI
148
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149 R O I_ raw P o s i t io n s2  =  [] ; % i n i t i a l  p o s i t i o n s
150 for  i3 =1: R O I_ n _ o f_ s l i c e s
151 ev a l  ( [ ’ R O I _ r a w P o s i t i o n s l_  ’ n u m 2 s t r ( i 3 )  ’ =  [ ] ; ’ ] ) ;
152 ev a l  ( [ ’ R O I _ r a w P o s i t i o n s l_  ’ n u m 2 s t r ( i 3 )  ’= R T _ S t r u c t u r e  .
RO IContourSequence  . I t e m .  ’ num 2str  ( i k )  ’ . C on tou rS equence  . I t e m .
’ n u m 2 s t r ( i 3 )  ’ . C o n to u rD a ta  ; ’ ] ) ;
153 ev a l  ( [ ’ R O I . r a w P o s i t i o n s 2  =  [ R O I . r a w P o s i t i o n s 2  ; R O I . r a w P o s i t i o n s l .  ’
num 2str  ( 13 ) ’ ] ; ’ ] ) ;
155 end
157 R O I . P o s t i o n s —r e s h a p e  ( R O I . r a w P o s i t i o n s 2  ,3 , s i z e  ( R O I . r a w P o s i t i o n s 2
, l ) / 3 )  % The x , y , z  p o s i t i o n s  of th e  TP ROI
158
159 t e s t = z e r o s  ( l e n g t h  ( R O I .P o s t i o n s )  ,1) ;
160 for  i l  2 =  1: l e n g t h  ( R O I . P o s t  ions)
161 i f  ( R O I . P o s t i o n s ( i l 2  , l ) ) < ( 1 0 * X ( l ) + V x _ s i z e / 2 )  | |  ( R O I .P o s t i o n s  (
i l 2 , 2 ) ) < (  1 0 * Y ( l ) + V y . s i z e / 2 )  I I R O I .P o s t io n s  ( i l 2  ,3)  <(10*Z(1)  +  
V z . s i z e  / 2 )  I I ( R O I .P o s t io n s  (i  12 ,1) ) > (1 0 * X ( e n d ) + V x . s i z e / 2 )  | | ( 
R O I . P o s t i o n s ( i l 2  ,2)  ) > ( 1 0 * Y ( e n d ) + V y . s i z e / 2 )  | | ( R O I .P o s t i o n s  ( 
i l 2  ,3) ) > (  10*Z(end) + V z . s i z e / 2 )
162 t e s t  ( i l 2  ) = i l 2  ;
163 end
164 end
165 t e s t  ( t e s t  ==0) =  [] ;
166 R O I .P o s t i o n s  ( t e s t  , : ) = [ ]  ;
167
169 T P R O Ijx= R O I.P os t ions  ( : ,  1 ) ; % i n i t i a l  v a lu e s
170 TP R O I .y = R O I .P o s t io n s  (: ,2)  ; % i n i t i a l  v a lu e s
171 T P R O L z= R O I .P o s t io n s  (: ,3) ; % i n i t i a l  v a lu e s
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m  MCR0Ijx=(1:  s iz e  (TPROIjx, 1) ) ’ ; % i n i t i a l  v a lu e s
m  MCROLy=(l :  s i z e  (TPROI_y, l )  ) ’ ; % i n i t i a l  v a lu e s
175 MCROI.z=(l :  s i z e  (TPROLz,  1) ) ’ ; % i n i t i a l  v a lu e s
176 MCROIn-awx=(l:  s i z e  (TPROIj x , ! )  ) % i n i t i a l  v a lu e s
177 MCROIj’a w y = ( l :  s i z e  ( T P R O L y , ! )  ) ’ ; % i n i t i a l  v a lu e s
178 M CROIj 'awz=(l :  s i z e  ( T P R O L z , ! )  ) ’ ; % i n i t i a l  v a lu e s
179
180 % This  t h r e e  lo o p s  f in d  th e  e q u i v a l e n t  voxe l  p o s t i o n s  ( x , y , z )  of
th e  c o n to u r e  TP p a t i e n t
181 % ROI ( e . g  PTV, Rectum, e t c . )  in t h e  v o x e l i s e d  MC p h a t o m / p a t i e n t  .
182 % th e  e q u i v e l e n t  x p o s i t i o n s  :
183 for  i 4 = l :  s i z e  (TPROIj c , 1)
184
185 for  j 1=1:  s iz e  (X, 1 )
186
13^  i f  ( a b s ( T P R 0 I j x ( i 4 )  - 1 0 . * X ( j l  ) ) < = V x _ s iz e /2 )
188
189 MCROInrawx( i4 )=X( j 1 ) ;
190 end
191 end
192
M CRO Ijx ( i4 )= f ind ( i sm em ber (X ,M C R O Iu-aw x( i4 ) )  ,1 ,  ’ f i r s t  ’ ) - l ;
end
197 % th e  e q u i v e l e n t  y p o s i t i o n s
198 for  i5 =1: s iz e  (T P R O L y, 1 )
200 fo r  j 2 = l :  s iz e  (Y, 1)
i f  ( abs (TPROLy ( i5 ) — 10*Y( j 2 ) ) < = ( V y _ s i z e /2 + 1 )  )
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204 MCROI j:awy ( i 5 ) =Y( j 2 ) ;
2 0 6
2 0 7
211
end
end
MCROLy( i5 ) = f i n d  (ismember  (Y,MCROIjrawy( i 5 ) ) , ! , ’ f i r s t  ’ ) 
- 1 ;
212 end
213
214 % t h e  e q u i v e l e n t  z p o s i t i o n s  :
215 fo r  i6 =1: s i z e  (T P R O L z , 1 )
216
217 fo r  j 3 = l :  s iz e  ( z ,  1)
218
219 i f  ( ab s  (TPROI_z( i6 ) —10*Z( j3 ) ) <=(0 .01+  V z . s i z e  / 2 )  )
220
221 MCROIjrawz ( i 6 )=Z ( j 3 ) ;
222
223 end
224
225 end
226
227 MCROI.Z( i 6 ) = f i n d  ( ismember (Z , MCROInrawz( i 6 ) ) ) —1;
228
229 end
230 % MC ROI c o n to u r  p o s i t i o n s  in a l l  s l i c e s :
231 M CRO I.raw Pos i t ions  =  [MCROI.x MCROLy MCROI_z] ; % l i s t i n g  a i l
e q i v a l e n t  p o s i t i o n s
232 M C R O I .Po s i t io n s= u n iq u e  (M C RO I.raw Pos i t ions  , ’rows ’ , ’ s t a b l e  ’ ) ;
%removing t h e  d u p l i a t e d  p o i n t s
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233 % C a l c u l a t e  a i l  p o i n t  i n s i d e  t h e  R O I  c o n t o u r
234
235 z s l i c e s = u n i q u e  ( M C R O I - P o s i t i o n s  ( : , 3 )  , ’ s t a b l e  ’ ) ;
236 % h e r e %
237 % s o r t e d z s l i c e s = f l i p u d  ( z  s l i c e s  ) ;
238
239 r e p i t i t i o n = h i s t c ( M C R O I _ P o s i t i o n s ( :  ,3 )  , z s l i c e s )  ; % c a l c u l a t e
t h e  z  p o t i o n s  r e p i t i t i o n  i n  t h e  R O I
240
241 a l  =  l ;  % i n i t i a l  v a l u e
242 a 2 = 0 ;  % i n i t i a l  v a l u e s
243 R O I D o s e = 0 ;  % i n i t i a l  v a l u e s
244 M a s k v o l = 0 ;  % i n i t i a l  v a l u e s
246
247
fo r  i =1: s iz e  ( r é p i t  i t  i o n  )
248 e v a l ( [ ’X _ ’ n u m 2 s t r ( i )  ’=MCROI_Posi t ions  ( a l  : r é p i t  i t  i o n  ( i )
+ a 2 , l ) ; ’ ] ) ;  % c a l u l a t e  th e  X p o t i o n s  fo r  t h e  i s l i c e
249 e v a l ( [ ’Y _ ’ n u m 2 s t r ( i )  ’= M C R O I_ P o s i t io n s (a l  : r e p i t i t i o n  ( i )
+ a 2 , 2 ) ; ’ ] ) ;  % c a l u l a t e  th e  Y p o t i o n s  fo r  t h e  i s l i c e
250 e v a l  ( [ ’M a s k . ’ n u m 2 s t r ( i )  ’= p o l y 2 m a s k ( X . ’ n u m 2 s t r ( i )  ’ ,Y .
’ n u m 2 s t r ( i )  ’ ,Nx,Ny) ; ’ ] ) ; % c r e a t e  th e  mask of t h e  
ROI c o n to u r  a t  s l i c e  i
251 a l = a l + r e p i t  i t  i o n  ( i ) ;
252 a 2 = a 2 + r e p i t i t i o n ( i )  ;
233 ev a l  ( [ ’M askvo l .  ’ n u m 2 s t r ( i )  ’=sum ( sum ( Mask. ’ n u m 2 s t r ( i )
’ ) ) ; ’ ] ) ;  % c a l c u l a t e  th e  ROI a r e a  of th e  i s l i c e
234 ev a l  ( [ ’r e a l M a s k .  ’ n u m 2 s t r ( i )  ’= u i n t 3 2  (Mask.  ’ n u m 2 s t r ( i )
% c o n v e r t  th e  Mask form b o o l i e n  to  u i n t 3 2
255 %here%
236 ev a l  ( [ ’ D o s e S l i c e .  ’ n u m 2 s t r ( i )  ’=MCDose3D ( : , : , z s l i c e s  ( i ) )
; ’ ] ) ; %  c a l u l a t e  th e  dose a t  s l i c e  i
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258 e v a l  ( [ ’ R O I D o s e _  ’ n u m 2 s t r ( i )  ’= r e a l M a s k _  ’ n u m 2 s t r ( i )
D o s e S l i c e .  ’ n u m 2 s t r ( i )  % c a l c u l a t e  t h e  d o s e
e a c h  v o x e l  i n s i d e  t h e  c o n t o u r
259 e v a l  ( [ ’ R O I D o s e = R O I D o s e - f - s u m (  s u m  ( R O I D o s e .  ’ n u m 2 s t r ( i )  ’ ) ) ;
’ ] ) ;  % C a l u l a t e  t h e  t o t a l  d o s e  i n s i d e  t h e  R O I  o f  
s l i c e  i
260 e v a l  ( [ ’ M a s k v o l = M a s k v o l + ( s u m ( M a s k v o l _  ’ n u m 2 s t r ( i )  ’ ) ) ; ’ ] )
; % C a l u l a t e  t h e  t o t a l  n u m b e r  o f  v o x e l  v o l u m e  o f  R O I
261
262
263
end
264 Volum eofROI=M askvol*Vx_s ize*Vy_s ize*Vz_size / lOO O; % C a l c u l a t e
th e  Volume of  t h e  ROI in cm"3
265
266 AverageDose=ROIDose/Maskvol  ; % C a l c u l a t e  th e  a v e ra g e  dose in  th e
ROI
267 raw D o seR O I l i s t  =  [] ;
268
270
fo r  k = l :  s i z e  ( r e p i t  i t  i o n  )
271 ev a l  ( [ ’r a w D o s e R O I l i s t - ’ n u m 2 s t r (k )  ’=ROIDose_ ’ n u m 2 s t r ( k
272 ev a l  ( [ ’ r a w D o seR O I l i s t  =  [ raw D oseR O Il i s t  ; r a w D o s e R O I l i s t -  ’
n um 2st r  (k)
273
end
276 R O I D o s e l i s t= r e s h a p e  ( raw D o seR O I l i s t  , s i z e  ( raw D o se R O Il i s t  ,1) * s i z e  (
r a w D o seR O I l i s t  ,2) , 1) ; % c r e a t e  t h e  l i s t  of
277 R O ID o se l i s t  ( ~ a n y ( R O ID o se l i s t  ,2) , : ) = [ ] ;  % dose a t  ROI
278
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279 % C a l c u l a t i n g  t h e  C u m u la t iv e  and d i f f e r e n t i a l  DVHs
280 DVH=zeros ( u in t3 2  (TPDosemax) , 1) ;
281 DVHdiff=zeros  ( u i n t 32 (TPDosemax) ,1) ;
282 maxdose=double  ( u i n t 32 (TPDosemax) ) ;
283 l i s t  of  a b s o l u t  e D o s e = z e r o s  (TPDosemax, 1 ) ;
284 %for  i =1: u in t3 2  (TPDosemax)
285 fo r  i = l :TPDosemax+l
286 DVH(i ) = d o u b l e ( 1 0 0 - ( 1 0 0 / s i z e  (R O ID o se l i s t  ,1) )*sum(
R O ID o se l i s t< = i  —1) ) ; % Cumulateve DVH
287 DVHdiff ( i ) = (1 0 0 /  s iz e  ( R O ID ose l i s t  , 1 ) ) *sum( R O I D o s e l i s t = i  )
; % D i f f e r e n t i a l  DVH
288 l i s t o f a b s o l u t e D o s e  ( i ) = a b s o lu t e D o s e  * ( i  - 1 )  / 1 0 0 . 0 ;
289 e n d
291
292 C u m u la t iv e D V H = [ l i s to f a b s o lu t e D o s e  DVH]; %The C m u la t iv e  DVH
293 D i f f e r e n t i a lD V H  =  [ l i s t o f a b s o l u t e D o s e  DVHdiff] ;
294
295 % c a I c u l a t i o n  of  D2%
296 d 2 _ l= f in d  (DVH<=2,1, ’ f i r s t  ’ ) ;
297 d 2 - 2 = f in d  (DVH>=2,1, ’ l a s t  ’ ) ;
298 d i f 2 .1 = a b s { D V H ( d 2 .1 ) - 2 ) ;
299 d i f 2 . 2 = a b s ( D V H ( d 2 .2 ) - 2 ) ;
300 D 2 = (d i f 2 .1  *d2_2+dif2_2  *d2 .1  ) / a b s  (DVH( d2 .1 )-DVH(d2.2 ) ) ;
301
302 % C a l c u l a t i o n  of  D98%
303 d 9 8 _ l= f in d  (DVH<=98,1, ’ f i r s t  ’ ) ;
304 d98_2=find  (DVH>=98,1, ’ l a s t  ’ ) ;
305 d i f 9 8 _ l = a b s  (DVH( d98_l  ) —98) ;
306 d i f9 8 _ 2 = ab s  (DVH( d98_2 ) —98) ;
307 D 9 8 = (d i f98_ l*d 98_2+d if98_2*d 98_ l ) /ab s(D V H (d 98_ l ) -D V H (d 98_2)  )
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308
310
311
% C a l c u l a t i o n  of  D95% 
d 9 5 - l = f i n d  (DVH<=95,1, ’ f i r s t ’ ) ; 
d 9 5 . 2 = f i n d ( D V H > = 9 5 , l , ’ l a s t ’ ) ; 
d i f 9 5 - l = a b s  (DVH( d95.1  ) -9 5 )  ; 
d i f9 5 _ 2 = a b s  (DVH( d95 .2  ) - 9 5 )  ;
D 9 5 = ( d i f 9 5 - l * d 9 5 . 2 + d i f 9 5 . 2 * d 9 5 .1 ) / a b s ( D V H ( d 9 5 .1 ) - D V H ( d 9 5 - 2 ) )
317
319
% C a l c u l a t i o n  of  D50% 
d 5 0 . 1 = f i n d ( D V H < = 5 0 , l , ’ f i r s t  ’ ) ;  
d 5 0 .2 = f in d (D V H > = 5 0 , l ,  ’ l a s t  ’ ) ; 
d i f 5 0 . 1 = a b s  (DVH( d50.1  ) - 5 0 )  ; 
d i f5 0 _ 2 = a b s  (DVH( d50 .2  ) - 5 0 )  ;
D 5 0 = (d i f 5 0 .1 * d 5 0 _ 2 + d i f 5 0 .2 * d 5 0 .1 ) / a b s ( D V H ( d 5 0 .1 ) - D V H ( d 5 0 .2 ) )
323
324
325
326
328
329
334
335
% C a l c u l a t i o n  t h e  Volume t h a t  r e c e i v e s  a t  l e a s t  c e r t i a n  Dose 
(Gy) V_DGy
r e l a t i v e D o s e 5 = u i n t 3 2  ( 5 * 1 0 0 / a b s o lu t e D o s e  ) ; %Convert  from 
a b s o l u t e  to  r e l a t i v e  
r e l a t i v e D  ose 1 0 = u in t  32 (10*100 /  a b s o lu t e  Dose ) 
r e l a t i v e D o s e 2 0 = u i n t 3 2  (20*100 /  a b s o lu t e  Dose ) 
r e l a t i v e D o s e 3 0 = u i n t 3 2  (30*100 /  a b s o l u t eDose ) 
r e l a t i v e D o s e 5 0 = u i n t 3 2  ( 5 0 * 1 0 0 / a b s o lu t e D o s e  ) 
r e l a t i v e D o s e 7 0 = u i n t 3 2  ( 7 0 * 1 0 0 / a b s o lu t e D o s e )
V5Gy=(100*DVH( r e l a t i v e D o s e 5  ) ) / lOO; % The c a l c u l a t e d  VJDGy
V10Gy=(100*DVH( r e l a t i v e D o s e l O  ) ) / lOO 
V20Gy=(100*DVH( r e l a t i v e D o s e 2 0 ) )  / lOO 
V30Gy=(100*DVH( r e l a t i v e D o s e 3 0 ) )  / 1 0 0
% The c a l c u l a t e d  VJDGy 
% The c a l c u l a t e d  VJDGy 
% The c a l c u l a t e d  VJDGy
V50Gy=(100*DVH( r e l a t i v e D o s e 5 0  ) ) / lOO; % The c a l c u l a t e d  VJDGy
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336 V70Gy=(100*DVH( r e l a t iv e D o se T O  ) ) /lOO; % The c a l c u l a t e d  VJDGy
337
338 % C a l c u l a t i o n  of Homogenei ty  index  , Confo rm i ty  index  ,
C o n fo rm i ty  number and G r a d ie n t  index
339 % if  ( R O I J n d e x = = 1 0 )  % ” 10” is t h e  ”PTV’ o rd e r  in th e
h o s p i t a l  R T - S t r u c t u r e  f i l e
340 % (User can change t h i s  number to  match th e  PTV o r d e r  in t h e r e
R T _ s t r u c t u r e  f i l e )
341
342 % Homogeneity index (HI):
343 HI=(D2-D98)/D50;
344
345 % C o n fo rm i ty  index  ( C l ) :
346 CI=sum( sum(sum(MCDose3D>=100) ) ) / s u m ( R O ID o se l i s t  >=100) ;
347
348
349 % C o n fo rm i ty  numvber (CN) :
350 CN=(sum( R O ID o se l i s t  >=100) ) " 2 / ( Maskvol*sum(sum (sum (
MCDose3D>=100)))) ;
351 % e n d
352
353 % G r a d ie n t  index  (GI) :
354 GI=sum(sum(sum(MCDose3D>=50)) ) /sum(sum(sum(MCDose3D>=100)
) ) ;
355
356 % C a l c u l a t e  t h e  s t a n d e r d  d e v i a t i o n  in dose a t  t h e  ROI
357 SD=std ( doub le  ( R O ID o se l i s t  ) )  ;
358
359 % C rea te  th e  MC RT P lan  Dose f i l e  to  be seen in MCCIP.exe
s o f tw a r e
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361 e v a l  ( [ ’Hospi ta lDVHl=RT_Doseinfo  . DVHSequence. I tem_ ’ n u m 2 s t r ( i k )  ’
. DVHData ; ’ ] ) ;
362
363 H osp i ta lD V H =reshape  (Hospi ta lDVHl ,2 , s i z e  (Hospi ta lDVHl , 1) /2 )
364 hd=HospitalDVH ( : , 1 ) ;
365 hdv=HospitalDVH (: ,2)  ;
366 n tem ax(H osp i ta lD V H  (: ,2)  ) ;
367
368 fo r  kk =  l: s i z e  (HospitalDVH , 1 )
369
370 HospitalDVH (kk , 1 )=kk*Hospita lDVH (kk , 1 ) ;
371 HospitalDVH (kk , 2)=Hospi ta lDVH (kk ,2) *100/mh;
372 end
374
375 % C re a te  a f i l e  w i th  a l l  p a r a m e t r s
376 Heading={ ’ROI Volume in cm"3 ’ ; ’mean Dose ’ ; ’D2 ’ ; ’D50 ’ ; ’D98 ’ ; ’
V_5Gy ’ ; ’V_10Gy ’ ; ’ V_20Gy ’ ; ’ V_30Gy ’ ; ’ V_50Gy ’ ; ’V_70Gy ’ ; ’HI ’ ; ’CI ’
; ’CN’ ; ’C I ’ ; ’T o t a l  MUs’ };
377 e v a l u a t i o n _ d a t a  =  [VolumeofROI ; AverageDose ;D2;D50;D98;V5Gy; VlOGy;
V20Gy ; V30Gy ; V50Gy ; V70Gy ; HI ; CI ;CN; CI ; TotaLMUs ] ;
378 H e a d in g 2 = { ’Dose^VIC (Gy) ’ , ’DVHdVlC (%) ’ } ;
379 %Heading3={ ’ Dose-TPS (Gy) ’ , ’DVIP-TPS ( % ) ’};
380 Rang 1 = ’A l ’
381 Rang2= ’ B1 ’
382 Rang3=’D l ’
383 Rang4= ’ D2 ’
384 %Rang5=’F l
385 %Rang6=’F 2 ’ ;
386 Spreadshea t=RO LN am e ;
387 x l s w r i t e  ( x l s f i l e  , Heading , S p r e a d s h e a t  , R a n g l ) ;
388 x l s w r i t e  ( x l s f i l e  , e v a l u a t i o n _ d a t a  , S p r e a d s h e a t  , Rang2) ;
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389 x l s w r i t e  ( x l s f i l e  , Heading2 , S p r e a d s h e a t  , RangS) ;
390 x l s w r i t e  ( x l s f i l e  , CumulativeDVH , S p r e a d s h e a t  , Rang4) ;
391 % x l s w r i t e  ( ’ p l a n _ e v a l _ p a r  . xls  ’ , Headings  , S p r e a d s h e a t  , RangS) ;
392 % x l s w r i t e  ( ’ p l a n _ e v a l _ p a r  . xls  ’ , HospitalDVH , S p r e a d s h e a t  , Rang6) ;
394 e n d
396 % C re a t in g  MC dose f i l e
397 raw spac ing= R T _D ose in fo  . P i x e l S p a c i n g  ;
398 RT_Doseinfo . NumberOfFrames=Nz ;
399 rawRows=RT_Doseinfo , Rows ;
400 rawColumn=RT_Doseinfo . Columns ;
401 RT-Doseinfo  . G r id F ra m e O f f s e tV e c to r  =0: Vz_s ize  : V z . s i z e  *(Nz—1) ;
402 r a w p o s i t io n = R T _ D o se in fo  . I m a g e P o s i t i o n P a t i e n t  ;
403
404 RT_Doseinfo . P i x e l S p a c in g  =  [Vx_size  ; Vy_size ] ;
405 Num_of_VoxelY=uint32 ( ( rawRows*rawspacing  (2) ) /  Vy_size ) ;
406 Num_of_VoxelX=uint32 ( ( raw Colum n*raw spac ing  ( 1 ) ) /  Vx_size ) ;
407 i n i t  i a l _ X = u i n t 3 2  ( ( r a w p o s i t i o n  (1) — 10*X(1) ) /  Vx_size  ) ;
408 i n i t i a l _ Y = u i n t 3 2  ( ( r a w p o s i t i o n  (2) — 10*Y(1) ) /  Vx_size ) ;
409 RT_Doseinfo . T i s s u e H e t  e r o g e n e i t  y C o r r e c t  i o n = ’ ’ ;
410 RT-Doseinfo  . I m a g e P o s i t i o n P a t i e n t  =  [10*X( 1) ; 1 0 * Y ( 1 ) ; 1 0 * Z ( 1 ) ] ;
411 rawMCD3E)t=MCDose3D ;
412
413 for  n l  =  l:Nz
414
415 rawMCDSD(: , 1 : i n i t i a l _ X  —l , n l ) =0;
416 rawMCDSD ( : , in i t ia l_X +N um_of_VoxelX  +  l:Nx, n i  ) =0;
417 rawMCD3D( 1 : i n i t i a l _ Y  — l , : , n l ) = 0 ;
418 rawMCDSD( in i t ia l_Y +N um _of_V oxelY  +  l :N y , : , n l ) = 0 ;
419
420 end
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421
422 RT_Doseinfo . Rows=Ny ;
423 R T _ D o se in fo . Columns=Nx;
424
425 fo r  k l  =  l:Nz
MCD3D(: ,kl)=rawMCD3D(: , k l )  ;
428
429 end
431 MCDose4D=reshape (MCD3D, s iz e  (MCD3D,1) , s i z e  (MCD3D,2) ,1 ,  s i z e  (MCD3D
. 3 ) ) ;
432
433 i f new==l
434 [ f i l e n a m e s  f o l d e r S ] =  u i p u t f i l e  ( ’ * . d c m S e l e c t  f i l e  to  save MC
dose f i l e  As ’ ) ;
435 f n l l n a m e S = f n l l f i l e  ( f o l d e r S , f i l e n a m e s  ) ;
436 d ic o m w r i te  (MCDose4D, fu l lnam eS , RT .Doseinfo  , ’ C re a te  ’ , ’ copy ’ ) ;
437 end
438
439 %end of f u n c t i o n
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